Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof

ABSTRACT

The invention relates to quinazoline compounds, the preparation method, use, and the pharmaceutical composition thereof. The said quinazoline compounds, which are represented by Formula (I), are phosphatidylinositol 3-kinase (PI3K) inhibitors, and can be applied to prevent and/or treat PI3K activity-related diseases, such as cancer, immune diseases, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders or neurological diseases.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No.16/473,901 filed Jun. 26, 2019, which claims priority under 35 U.S.C. §371 to International Patent Appln. No. PCT/CN2017/118771, filed Dec. 26,2017; which claims priority to: Chinese Patent Appln. No.CN201611211589.5, filed Dec. 26, 2016; Chinese Patent Appln. No.CN201611204309.8, filed Dec. 26, 2016; and to Chinese Patent Appln. No.CN201611214102.9, filed Dec. 26, 2016, the contents of each of which areherein incorporated by reference in their entirety.

FIELD

This invention belongs to the technical field of pharmacy, and relatesto a series of quinazoline compounds, their preparation method, use, andpharmaceutical composition.

BACKGROUND

Phosphatidylinositol 3-kinases (PI3K) belong to lipid kinases family andcan be divided into three classes (I, II and III) according todifferences of their structure, regulating effect and lipid substratespecificities. At present, the most intensively studied are class IPI3Ks, which are heterodimers consisting of a regulatory subunit (p85)and a catalytic subunit (p110). Class I PI3Ks include 4 subtypes. Amongthem, two subtypes, PI3Kα and PI3Kβ, are widely existed in variouscells, while the other two subtypes PI3Kδ and PI3Kγ are mainlydistributed in leukocytes (Vanhaesebroeck, et al., Trends Biochem Sci.,2005,30(4):194-204). As a main downstream effector of receptor tyrosinekinase (RTK) and G protein coupled receptor (GPCR), PI3K generatesphosphatidylinositol 3,4,5-triphosphate (PIP3) by catalyzingphosphatidylinositol 4,5-diphosphate (PIP2), thereby transductingsignals of various growth factors and cytokines into cells. Then PIP3,as intracellular second messenger, can activate serine/threonine proteinkinase B (AKT) and downstream effectors including mammalian target ofrapamycin (mTOR), thereby regulating multiple cell functions.

PI3K signaling pathway is one of the most common abnormal signalingpathways in tumor cells, and has key influence on the occurrence anddevelopment of tumors. In particular, amplification and mutation of thePIK3CA gene, which encoding the p110α, have frequently occurred in mosttumors such as breast cancer, lung cancer, intestinal cancer, ovariancancer, head and neck cancer, stomach cancer, prostate cancer, braincancer, liver cancer, gastrointestinal tumor and leukemia (Zhao, et al.Nat. Drug Discov. 2009, 8:627-644). In recent years, PI3K and otherrelated nodes in its pathway such as AKT and mTOR have become populartargets for targeting anti-tumor drugs. PI3K inhibitors with variousstructural skeleton types have been reported and all exhibited excellentantitumor effect in cellular and animal models, and many compounds haveentered clinical trials as monotherapy or combination therapy for solidtumor and hematologic tumor, such as BKM120 (Novartis, phase IIIclinical trial), BEZ235 (Novartis, phase II clinical trial), PF-05212384(Pfizer, phase II clinical trial), BAY 80-6946 (Bayer, phase IIIclinical trial), XL147 (Exelixis, phase I/II clinical trial), etc. In2014, the first PI3K inhibitor, Idelalisib (Gilead, PI3Kδ selectiveinhibitor), was approved by FDA for the treatment of chronic lymphocyticleukemia (CLL), recurrent follicular B cell non-hodgkin's lymphoma (FL)and recurrent small lymphocytic lymphoma (SLL). In addition to tumor,PI3K also plays an important role in regulating inflammation, immunediseases, cardiovascular diseases, viral infections,metabolism/endocrine function disorders or neurological diseases. Somecompounds such as GSK2269557 (chronic obstructive pulmonary disease,phase II clinical trial), GSK2126458 (idiopathic pulmonary fibrosis,phase I clinical trial), UCB-5857 (primary sjogren's syndrome, phase IIclinical trial), and RV-1729 (chronic obstructive pulmonary disease,phase I clinical trial), have entered clinical trials against thesediseases.

PI3K has become a very attractive drug target. However, there is still aneed to develop safer and more effective PI3K inhibitors for preventionand/or treatment of cancers, immune diseases, cardiovascular diseases,viral infections, inflammation, metabolism/endocrine function disordersor neurological diseases.

SUMMARY

The technical problem to be solved by the present invention is toprovide a novel PI3K inhibitor, and a preparation method, apharmaceutical composition and use thereof.

The PI3K inhibitor has a strong inhibitory activity against Class IPI3K, including PI3Kα, PI3Kβ, PI3Kγ and/or PI3Kδ, especially PI3Kα,resulting a better prevention and/or treatment effect on PI3K-mediateddiseases such as cancer, autoimmune diseases, cardiovascular diseases,viral infections, inflammation, metabolism/endocrine function disordersor neurological diseases.

In order to solve the above technical problems, the present inventionprovides the following technical solutions.

The first aspect of the present invention is to provide a compoundrepresented by Formula (I), or a stereoisomer, a geometric isomer, atautomer or a pharmaceutically acceptable salt thereof:

wherein,

R₄ is C₁₋₃ alkyl;

L is selected from a single bond or C₁₋₃ alkylene, wherein the C₁₋₃alkylene is optionally substituted with one or more Ra;

Ra is selected from hydrogen, halogen or C₁₋₃ alkyl;

R₁ is selected from hydrogen, C₁₋₃ alkyl, C₁₋₃ alkoxy, 3- to 7-memberedcycloalkyl, 3- to 7-membered heterocycloalkyl or 5- to 6-memberedheteroaryl; when said R₁ is not hydrogen, it is optionally substitutedwith m R₆;

m is 0, 1, 2, 3 or 4;

each R₆ is independently selected from halogen, cyano, hydroxyl,trifluoromethyl, C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₃ hydroxyalkyl, C₁₋₃alkylamino or di(C₁₋₃ alkyl)amino;

R₂ is selected from C₁₋₃ alkoxy, halogen or C₁₋₃ alkyl;

R₃ is selected from C₁₋₃ alkyl, 3- to 7-membered cycloalkyl, 6- to10-membered aryl or 5- to 6-membered heteroaryl, wherein 6- to10-membered aryl and 5- to 6-membered heteroaryl are optionallysubstituted with one or more groups that are independently selected fromhydrogen, halogen, C₁₋₃ alkyl, amino, C₁₋₃ alkylamino, di(C₁₋₃alkyl)amino, trifluoromethyl, difluoromethyl, cyano or C₁₋₃ alkoxy; R₅is selected from hydrogen, amino, C₁₋₃ alkylamino, C₁₋₃alkylcarbonylamino or cyclopropylmethylamino.

In a preferred embodiment, the present invention provides a compoundrepresented by Formula (II), or a stereoisomer, a geometric isomer, atautomer or a pharmaceutically acceptable salt thereof:

wherein,

L is selected from a single bond or C₁₋₃ alkylene, wherein the C₁₋₃alkylene is optionally substituted with one or more Ra;

Ra is selected from hydrogen, halogen or C₁₋₃ alkyl, preferably C₁₋₃alkyl;

R₁ is selected from hydrogen, C₁₋₃ alkyl, C₁₋₃ alkoxy, 3- to 7-memberedcycloalkyl or 3- to 7-membered heterocycloalkyl; when R₁ is nothydrogen, it is optionally substituted with m R₆;

m is 0, 1, 2, 3 or 4;

each R₆ is independently selected from halogen, cyano, hydroxyl,trifluoromethyl, C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₃ hydroxyalkyl, C₁₋₃alkylamino or di(C₁₋₃ alkyl)amino;

R₂ is selected from C₁₋₃ alkoxy, halogen or C₁₋₃ alkyl;

R₃ is selected from C₁₋₃ alkyl, 3- to 7-membered cycloalkyl, 6- to10-membered aryl or 5- to 6-membered heteroaryl, wherein 6- to10-membered aryl and 5- to 6-membered heteroaryl are optionallysubstituted with one or more groups that are independently selected fromhydrogen, halogen, C₁₋₃ alkyl, amino, C₁₋₃ alkylamino, di(C₁₋₃alkyl)amino, trifluoromethyl, difluoromethyl, cyano or C₁₋₃ alkoxy.

In a further preferred embodiment, the present invention provides acompound represented by Formula (II), or a stereoisomer, a geometricisomer, a tautomer or a pharmaceutically acceptable salt thereof,

wherein,

L is selected from a single bond or C₁₋₃ alkylene, wherein C₁₋₃ alkyleneis optionally substituted with one or more Ra;

Ra is selected from hydrogen, halogen or C₁₋₃ alkyl, preferably C₁₋₃alkyl;

R₁ is selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl;optionally, R₁ is substituted with m R₆;

m is 0, 1, 2, 3 or 4;

each R₆ is independently selected from halogen, cyano, hydroxyl,trifluoromethyl, C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₃ hydroxyalkyl, C₁₋₃alkylamino or di(C₁₋₃ alkyl)amino;

R₂ is selected from C₁₋₃ alkoxy, halogen or C₁₋₃ alkyl;

R₃ is selected from C₁₋₃ alkyl, 3- to 7-membered cycloalkyl, 6- to10-membered aryl or 5- to 6-membered heteroaryl, wherein 6- to10-membered aryl and 5- to 6-membered heteroaryl are optionallysubstituted with one or more groups that are independently selected fromhydrogen, halogen, C₁₋₃ alkyl, amino, C₁₋₃ alkylamino, di(C₁₋₃alkyl)amino, trifluoromethyl, difluoromethyl, cyano or C₁₋₃ alkoxy.

In a still further preferred embodiment, the present invention providesa compound represented by formula (II), or a stereoisomer, a geometricisomer, a tautomer or a pharmaceutically acceptable salt thereof,

wherein,

L is selected from a single bond or C₁₋₃ alkylene, wherein C₁₋₃ alkyleneis optionally substituted with one or more Ra;

Ra is selected from hydrogen, halogen or C₁₋₃ alkyl, preferably C₁₋₃alkyl;

R₁ is 3- to 7-membered heterocycloalkyl containing oxygen, and R₁ isoptionally substituted with m R₆.

m is 0, 1, 2, 3 or 4;

each R₆ is independently selected from halogen, cyano, hydroxyl,trifluoromethyl, C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₃ hydroxyalkyl, C₁₋₃alkylamino or di(C₁₋₃ alkyl)amino;

R₂ is selected from C₁₋₃ alkoxy, halogen or C₁₋₃ alkyl;

R₃ is selected from C₁₋₃ alkyl, 3- to 7-membered cycloalkyl, 6- to10-membered aryl or 5- to 6-membered heteroaryl, wherein 6- to10-membered aryl and 5- to 6-membered heteroaryl are optionallysubstituted with one or more groups that are independently selected fromhydrogen, halogen, C₁₋₃ alkyl, amino, C₁₋₃ alkylamino, di(C₁₋₃alkyl)amino, trifluoromethyl, difluoromethyl, cyano or C₁₋₃ alkoxy.

In a further preferred embodiment, R₁ is selected from:

m is 0, 1, 2, 3 or 4;

each R₆ is independently selected from halogen, cyano, hydroxyl,trifluoromethyl, C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₃ hydroxyalkyl, C₁₋₃alkylamino or di(C₁₋₃ alkyl)amino.

In a further preferred embodiment, R₁ is selected from:

m is 0, 1, 2, 3 or 4;

each R₆ is independently selected from halogen, cyano, hydroxyl,trifluoromethyl, C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₃ hydroxyalkyl, C₁₋₃alkylamino or di(C₁₋₃ alkyl)amino.

In a further preferred embodiment, each R₆ is independently selectedfrom F, methyl or methoxy.

In a still further preferred embodiment, the present invention providesa compound represented by formula (II), or a stereoisomer, a geometricisomer, a tautomer or a pharmaceutically acceptable salt thereof,

wherein,

L is selected from a single bond or —CH₂—,

R₁ is selected from hydrogen, C₁₋₃ alkyl, C₁₋₃ alkoxy, 3- to 7-memberedcycloalkyl or 3- to 7-membered heterocycloalkyl; preferably, R₁ isselected from 3- to 7-membered cycloalkyl, including but not limited tocyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; or preferably, R₁is selected from 3- to 7-membered heterocycloalkyl and furtherpreferably, 3- to 7-membered oxygen-containing heterocycloalkyl,including but not limited to

when R₁ is not hydrogen, it is optionally substituted with m R₆;

m is 0, 1, 2, 3 or 4;

each R₆ is independently selected from halogen, cyano, hydroxyl,trifluoromethyl, C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₃ hydroxyalkyl, C₁₋₃alkylamino or di(C₁₋₃ alkyl)amino; preferably, each R₆ is independentlyselected from F, methyl or methoxy;

R₂ is selected from C₁₋₃ alkoxy, halogen or C₁₋₃ alkyl;

R₃ is selected from C₁₋₃ alkyl, 3- to 7-membered cycloalkyl, 6- to10-membered aryl or 5- to 6-membered heteroaryl, wherein 6- to10-membered aryl and 5- to 6-membered heteroaryl are optionallysubstituted with one or more groups that are independently selected fromhydrogen, halogen, C₁₋₃ alkyl, amino, C₁₋₃ alkylamino, di(C₁₋₃alkyl)amino, trifluoromethyl, difluoromethyl, cyano or C₁₋₃ alkoxy.

In a still further preferred embodiment, the present invention providesa compound represented by formula (II), or a stereoisomer, a geometricisomer, a tautomer or a pharmaceutically acceptable salt thereof,

wherein,

L is selected from a single bond or C₁₋₃ alkylene, wherein C₁₋₃ alkyleneis optionally substituted with one or more Ra; preferably, L is selectedfrom a single bond or —CH₂—;

Ra is selected from hydrogen, halogen or C₁₋₃ alkyl, preferably, C₁₋₃alkyl;

R₁ is selected from hydrogen, C₁₋₃ alkyl, C₁₋₃ alkoxy, 3- to 7-memberedcycloalkyl or 3- to 7-membered heterocycloalkyl; preferably, R₁ isselected from 3- to 7-membered cycloalkyl, including but not limited tocyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; or preferably, R₁is selected from 3- to 7-membered heterocycloalkyl and furtherpreferably 3- to 7-membered heterocycloalkyl containing oxygen,including but not limited to

when R₁ is not hydrogen, it is optionally substituted with m R₆;

m is 0, 1, 2, 3 or 4;

each R₆ is independently selected from halogen, cyano, hydroxyl,trifluoromethyl, C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₃ hydroxyalkyl, C₁₋₃alkylamino or di(C₁₋₃ alkyl)amino; preferably, each R₆ is independentlyselected from F, methyl or methoxy;

R₂ is selected from methoxy, chloro or methyl.

R₃ is selected from C₁₋₃ alkyl, 3- to 7-membered cycloalkyl, 6- to10-membered aryl or 5- to 6-membered heteroaryl, wherein 6- to10-membered aryl and 5- to 6-membered heteroaryl are optionallysubstituted with one or more groups that are independently selected fromhydrogen, halogen, C₁₋₃ alkyl, amino, C₁₋₃ alkylamino, di(C₁₋₃alkyl)amino, trifluoromethyl, difluoromethyl, cyano or C₁₋₃ alkoxy.

In a still further preferred embodiment, the present invention providesa compound represented by formula (II), a stereoisomer, a geometricisomer, a tautomer or a pharmaceutically acceptable salt thereof,

wherein,

L is selected from a single bond or C₁₋₃ alkylene, wherein C₁₋₃ alkyleneis optionally substituted with one or more Ra; preferably, L is selectedfrom a single bond or —CH₂—;

Ra is selected from hydrogen, halogen or C₁₋₃ alkyl, preferably, C₁₋₃alkyl;

R₁ is selected from hydrogen, C₁₋₃ alkyl, C₁₋₃ alkoxy, 3- to 7-memberedcycloalkyl or 3- to 7-membered heterocycloalkyl; preferably, R₁ isselected from 3- to 7-membered cycloalkyl, including but not limited tocyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; or preferably, R₁is selected from 3- to 7-membered heterocycloalkyl and furtherpreferably 3- to 7-membered heterocycloalkyl containing oxygen,including but not limited to

when R₁ is not hydrogen, it is optionally substituted with m R₆;

m is 0, 1, 2, 3 or 4;

each R₆ is independently selected from halogen, cyano, hydroxyl,trifluoromethyl, C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₃ hydroxyalkyl, C₁₋₃alkylamino or di(C₁₋₃ alkyl)amino; preferably, each R₆ is independentlyselected from F, methyl or methoxy;

R₂ is selected from C₁₋₃ alkoxy, halogen or C₁₋₃ alkyl; preferably, R₂is selected from methoxy, chloro or methyl;

R₃ is selected from C₁₋₃ alkyl, 3- to 7-membered cycloalkyl, phenyl orthienyl, wherein phenyl or thienyl are optionally substituted with oneor more groups that are independently selected from hydrogen, halogen,C₁₋₃ alkyl, amino, C₁₋₃ alkylamino, di(C₁₋₃ alkyl)amino,trifluoromethyl, difluoromethyl, cyano or C₁₋₃ alkoxy.

In a further preferred embodiment, R₃ is selected from phenyl orthienyl, wherein phenyl or thienyl is optionally substituted with one ormore substitutents that are independently selected from fluoro orchloro.

Specifically, the compounds preferred according to the present inventionare as follows:

In another preferred embodiment, the present invention provides acompound represented by formula (III), or a stereoisomer, a geometricisomer, a tautomer or a pharmaceutically acceptable salt thereof,

wherein,

R₇ is selected from C₁₋₃ alkyl, C₁₋₃ alkylcarbonyl or cyclopropylmethyl;

L is selected from a single bond or C₁₋₃ alkylene, wherein C₁₋₃ alkyleneis optionally substituted with one or more Ra;

Ra is selected from hydrogen, halogen or C₁₋₃ alkyl;

R₃ is selected from C₁₋₃ alkyl, 3- to 7-membered cycloalkyl, 6- to10-membered aryl or 5- to 6-membered heteroaryl, wherein 6- to10-membered aryl and 5- to 6-membered heteroaryl are optionallysubstituted with at least one group that is selected from hydrogen,halogen, C₁₋₃ alkyl, amino, C₁₋₃ alkylamino, di(C₁₋₃ alkyl)amino,trifluoromethyl, difluoromethyl, cyano or C₁₋₃ alkoxy;

ring A is selected from 3- to 7-membered cycloalkyl or 3-7heterocycloalkyl; each R₆ is independently selected from hydrogen, C₁₋₃alkyl, halogen, cyano, trifluoromethyl, C₁₋₃ alkoxy, C₁₋₃ alkylsubstituted with hydroxyl, C₁₋₃ alkylamino, or di(C₁₋₃ alkyl)amino;

m is 0, 1, 2, 3 or 4.

In a further preferred embodiment, the present invention provides acompound represented by formula (III), or a stereoisomer, a geometricisomer, a tautomer or a pharmaceutically acceptable salt thereof,

wherein,

R₇ is selected from C₁₋₃ alkyl, C₁₋₃ alkylcarbonyl or cyclopropylmethyl;L is selected from a single bond or C₁₋₃ alkylene, wherein C₁₋₃ alkyleneis optionally substituted with one or more Ra;

Ra is selected from hydrogen, halogen or C₁₋₃ alkyl;

R₃ is selected from C₁₋₃ alkyl, 3- to 7-membered cycloalkyl, 6- to10-membered aryl or 5- to 6-membered heteroaryl, wherein 6- to10-membered aryl and 5- to 6-membered heteroaryl are optionallysubstituted with at least one group that is selected from hydrogen,halogen, C₁₋₃ alkyl, amino, C₁₋₃ alkylamino, di(C₁₋₃ alkyl)amino,trifluoromethyl, difluoromethyl, cyano or C₁₋₃ alkoxy;

ring A is selected from cyclopropyl, cyclobutyl, cyclopentyl andcyclohexyl;

each R₆ is independently selected from hydrogen, C₁₋₃ alkyl, halogen,cyano, trifluoromethyl, C₁₋₃ alkoxy, C₁₋₃ alkyl substituted withhydroxyl, C₁₋₃ alkylamino or di(C₁₋₃ alkyl)amino;

m is 0, 1, 2, 3 or 4.

In a still further preferred embodiment, the present invention providesa compound represented by formula (III), or a stereoisomer, a geometricisomer, a tautomer or a pharmaceutically acceptable salt thereof,

wherein,

R₇ is selected from C₁₋₃ alkyl, C₁₋₃ alkylcarbonyl or cyclopropylmethyl;

L is selected from a single bond or C₁₋₃ alkylene, wherein C₁₋₃ alkyleneis optionally substituted with one or more Ra;

Ra is selected from hydrogen, halogen or C₁₋₃ alkyl;

R₃ is selected from hydrogen, C₁₋₃ alkyl, 3- to 7-membered cycloalkyl,6- to 10-membered aryl or 5- to 6-membered heteroaryl, wherein 6- to10-membered aryl and 5- to 6-membered heteroaryl are optionallysubstituted with at least one group that is selected from halogen, C₁₋₃alkyl, amino, C₁₋₃ alkylamino, di(C₁₋₃ alkyl)amino, trifluoromethyl,difluoromethyl, cyano or C₁₋₃ alkoxy;

ring A is 3- to 7-membered heterocycloalkyl containing oxygen;

each R₆ is independently selected from hydrogen, C₁₋₃ alkyl, halogen,cyano, trifluoromethyl, C₁₋₃ alkoxy, hydroxyl-substituted C₁₋₃ alkyl,C₁₋₃ alkylamino, or di(C₁_3 alkyl)amino;

m is 0, 1, 2, 3 or 4.

In a further preferred embodiment, ring A is selected from:

each R₆ is independently selected from hydrogen, C₁₋₃ alkyl, halogen,cyano, trifluoromethyl, C₁₋₃ alkoxy, C₁₋₃ alkyl substituted withhydroxyl, C₁₋₃ alkylamino or di(C₁₋₃ alkyl)amino;

m is 0, 1, 2, 3 or 4.

In a further preferred embodiment, each R₆ is independently selectedfrom methyl.

In a still further preferred embodiment, the present invention providesa compound represented by formula (III), or a stereoisomer, a geometricisomer, a tautomer or pharmaceutically acceptable salt,

wherein,

R₇ is selected from C₁₋₃ alkyl, C₁₋₃ alkylcarbonyl or cyclopropylmethyl;

L is selected from a single bond or —CH₂—;

R₃ is selected from C₁₋₃ alkyl, 3- to 7-membered cycloalkyl, 6- to10-membered aryl or 5- to 6-membered heteroaryl, wherein 6- to10-membered aryl and 5- to 6-membered heteroaryl are optionallysubstituted with at least one group that is selected from hydrogen,halogen, C₁₋₃ alkyl, amino, C₁₋₃ alkylamino, di(C₁₋₃ alkyl)amino,trifluoromethyl, difluoromethyl, cyano or C₁₋₃ alkoxy;

ring A is selected from 3- to 7-membered cycloalkyl or 3- to 7-memberedheterocycloalkyl; preferably, ring A is selected from 3- to 7-memberedcycloalkyl, including but not limited to cyclopropyl, cyclobutyl,cyclopentyl and cyclohexyl; or preferably, ring A is selected from 3- to7-membered heterocycloalkyl and further preferably 3- to 7-memberedheterocycloalkyl containing oxygen, including but not limited to

each R₆ is independently selected from hydrogen, C₁₋₃ alkyl, halogen,cyano, trifluoromethyl, C₁₋₃ alkoxy, hydroxyl-substituted C₁₋₃ alkyl,C₁₋₃ alkylamino or di(C₁₋₃ alkyl)amino;

m is 0, 1, 2, 3 or 4.

In a still further preferred embodiment, the present invention providesa compound represented by formula (III), or a stereoisomer, a geometricisomer, a tautomer or a pharmaceutically acceptable salt thereof.

wherein,

R₇ is selected from methyl, ethyl, cyclopropylmethyl or acetyl;

L is selected from a single bond or C₁₋₃ alkylene, wherein the C₁₋₃alkylene is optionally substituted with one or more Ra; preferably, L isselected from a single bond or —CH₂—.

Ra is selected from hydrogen, halogen or C₁₋₃ alkyl; preferably, C₁₋₃alkyl;

R₃ is selected from C₁₋₃ alkyl, 3- to 7-membered cycloalkyl, 6- to10-membered aryl or 5- to 6-membered heteroaryl, wherein 6- to10-membered aryl and 5- to 6-membered heteroaryl are optionallysubstituted with at least one group that is selected from hydrogen,halogen, C₁₋₃ alkyl, amino, C₁₋₃ alkylamino, di(C₁₋₃ alkyl)amino,trifluoromethyl, difluoromethyl, cyano or C₁₋₃ alkoxy;

ring A is selected from 3- to 7-membered cycloalkyl or 3- to 7-memberedheterocycloalkyl; preferably, ring A is selected from 3- to 7-memberedcycloalkyl, including but not limited to cyclopropyl, cyclobutyl,cyclopentyl and cyclohexyl; or preferably, ring A is selected from 3- to7-membered heterocycloalkyl and further preferably 3- to 7-memberedheterocycloalkyl containing oxygen, including but not limited to

each R₆ is independently selected from hydrogen, C₁₋₃ alkyl, halogen,cyano, trifluoromethyl, C₁₋₃ alkoxy, C₁₋₃ alkyl substituted withhydroxyl, C₁₋₃ alkylamino or di(C₁₋₃ alkyl)amino;

m is 0, 1, 2, 3 or 4.

In a still further preferred embodiment, the present invention providesa compound represented by formula (III), or a stereoisomer, a geometricisomer, a tautomer or a pharmaceutically acceptable salt thereof,

wherein,

R₇ is selected from C₁₋₃ alkyl, C₁₋₃ alkylcarbonyl or cyclopropylmethyl;preferably, R₁ is selected from methyl, ethyl, cyclopropylmethyl oracetyl;

L is selected from a single bond or C₁₋₃ alkylene, wherein the C₁₋₃alkylene is optionally substituted with one or more Ra; preferably, L isselected from a single bond or —CH₂—;

Ra is selected from hydrogen, halogen or C₁₋₃ alkyl; preferably C₁₋₃alkyl;

R₃ is selected from C₁₋₃ alkyl, 3- to 7-membered cycloalkyl, phenyl orthienyl, wherein the phenyl and thienyl are optionally substituted withone or more groups that are independently selected from hydrogen,halogen, C₁₋₃ alkyl, amino, C₁₋₃ alkylamino, di(C₁₋₃ alkyl)amino,trifluoromethyl, difluoromethyl, cyano or C₁₋₃ alkoxy;

ring A is selected from 3- to 7-membered cycloalkyl or 3- to 7-memberedheterocycloalkyl; preferably, ring A is selected from 3- to 7-memberedcycloalkyl, including but not limited to cyclopropyl, cyclobutyl,cyclopentyl and cyclohexyl; or preferably, ring A is selected from 3- to7-membered heterocycloalkyl and further preferably 3- to 7-memberedheterocycloalkyl containing oxygen, including but not limited to

each R₆ is independently selected from hydrogen, C₁₋₃ alkyl, halogen,cyano, trifluoromethyl, C₁₋₃ alkoxy, hydroxyl-substituted C₁₋₃ alkyl,C₁₋₃ alkylamino or di(C₁₋₃ alkyl)amino;

m is 0, 1, 2, 3 or 4.

In a further preferred embodiment, R₃ is selected from phenyl orthienyl, wherein phenyl and thienyl are optionally substituted with oneor more substitutents that are independently selected from fluoro orchloro.

Specifically, the compounds preferred according to the invention are asfollows:

In a still preferred embodiment, the present invention provides acompound represented by formula (IV), or a stereoisomer, a geometricisomer, a tautomer or a pharmaceutically acceptable salt thereof,

wherein,

R₄ is C₁₋₃ alkyl, preferably methyl;

L is selected from a single bond or C₁₋₃ alkylene, wherein the C₁₋₃alkylene is optionally substituted with one or more Ra;

Ra is selected from hydrogen, halogen or C₁₋₃ alkyl;

R₁ is selected from hydrogen, C₁₋₃ alkyl, C₁₋₃ alkoxy, 3- to 7-memberedcycloalkyl, 3- to 7-membered heterocycloalkyl or 5- to 6-memberedheteroaryl. When R₁ is not hydrogen, it is optionally substituted with mR₆;

m is 0, 1, 2, 3 or 4;

each R₆ is independently selected from halogen, cyano, hydroxyl,trifluoromethyl, C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₃ hydroxyalkyl, C₁₋₃alkylamino or di(C₁₋₃ alkyl)amino;

R₂ is selected from C₁₋₃ alkoxy, halogen or C₁₋₃ alkyl;

R₃ is selected from C₁₋₃ alkyl, 3- to 7-membered cycloalkyl, 6- to10-membered aryl or 5- to 6-membered heteroaryl, wherein 6- to10-membered aryl and 5- to 6-membered heteroaryl are optionallysubstituted with one or more groups that are independently selected fromhydrogen, halogen, C₁₋₃ alkyl, amino, C₁₋₃ alkylamino, di(C₁₋₃alkyl)amino, trifluoromethyl, difluoromethyl, cyano or C₁₋₃ alkoxy.

In a further preferred embodiment, the present invention provides acompound represented by formula (IV), or a stereoisomer, a geometricisomer, a tautomer or a pharmaceutically acceptable salt thereof,

wherein,

R₄ is C₁₋₃ alkyl, preferably methyl;

L is selected from a single bond or C₁₋₃ alkylene, wherein the C₁₋₃alkylene is optionally substituted with one or more Ra;

Ra is selected from hydrogen, halogen or C₁₋₃ alkyl;

R₁ is selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl;R₁ is optionally substituted with m R₆;

m is 0, 1, 2, 3 or 4;

each R₆ is independently selected from halogen, cyano, hydroxyl,trifluoromethyl, C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₃ hydroxyalkyl, C₁₋₃alkylamino or di(C₁₋₃ alkyl)amino;

R₂ is selected from C₁₋₃ alkoxy, halogen or C₁₋₃ alkyl;

R₃ is selected from C₁₋₃ alkyl, 3- to 7-membered cycloalkyl, 6- to10-membered aryl or 5- to 6-membered heteroaryl, wherein 6- to10-membered aryl and 5- to 6-membered heteroaryl are optionallysubstituted with one or more groups that are independently selected fromhydrogen, halogen, C₁₋₃ alkyl, amino, C₁₋₃ alkylamino, di(C₁₋₃alkyl)amino, trifluoromethyl, difluoromethyl, cyano or C₁₋₃ alkoxy.

In a still further preferred embodiment, the present invention providesa compound represented by formula (IV), or a stereoisomer, a geometricisomer, a tautomer or a pharmaceutically acceptable salt,

wherein,

R₄ is C₁₋₃ alkyl, preferably methyl;

L is selected from a single bond or C₁₋₃ alkylene, wherein the C₁₋₃alkylene is optionally substituted with one or more Ra;

Ra is selected from hydrogen, halogen or C₁₋₃ alkyl;

R₁ is 3- to 7-membered heterocycloalkyl containing oxygen, and R₂ isoptionally substituted with m R₆;

m is 0, 1, 2, 3 or 4;

each R₆ is independently selected from halogen, cyano, hydroxyl,trifluoromethyl, C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₃ hydroxyalkyl, C₁₋₃alkylamino or di(C₁₋₃ alkyl)amino;

R₂ is selected from C₁₋₃ alkoxy, halogen or C₁₋₃ alkyl;

R₃ is selected from C₁₋₃ alkyl, 3- to 7-membered cycloalkyl, 6- to10-membered aryl or 5- to 6-membered heteroaryl, wherein 6- to10-membered aryl and 5- to 6-membered heteroaryl are optionallysubstituted with one or more groups that are independently selected fromhydrogen, halogen, C₁₋₃ alkyl, amino, C₁₋₃ alkylamino, di(C₁₋₃alkyl)amino, trifluoromethyl, difluoromethyl, cyano or C₁₋₃ alkoxy.

In a further preferred embodiment, R₁ is selected from:

m is 0, 1, 2, 3 or 4;

each R₆ is independently selected from halogen, cyano, hydroxyl,trifluoromethyl, C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₃ hydroxyalkyl, C₁₋₃alkylamino or di(C₁₋₃ alkyl)amino.

In a further preferred embodiment, R₂ is selected from:

m is 0, 1, 2, 3 or 4;

each R₆ is independently selected from halogen, cyano, hydroxyl,trifluoromethyl, C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₃ hydroxyalkyl, C₁₋₃alkylamino or di(C₁₋₃ alkyl)amino.

In a further preferred embodiment, R₆ is independently selected from For methyl.

In a still further preferred embodiment, the present invention providesa compound represented by formula (IV), or a stereoisomer, a geometricisomer, a tautomer or a pharmaceutically acceptable salt thereof,

wherein,

R₄ is C₁₋₃ alkyl, preferably methyl;

L is selected from a single bond or —CH₂—,

R₁ is selected from hydrogen, C₁₋₃ alkyl, C₁₋₃ alkoxy, 3- to 7-memberedcycloalkyl, 3- to 7-membered heterocycloalkyl or 5- to 6-memberedheteroaryl; preferably, R₁ is selected from 3- to 7-membered cycloalkyl,including but not limited to cyclopropyl, cyclobutyl, cyclopentyl andcyclohexyl; or preferably, R₁ is 3- to 7-membered heterocycloalkyl andfurther preferably 3- to 7-membered heterocycloalkyl containing oxygen,including but not limited to

preferably including but not limited to

when R₁ is not hydrogen, it is optionally substituted with m R₆.

m is 0, 1, 2, 3 or 4;

each R₆ is independently selected from halogen, cyano, hydroxyl,trifluoromethyl, C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₃ hydroxyalkyl, C₁₋₃alkylamino or di(C₁₋₃ alkyl)amino; preferably, Rb is independentlyselected from F or methyl;

R₂ is selected from C₁₋₃ alkoxy, halogen or C₁₋₃ alkyl;

R₃ is selected from C₁₋₃ alkyl, 3- to 7-membered cycloalkyl, 6- to10-membered aryl or 5- to 6-membered heteroaryl, wherein 6- to10-membered aryl and 5- to 6-membered heteroaryl are optionallysubstituted with one or more groups that are independently selected fromhydrogen, halogen, C₁₋₃ alkyl, amino, C₁₋₃ alkylamino, di(C₁₋₃alkyl)amino, trifluoromethyl, difluoromethyl, cyano or C₁₋₃ alkoxy.

In a still further preferred embodiment, the present invention providesa compound represented by formula (IV), or a stereoisomer, a geometricisomer, a tautomer or a pharmaceutically acceptable salt thereof,

wherein,

R₄ is C₁₋₃ alkyl, preferably methyl;

L is selected from a single bond or C₁₋₃ alkylene, wherein the C₁₋₃alkylene is optionally substituted with one or more Ra; preferably, L isselected from a single bond or —CH₂—;

R₁ is selected from hydrogen, C₁₋₃ alkyl, C₁₋₃ alkoxy, 3- to 7-memberedcycloalkyl, 3- to 7-membered heterocycloalkyl or 5- to 6-memberedheteroaryl; preferably, R₁ is selected from 3- to 7-membered cycloalkyl,including but not limited to cyclopropyl, cyclobutyl, cyclopentyl andcyclohexyl; or preferably, R₁ is 3- to 7-membered heterocycloalkyl andfurther preferably 3- to 7-membered heterocycloalkyl containing oxygen,including but not limited to

preferably including but not limited to

when R₁ is not hydrogen, it is optionally substituted with m R₆;

m is 0, 1, 2, 3 or 4;

each R₆ is independently selected from halogen, cyano, hydroxyl,trifluoromethyl, C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₃ hydroxyalkyl, C₁₋₃alkylamino or di(C₁₋₃ alkyl)amino; preferably, Rb is independentlyselected from F or methyl;

R₂ is selected from methoxy, chloro or methyl;

R₃ is selected from C₁₋₃ alkyl, 3- to 7-membered cycloalkyl, 6- to10-membered aryl or 5- to 6-membered heteroaryl, wherein 6- to10-membered aryl and 5- to 6-membered heteroaryl are optionallysubstituted with one or more groups that are independently selected fromhydrogen, halogen, C₁₋₃ alkyl, amino, C₁₋₃ alkylamino, di(C₁₋₃alkyl)amino, trifluoromethyl, difluoromethyl, cyano or C₁₋₃ alkoxy.

In a still further preferred embodiment, the present invention providesa compound represented by formula (IV), or a stereoisomer, a geometricisomer, a tautomer or a pharmaceutically acceptable salt thereof,

wherein,

R₄ is C₁₋₃ alkyl, preferably methyl;

L is selected from a single bond or C₁₋₃ alkylene, wherein the C₁₋₃alkylene is optionally substituted with one or more Ra; preferably, L isselected from a single bond or —CH₂—;

R₁ is selected from hydrogen, C₁₋₃ alkyl, C₁₋₃ alkoxy, 3- to 7-memberedcycloalkyl, 3- to 7-membered heterocycloalkyl or 5- to 6-memberedheteroaryl; preferably, R₁ is selected from 3- to 7-membered cycloalkyl,including but not limited to cyclopropyl, cyclobutyl, cyclopentyl andcyclohexyl; or preferably, R₁ is 3- to 7-membered heterocycloalkyl andfurther preferably 3- to 7-membered heterocycloalkyl containing oxygen,including but not limited to

preferably including but not limited to

when R₁ is not hydrogen, it is optionally substituted with m R₆.

m is 0, 1, 2, 3 or 4;

each R₆ is independently selected from halogen, cyano, hydroxyl,trifluoromethyl, C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₃ hydroxyalkyl, C₁₋₃alkylamino or di(C₁₋₃ alkyl)amino; preferably, Rb is independentlyselected from F or methyl;

R₂ is selected from C₁₋₃ alkoxy, halogen or C₁₋₃ alkyl; preferably, R₂is selected from methoxy, chloro or methyl;

R₃ is selected from hydrogen, C₁₋₃ alkyl, 3- to 7-membered cycloalkyl,phenyl or thienyl, wherein the phenyl or thienyl are optionallysubstituted with one or more groups that are independently selected fromhalogen, C₁₋₃ alkyl, amino, C₁₋₃ alkylamino, di(C₁_3 alkyl)amino,trifluoromethyl, difluoromethyl, cyano or C₁₋₃ alkoxy.

In a further preferred embodiment, R₃ is selected from phenyl orthienyl, wherein phenyl and thienyl are optionally substituted with oneor more substitutents independently selected from fluoro or chloro.

Specifically, the compounds preferred according to the invention are asfollows:

The second aspect of the present invention provides a method forpreparing the said compound, or a stereoisomer, a geometric isomer, atautomer or a pharmaceutically acceptable salt thereof, which includesthe following steps of:

(1) using compound A as starting material and preparing compound B viabromination reaction;

(2) reacting compound B with triphosgene to afford compound C;

(3) reacting compound C with N,O-dimethylhydroxylamine hydrochloride toafford compound D;

(4) attacking Compound D with methylmagnesium bromide to give compoundE; (5) reacting Compound E with 50% cyanamide in water to obtaincompound F containing a quinazoline skeleton;

(6) protecting compound F via cyclization with 2,5-hexanedione to givecompound G; (7) reacting compound G with aluminum trichloride to removethe methyl group to afford the general intermediate H;

(8) reacting the intermediate H with various alcohol via Mitsunobureaction, or reacting the intermediate H with halide to obtain compoundI;

(9) deprotecting compound I with hydroxylamine hydrochloride to givecompound J;

(10) coupling compound F and compound J with substitutedpyridine-3-boronic acid pinacol ester under Suzuki reaction conditionsto obtain the above-mentioned compound, the stereoisomer, geometricisomer, tautomer or pharmaceutically acceptable salt thereof, orreacting compound J with bis(pinacolato)diboron to obtain acorresponding boronic acid pinacol ester, and then coupling the boronicacid pinacol ester with substituted 3-bromopyridine to obtain theabove-mentioned compound, or the stereoisomer, geometric isomer,tautomer or pharmaceutically acceptable salt thereof.

The second aspect of the present invention also provides another methodfor preparing the said compound, or a stereoisomer, a geometric isomer,a tautomer or a pharmaceutically acceptable salt thereof, which includesthe following steps of:

(1) using compound A as starting material and preparing compound B viabromination reaction;

(2) reacting compound B with triphosgene to afford compound C;

(3) reacting compound C with N,O-dimethylhydroxylamine hydrochloride toafford compound D;

(4) attacking Compound D with methylmagnesium bromide to give compoundE; (5) reacting Compound E with 50% cyanamide in water to obtaincompound F containing a quinazoline skeleton;

(6) protecting compound F via cyclization with 2,5-hexanedione to givecompound G;

(7) reacting compound G with aluminum trichloride to remove the methylgroup to afford the general intermediate H;

(8) reacting the intermediate H with various alcohol via Mitsunobureaction, or reacting the intermediate H with halide to obtain compoundI;

(9) deprotecting compound I with hydroxylamine hydrochloride to givecompound J;

(10) using sodium hydride or pyridine as base and reacting compound Jwith alkyl halide or alkyl acyl chloride to afford compound K;

(11) coupling compound K with substituted pyridine-3-boronic acidpinacol ester under Suzuki reaction conditions to obtain theabove-mentioned compound, the stereoisomer, geometric isomer, tautomeror pharmaceutically acceptable salt thereof.

The second aspect of the present invention also provides another methodfor preparing the said compound, or a stereoisomer, a geometric isomer,a tautomer or a pharmaceutically acceptable salt thereof, which includesthe following steps of:

(1) using compound A as starting material and preparing compound B viabromination reaction;

(2) reacting compound B with triphosgene to afford compound C;

(3) reacting compound C with N,O-dimethylhydroxylamine hydrochloride toafford compound D;

(4) attacking compound D with methylmagnesium bromide to give compoundE;

(5) reacting compound E with ammonium formate and formamide to obtaincompound L containing a quinazoline skeleton.

(6) reacting compound L with aluminum trichloride to remove the methylgroup to afford the general intermediate M.

(7) reacting the intermediate M with various alcohol via Mitsunobureaction, or reacting the intermediate M with halide to obtain compoundN;

(8) coupling compound N with substituted pyridine-3-boronic acid pinacolester under Suzuki reaction conditions to obtain the above-mentionedcompound, the stereoisomer, geometric isomer, tautomer orpharmaceutically acceptable salt thereof, or reacting compound N withbis(pinacolato)diboron to obtain a corresponding boronic acid pinacolester, and then coupling the boronic acid pinacol ester with substituted3-bromopyridine to obtain the above-mentioned compound, or thestereoisomer, geometric isomer, tautomer or pharmaceutically acceptablesalt thereof.

The third aspect of the present invention provides a pharmaceuticalcomposition, which comprise an above-mentioned compound, or astereoisomer, a geometric isomer, a tautomer or a pharmaceuticallyacceptable salt thereof, as well as an optional pharmaceuticallyacceptable carrier and/or excipient. Preferably, the pharmaceuticalcomposition further comprises one or more active pharmaceuticalingredients for prevention and/or treatment of cancer, immune diseases,cardiovascular diseases, viral infections, inflammation,metabolism/endocrine function disorders or neurological diseases inaddition to the above-mentioned compound, or the stereoisomer, thegeometric isomer, the tautomer or the pharmaceutically acceptable saltthereof. Preferably, the pharmaceutical composition is apharmaceutically acceptable pharmaceutical preparation for preventionand/or treatment of cancer, immune diseases, cardiovascular diseases,viral infections, inflammation, metabolism/endocrine function disordersor neurological diseases.

In another aspect, the present invention also provides a pharmaceuticalpreparation, which comprises at least one compound mentioned above, or astereoisomer, a geometric isomer, a tautomer or a pharmaceuticallyacceptable salt thereof, and optionally a pharmaceutically acceptablecarrier and/or excipient. Preferably, the pharmaceutical preparation isselected from the following preparations: parenteral preparation, suchas solution for injection or suspension; enteral preparation, such asoral preparation, e.g. tablet or capsule; topical preparation such aslotion, gel, ointment, emulsion, nasal preparation, suppository,transdermal preparation or ophthalmic preparation.

In another aspect, the present invention also provides use of thecompound, or a stereoisomer, a geometric isomer, a tautomer or apharmaceutically acceptable salt thereof, or the pharmaceuticalcomposition in the preparation of a medicament for preventing and/ortreating cancer, immune diseases, cardiovascular diseases, viralinfections, inflammation, metabolism/endocrine function disorders orneurological diseases. In other words, the present invention provides amethod for prevention and/or treatment of cancer, immune diseases,cardiovascular diseases, viral infections, inflammation,metabolism/endocrine function disorders or neurological diseases. Themethod includes administering a prophylactically and/or therapeuticallyeffective amount of the compound, the stereoisomer, the geometricisomer, the tautomer or the pharmaceutically acceptable salt thereof, orthe pharmaceutical composition to a subject in need thereof.

Some of the terms used in the present invention are defined as follows,and other undefined terms have the meaning known to those skilled in theart.

Halogen refers to fluorine, chlorine, bromine or iodine.

C₁₋₃ alkylene refers to a straight or branched bivalent saturatedhydrocarbon radical having 1 to 3 carbon atoms. Examples of such groupsinclude, but are not limited to: methylene (—CH₂—), ethylene (—CH₂CH₂—),and propylene (—CH₂CH₂CH₂—).

C₁₋₃ alkyl refers to a straight or branched saturated aliphatichydrocarbon radical having 1 to 3 carbon atoms. Examples of such groupsinclude, but are not limited to: methyl, ethyl, propyl, isopropyl.

3- To 7-membered cycloalkyl refers to a saturated monocyclic, fused,spirolcyclic or polycyclic structure having 3 to 7 carbon ring atoms.Examples of such groups include, but are not limited to: cyclopropyl,cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl and cycloheptyl.

3- To 7-membered heterocycloalkyl refers to a saturated or partiallyunsaturated (i.e. having one or more double bonds and/or triple bonds inring) carbon ring group having 3 to 7 ring atoms, wherein one or morering atoms are heteroatoms selected from nitrogen, oxygen or S(O)m (m isan integer of 0-2), but not including —O—O—, —O—S— or —S—S— as part ofthe ring, and the rest of ring atoms are carbon. Specific examples of 3-to 7-membered saturated heterocycloalkyl include but are not limited to:oxiranyl, aziridinyl, azetidinyl, oxetanyl, thiacyclobutyl,dihydrofuranyl, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl,imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl,thiazolidinyl, isothiazolidinyl, 1,4-dioxanyl, 1,3-dioxanyl,1,3-dithiacyclohexyl, piperidyl, morpholinyl, piperazinyl,dihydropyranyl, tetrahydropyranyl, tetrahydrothiopyranyl, etc.;preferably, oxacyclobutyl, tetrahydrofuranyl, tetrahydropyranyl,piperidinyl, morpholinyl, piperazinyl.

C₁₋₃ alkoxy refers to —O-alkyl, wherein the alkyl contains 1 to 3 carbonatoms and is straight, branched or cyclic. Examples of such groupsinclude, but are not limited to: methoxy, ethoxy, n-propoxy,iso-propoxy, or cyclopropoxy.

Aryl refers to a monocyclic or bicyclic aromatic carbon ring group,which usually has 6 to 10 carbon atoms, such as phenyl or naphthyl,preferably phenyl.

Heteroaryl refers to 5- or 6-membered aromatic heterocyclic group of asingle ring, including but not limited to: 5-membered heteroaryl: furyl,thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl,imidazolyl, pyrazolyl, triazolyl (1,2,4-triazolyl, 1,3,4-triazolyl or1,2,3-triazolyl), thiadiazolyl (1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl,1,2,3-thiadiazolyl or 1,2,4-thiadiazolyl) and oxadiazolyl(1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl or1,2,4-oxadiazolyl), and 6-membered heteroaryl: pyridinyl, pyrimidinyl,pyrazinyl and pyridazinyl, and bicyclic group such as benzofuranyl,benzothienyl, indazolyl, purinyl, quinolyl, isoquinolyl, phthalazinyl,naphthyridinyl, chinocalinyl, quinazolinyl, cinnolyl, pteridyl,indolizinyl, indolyl, isoindolyl. The preferred heteroaryl groups arethienyl, thiazolyl, pyridyl and pyrimidyl.

A single bond refers to direct connection of two groups, for example, inO-L-R, when L is a single bond, actually the structure is O—R.

“Optionally” means that the event or environment described subsequentlycan but does not have to occur, and the description includes thesituation where the event or circumstance occurs or does not occur. Forexample, “alkyl optionally substituted with halogen” means that halogencan but does not have to exist. The description includes situation ofalkyl substituted with halogen and situation of alkyl unsubstituted withhalogen.

If a group, for example, “R₆”, is depicted as “floating” on ring A inthe formula:

it means that “R₆” may reside on any atom of the ring system, and isconsidered as replacement of a depicted, implied or clearly definedhydrogen on one of the ring atoms, as long as a stable structure isformed.

The compound of the present invention may contain one or more chiralcenters, which exist in different stereoisomeric forms. Allstereoisomeric forms of the compound of the present invention, includingbut not limited to diastereomer, enantiomer and atropisomer and theirmixture (such as racemic mixture) are included in the scope of thepresent invention.

The compound of the present invention includes its geometrical isomer.For example, if the compound of the present invention contains doublebond or fused ring, these compounds can have geometrical isomers, andtheir cis-form and trans-form and mixture of cis-forms and trans-formsare included in the scope of the present invention.

The compound of the present invention includes its tautomer. Tautomerrefers to structural isomers of different energies that are mutuallyconverted via low energy barriers, such as ketone-enol and imine-enaminetautomerizations.

The compound of the present invention also includes itsisotopically-labelled compound, wherein one or more atoms are replacedby an atom having the same atomic number but different atomic mass ormass number usually found in nature. Examples include but are notlimited to: hydrogen isotopes ²H and ³H; carbon isotopes ¹¹C, ¹³C and¹⁴C; chlorine isotope ³⁶Cl; fluorine isotope ¹⁸F; iodine isotopes ¹²³Iand ¹²⁵I; nitrogen isotopes ¹³N and ¹⁵N; oxygen isotopes ¹⁵O, ¹⁷ and180; phosphorus isotope ³²P and sulfur isotope ³⁵S.

Various hydrates, solvates and polymorphs of the compound of the presentinvention or its salt are also included in the scope of the presentinvention.

The prodrug of the compound of the present invention is also included inthe scope of the present invention. Some derivatives of the compound ofthe present invention have weak or no pharmacological activitythemselves, but when these derivatives are administered in vivo or tobody, they can be converted into the compound of the present inventionhaving pharmacological activity by means of such as hydrolytic cleavage,and these derivatives are referred to as prodrugs. Further informationon prodrug use can be found in Pro-drugs as Novel Delivery Systems, Vol.14, ACS Symposium Series (T. Higuchi and W. Stella) and BioreversibleCarriers in Drug Design, Pergamon Press, 1987 (ed. E. b. Roche, AmericanPharmaceutical Association).

The compound of the present invention includes pharmaceuticallyacceptable salt. Pharmaceutically acceptable salt refers to a salt thatis pharmaceutically acceptable and has pharmacological activity requiredby the parent compound. The pharmaceutically acceptable salt wasdescribed in detail by Berge et al. in J. Pharma. Sci., 1977,66, 1-19,and the literature is hereby incorporated by reference. The compound ofthe present invention can include sufficient acidic groups, sufficientalkaline groups or functional groups with both acidic and alkalineproperties, and react with corresponding inorganic or organic bases, orinorganic and organic acids to form pharmaceutically acceptable salt.Examples of pharmaceutically acceptable salt include sulfate salt,pyrosulfate salt, bisulfate salt, sulfite salt, bisulfite salt,phosphate salt, monohydrogen phosphate salt, dihydrogen phosphate salt,metaphosphate salt, pyrophosphate salt, hydrochloride, hydrobromide,hydriodate salt, acetate salt, propionate salt, decanoate salt,caprylate salt, acrylate salt, formate salt, isobutyrate salt, caproatesalt, enanthate salt, propiolate salt, oxalate salt, malonate salt,succinate salt, suberate salt, sebacate salt, fumarate salt, maleatesalt, acetylene-1,4-dicarboxylate salt, butyne-1,6-dicarboxylate salt,benzoate salt, chlorinated benzoate salt, methylbenzoate salt,dinitrobenzoate salt, hydroxybenzoate salt, methoxybenzoate salt,phthalate salt, sulfonate salt, xylenesulfonate salt, phenylacetatesalt, phenylpropionate salt, phenylbutyrate salt, citrate salt, lactatesalt, gamma-hydroxybutyrate salt, hydroxyacetate salt, tartrate salt,methane sulfonate salt, propanesulfonate salt, naphthalene-1-sulfonatesalt, naphthalene-2-sulfonate salt and mandelate salt.

When the compound of the present invention is used as drug, it isusually administered in the form of pharmaceutical composition.Therefore, pharmaceutical composition comprising the compound of thepresent invention and pharmaceutically acceptable carriers, diluents orexcipients is also included in the scope of the invention. The carriers,auxiliaries and excipients used herein include any and all solvents,diluents or other liquid excipients, dispersants or suspending agents,surfactants, isotonic agents, thickeners or emulsifiers, preservatives,solid binders, lubricants, etc. suitable for the desired specificpreparation. Various carriers for preparing pharmaceutically acceptablecompositions and known technique for their preparation are disclosed inRemington: The Science and Practice of Pharmacy, 21^(st) edition, 2005,ed. D. B. Troy, Lippincott Williams & Wilkins, Philadelphia,Encyclopedia of Pharmaceutical Technology, eds. and J. Swarbrick, J. C.Boylan, 1988-1999, Marcel Dekker, New York, the contents of which arehereby incorporated by reference.

The composition of the present invention can be administered in anyroute suitable for diseases to be treated, in particular administrationroutes as follows: parenterally, such as in injection solution orsuspension form; transenterally, such as orally, for example in tabletor capsule form; topically, such as in lotion, gel, ointment or emulsionform or in nasal or suppository form. Topical administration is forexample applied to the skin. Another form of topical administration isadministration to eye.

Pharmaceutical composition can be administered in solid, semi-solid,liquid or gaseous form, or can be as dried powder, such as infreeze-drying form. Pharmaceutical composition can be packaged intransportable form, including, for example, solid preparation such ascapsule, medicine capsule, cachet, gelatin, paper, tablet, suppository,pellet, pill, lozenge and pastille. The packaging type generally dependson administration route. Implantable sustained release preparations aswell as transdermal preparations are also included.

Examples of materials as pharmaceutically acceptable carrier include,but are not limited to: ion exchanger, alumina, aluminum stearate,lecithin, serum protein (e.g. human serum albumin), buffering substance(e.g., phosphate salt), glycine, sorbic acid and potassium sorbate,partial glyceride mixture of saturated fatty acids, water, salt orelectrolyte (for example, protamine sulfate, disodium hydrogenphosphate, potassium hydrogen phosphate, sodium chloride, zinc salt),colloidal silicon dioxide, magnesium trisilicate, polyvinylpyrrolidone,polyacrylate, wax, polyethylene-polyoxypropylene block copolymer,lanolin, sugar (e.g. lactose, glucose and sucrose), starch (such as cornstarch and potato starch), cellulose and its derivatives such as sodiumcarboxymethyl cellulose, ethyl cellulose and cellulose acetate;Tragacanth powder; malt; gelatin; talc powder; excipient such as cocoabutter and wax for suppository; oil such as peanut oil, cottonseed oil,safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycolsuch as propylene glycol or polyethylene glycol; ester such as ethyloleate and ethyl laurate; agar; buffer agent such as magnesium hydroxideand aluminum hydroxide; alginic acid; pyrogen-free water; isotonicbrine; Ringer's liuqid; ethanol; and phosphate buffer, and othernon-toxic and compatible lubricants such as sodium lauryl sulfate andmagnesium stearate.

According to the judge of preparation preparing personnel, colorant,releaser, coating agent, sweetener, flavoring agent, fragrant agent,preservative and antioxidant can also be present in the composition.

The compound of the present invention can be used alone or incombination with other therapeutic agents for treating the diseases orsymptoms (such as cancer) described in the invention. In someembodiments, the compound of the present invention is combined inpharmaceutical combination preparation or combined in administrationscheme as combination therapy with a second compound havinghigh-proliferation resistance or for treating highly proliferativediseases (such as cancer). The second compound in the pharmaceuticalcombination preparation or quantitative administration scheme preferablyhas activity complementary to the compound of the present invention, sothat they do not adversely affect each other. Such compoundsappropriately exist in combination with quantity that is effective forplanning purpose. In one embodiment, the compound of the presentinvention is combined with other anti-tumor drugs. The antitumor drugsinclude: alkylating agents including but not limited tocyclophosphamide, nitrogen mustard, melphalan, chlorambucil, carmostine;platinum metals including but not limited to carboplatin, cisplatin,oxaliplatin; topoisomerase inhibitors including but not limited totopotecan, camptothecin, topotecan, irinotecan; antibiotics includingbut not limited to anisomycin, actinomycin D, daunorubicin, doxorubicin,mitoxantrone, bleomycin and mithramycin; anti-microtubule oranti-mitotic agents including but not limited to paclitaxel,vinorelbine, docetaxel, doxorubicin; antimetabolites including but notlimited to fluorouracil, methotrexate, cytarabine, mecaptopurine,thioguanine and gemcitabine; antibodies including but not limited toherceptin and bevacizumab; hormones including but not limited toletrazole, vorazole, tamoxifen, toremifene, fulvestrant, flutamide,nilutamide and triptorelin; kinase inhibitors such as EGFR kinaseinhibitors including but not limited to gefitinib, erlotinib, lapatiniband afatinib; VEGFR inhibitors including but not limited to sorafenib,regorafenib, sunitinib, cabozantinib, pazopanib, vandetanib, axitinib;ALK inhibitors including but not limited to crizotinib, ceritinib andalectinib; Bcr-Abl inhibitors including but are not limited to imatinib,ponatinib, nilotinib and dasatinib; BTK inhibitors including but notlimited to ibrutinib; B-RAF inhibitors including but not limited tovemurafenib; Cyclin-dependent kinase CDK4/6 inhibitor palbociclib; mTORinhibitors including but not limited to rapamycin and everolimus;deacetylase inhibitors including but not limited to vorinostat; andPD1/PDL1 antibodies such as Keytruda (Pembrolizumab) and Opdivo(Nivolumab).

In the fourth aspect of the present invention, there is provided use ofthe compound, its stereoisomer, geometric isomer, tautomer orpharmaceutically acceptable salt in the first aspect, or thepharmaceutical composition in the third aspect in the preparation ofmedicaments for preventing and/or treating PI3K-mediated diseases.Wherein, PI3K-mediated diseases include cancer, immune diseases,cardiovascular diseases, viral infections, inflammation,metabolism/endocrine function disorders or neurological diseases.

The compound of the present invention has high inhibitory activityagainst PI3Kα, and has strong anti-proliferative activity against humanlung cancer cell NCI-H460 with high expression of PI3Kα in vitro.Efficacy study in vivo shows that the compound of the present inventionhas significant inhibitory effect on growth of human lung cancer cellline NCI-H460 and human gastric cancer cell line HGC-27 in subcutaneousxenograft tumor in nude mice, both in tumor volume and tumor weight.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a tumor growth curve, which shows growth inhibitory effect ofExample 9 on human lung cancer NCI-H460 subcutaneous xenograft tumor innude mice.

FIG. 2 is a tumor growth curve, which shows growth inhibitory effect ofExample 44 on human lung cancer NCI-H460 subcutaneous xenograft tumor innude mice.

FIG. 3 is a tumor growth curve, which shows growth inhibitory effect ofExample 32 on human gastric cancer HGC-27 subcutaneous xenograft tumorin nude mice.

DETAILED DESCRIPTION

The followings are the specific examples of the present invention, whichfurther describe the technical solution of the present invention, butthe protection scope of the present invention is not limited to theseexamples. Any change or equivalent substitution that does not departfrom the present invention is included in the protection scope of thepresent invention.

In the following examples, molecule with single chiral center exists inthe form of racemic mixture unless structural formula or chemical nameis specified otherwise. Molecules with two or more chiral centers existin form of diastereomer racemic mixture unless structural formula orchemical name is specified otherwise. Single enantiomer/diastereomer canbe obtained by methods known to those skilled in the art.

Methods of Preparation

The compounds of the present invention can be synthesized according tothe synthetic scheme in the present invention and/or techniques wellknown in the art. For example, the compounds provided by the inventioncan be prepared according to the following general synthetic method.

General Synthetic Method

Particularly, in the general synthetic method, the quinazoline compoundsof the present invention can be prepared by 10-step reactions. Forexample, the starting material A was converted to compound B bybromination reaction, which was reacted with triphosgene to affordcompound C. Compound C was reacted with N,O-dimethylhydroxylaminehydrochloride to afford compound D, which was attacked withmethylmagnesium bromide to give compound E. Compound E was reacted with50% cyanamide in water to obtain compound F containing a quinazolineskeleton, whose amino group was protected by cyclization with2,5-hexanedione. The obtained compound G was reacted with aluminumtrichloride to remove the methyl group to afford the generalintermediate H. The intermediate H was reacted with various alcohol viaMitsunobu reaction, or reacted with halide to obtain compound I, whichwas deprotected by hydroxylamine hydrochloride to give compound J. UnderSuzuki reaction conditions known by those skilled in the art, compound Fand J were coupled with substituted pyridine-3-boronic acid pinacolester to obtain compounds 1-28. Alternatively, compound J was reactedwith bis(pinacolato)diboron to give the corresponding boronic acidpinacol ester, which was then coupled with substituted 3-bromopyridineto obtain the final product compounds 1-28.

In another general synthetic method, the quinazoline compounds of thepresent invention can be prepared by 11-step reactions. For example, thestarting material A was converted to compound B by bromination reaction,which was reacted with triphosgene to afford compound C. Compound C wasreacted with N, O-dimethylhydroxylamine hydrochloride to afford compoundD, which was attacked by methylmagnesium bromide to give compound E.Compound E was reacted with 50% cyanamide in water to obtain compound Fcontaining a quinazoline skeleton, whose amino group was protected bycyclization with 2,5-hexanedione. The obtained compound G was reactedwith aluminum trichloride to remove the methyl group to afford thegeneral intermediate H. The intermediate H was reacted with variousalcohol via Mitsunobu reaction, or reacted with various halide to obtaincompound I, which was deprotected by hydroxylamine hydrochloride to givecompound J. Using sodium hydride or pyridine as base, compound J wasreacted with alkyl halide or alkyl acyl chloride to afford compound K.Under Suzuki reaction conditions known by those skilled in the art,compound K was coupled with substituted pyridine-3-boronic acid pinacolester to obtain compounds 29-43.

In another general synthetic method, the quinazoline compounds of thepresent invention can be prepared by 8-step reactions. For example, thestarting material A was converted to compound B by bromination reaction,which was reacted with triphosgene to afford compound C. Compound C wasreacted with N, O-dimethylhydroxylamine hydrochloride to afford compoundD, which was attacked with methylmagnesium bromide to give compound E.Compound E was reacted with ammonium formate and formamide obtaincompound L containing a quinazoline skeleton, which was reacted withaluminum trichloride to remove the methyl group to afford the generalintermediate M. The intermediate M was reacted with various alcohol viaMitsunobu reaction, or reacted with halide to obtain compound N. UnderSuzuki reaction conditions known by those skilled in the art, compoundsL and N was coupled with substituted pyridine-3-boronic acid pinacolester to obtain compounds 44-73. Alternatively, compound N was reactedwith bis(pinacolato)diboron to give the corresponding boronic acidpinacol ester, which was then coupled with substituted 3-bromopyridineto obtain the final product compounds 44-73.

The compounds of the present invention can be synthesized according toone or more synthetic schemes and/or techniques well known in the art.Those skilled in the art should realize that the synthetic method ofsome embodiments described in detail in the present invention can beeasily applied to other embodiments. In some embodiments, the compounddescribed herein can be prepared by appropriate combinations ofsynthetic methods known in the art. Many starting materials and otherreagents can be purchased from commercial suppliers, such as Alfa aesar(China) chemical co., LTD., or easily prepared by synthetic methodscommonly used in the art.

¹H NMR spectra were recorded on instruments operated at 400 MHz or 500MHz. ¹H NMR spectra were obtained in solution form (reported as ppm),using CDCl₃ (7.26 ppm) or DMSO-d₆ (2.50 ppm) or internal standardtetramethylsilane (0.00 ppm) as reference standard. When reporting peakmultiplicity, the following abbreviations are used: s (singlet), d(doublet), t (triplet), q (quartet), m (multiplet), br (broad peak), dd(double-doublet), dt (double-triplet). The given coupling constant ismeasured in Hertz (Hz).

(R)- and (S)-isomers of non-restrictive exemplary compounds, if present,can be separated by methods known by those skilled in the art if needed,such as can be separated by, for example, crystallization throughforming diastereomeric salts or complexes; can be separated by, forexample, crystallization or chromatography through formingdiastereomeric derivatives; by allowing one enantiomer to selectivelyreact with an enantiomer specific reagent, then separating the modifiedand unmodified enantiomers; or through chromatographic separation inchiral environment such as chiral chromatographic column. Selectively,specific enantiomers can be prepared by asymmetric synthesis usingoptically-active reagents, substrates, catalysts or solvents, orprepared by converting one enantiomer into another one throughasymmetric conversion.

In the following preparative methods and examples, “Me” means methyl,“Et” means ethyl, “Ph” means phenyl, “PE” means petroleum ether, “EtOAc”means ethyl acetate, “MeOH” means methanol, “DMF” means N,N-dimethylformamide, “CDCl₃” means chloroform-d, “DMSO-d₆” means dimethylsulfoxide-d₆, “NMP” means 1-methyl-2-pyrrolidinone, “DCM” meansdichloromethane, “DCE” means 1,2-dichloroethane, “THF” meanstetrahydrofuran, “HCl” means hydrochloric acid, “TsOH” means4-methylbenzenesulfonic acid, “AlCl₃” means aluminium chloride, “TEA”means trimethylamine, “NBS” means N-bromosuccinimide, “Na₂SO₄” meanssodium sulphate, “K₂CO₃” means potassium carbonate, “MeMgBr” meansmethylmagnesium bromide, “DEAD” means diethyl azodicarboxylate, “PPh₃”means triphenylphosphine, “PdCl₂(dppf)” means[1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), “Ar” meansargon, “M” means molarity, “r.t.” means room temperature, “min” meansminute, “h” means hour, “mL” means milliliter, “mmol” means millimole,“μM” means micromole, “nM” means nanomole, “° C.” means degree Celsius.

Preparation of General Intermediate (H) Step 1: Preparation of2-amino-5-bromo-3-methoxybenzoic acid (B)

NBS (28.04 g, 157.5 mmol) was added to a solution of2-amino-3-methoxylbenzoic acid (25.08 g, 150 mmol) in DMF (200 mL) infive portions over 20 minutes. The mixture was stirred at r.t. for 2 h.The reaction mixture was diluted with water (2 L) and extracted withEtOAc (500 mL×4). The combined organic layers were washed with water(500 mL×3) and brine (500 mL), dried over anhydrous Na₂SO₄, filtered andconcentrated to afford the crude product (B) as a black brown solid (35g, 95% yield), which was used in the next step without purification.

¹H NMR (400 MHz, DMSO-d₆) δ 7.42 (d, J=2.2 Hz, 1H), 7.07 (d, J=2.2 Hz,1H), 3.84 (s, 3H).

Step 2: Preparation of6-bromo-8-methoxy-2H-benzo[d][1,3]oxazine-2,4(1H)-dione (C)

A mixture of compound (B) (35 g, 142.2 mmol) and triphosgene (32 g,107.8 mmol) in anhydrous THF (350 mL) was refluxed for 3 h. Aftercooling to r.t., the resulting solid was collected by filtration, washedwith PE/EtOAc solution (1:1, v/v, 200 mL), and dried to afford theproduct (C) as a pale yellow solid (30.78 g, 80% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 11.43 (s, 1H), 7.56 (d, J=2.0 Hz, 1H), 7.55(d, J=2.0 Hz, 1H), 3.92 (s, 3H).

Step 3: Preparation of 2-amino-5-bromo-N,3-dimethoxy-N-methylbenzamide(D)

A mixture of compound (C) (30.78 g, 113.12 mmol),N,O-dimethylhydroxylamine hydrochloride (16.55 g, 169.68 mmol) and TEA(26.7 mL, 192.3 mmol) in 1,4-dioxane (300 mL) was refluxed overnight.The volatiles were removed under reduced pressure. The residue wasdiluted with water (500 mL), and extracted with EtOAc (200 mL×3). Thecombined organic layers were washed with water (200 mL×2) and brine (200mL), dried with anhydrous Na₂SO₄, filtered and concentrated. The residuewas purified by flash column chromatography (silica gel, PE/EtOAc=4:1,v/v) to afford the product (D) as a yellow oil (29.73 g, 91% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 7.01 (d, J=2.0 Hz, 1H), 6.97 (d, J=2.0 Hz,1H), 5.10 (br s, 2H), 3.82 (s, 3H), 3.53 (s, 3H), 3.22 (s, 3H).

Step 4: Preparation of 1-(2-amino-5-bromo-3-methoxyphenyl)ethanone (E)

To a solution of compound (D) (29.73 g, 103 mmol) in anhydrous THF (300mL) at −20° C. under argon atmosphere was added methylmagnesium bromide(1M in THF, 206 mL, 206 mmol) dropwise over 30 minutes. The resultingreaction mixture was stirred at −20° C. for 30 minutes, and thenquenched with saturated aqueous NH₄Cl solution. The mixture was dilutedwith water (1 L) and extracted with EtOAc (300 mL×3). The combinedorganic layers were washed with water (300 mL×2) and brine (300 mL),dried over anhydrous Na₂SO₄, filtered and concentrated. The residue waspurified by flash column chromatography (silica gel, PE/EtOAc=15:1, v/v)to afford the product (E) as a yellow oil (6.5 g, 26% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 7.50 (d, J=2.0 Hz, 1H), 7.08 (d, J=2.0 Hz,1H), 7.04 (s, 2H), 3.84 (s, 3H), 2.51 (s, 3H).

Step 5: Preparation of 6-bromo-8-methoxy-4-methylquinazolin-2-amine (F)

A mixture of compound (E) (7.41 g, 30.36 mmol), and concentrated HCl (10mL) in 50% cyanamide in water (74 mL) was stirred at 120° C. for 15 min.The reaction mixture was cooled to r.t. and diluted with water (300 mL).The resulting solid was collected by filtration, washed with water (100mL) and ethanol (30 mL), dried to affor the product (F) as a pale yellowsolid (8.00 g, 98% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 7.67 (d, J=2.0 Hz, 1H), 7.20 (d, J=2.0 Hz,1H), 6.90 (br s, 2H), 3.88 (s, 3H), 2.67 (s, 3H).

Step 6: Preparation of6-bromo-2-(2,5-dimethyl-1H-pyrrol-1-yl)-8-methoxy-4-mthylquinazoline (G)

A mixture of compound (F) (8.00 g, 29.84 mmol), 2,5-hexanedione (13.61g, 119.36 mmol) and p-toluenesulfonic acid monohydrate (0.568 g, 2.98mmol) in NMP (80 mL) and toluene (80 mL) was refluxed to separate waterat 160° C. for 6 h. The reaction mixture was cooled to r.t., evaporatedunder reduced pressure to remove toluene, diluted with water (400 mL)and extracted with EtOAc (100 mL×3). The combined organic layers werewashed with water (100 mL×3) and brine (100 mL), dried over anhydrousNa₂SO₄, filtered and concentrated. The residue was purified by columnchromatography (silica gel, PE/EtOAc=30:1, v/v) to afford the product(G) as a yellow solid (8.95 g, 87% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 8.04 (d, J=1.8 Hz, 1H), 7.57 (d, J=1.8 Hz,1H), 5.84 (s, 2H), 4.01 (s, 3H), 2.92 (s, 3H), 2.30 (s, 6H).

Step 7: Preparation of6-bromo-2-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methylquinazolin-8-ol (H)

To a solution of compound (G) (3.27 g, 9.56 mmol) in DCE (300 mL) wasadded AlCl₃ (3.83 g, 28.68 mmol). The resulting reaction mixture wasstirred at 80° C. for 1.5 h. The reaction mixture was cooled to r.t.,diluted with water (300 mL) and extracted with DCM (300 mL×2). Thecombined organic layers were washed with water (200 mL) and brine (100mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residuewas purified by flash column chromatography (silica gel, PE/EtOAc=50:1,v/v) to afford the product (H) as a yellow solid (2.41 g, 77% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 10.64 (s, 1H), 7.93 (d, J=2.0 Hz, 1H), 7.44(d, J=2.0 Hz, 1H), 5.84 (s, 2H), 2.91 (s, 3H), 2.29 (s, 6H).

Preparation of General Intermediate (M) Step 1: Preparation of6-bromo-8-methoxy-4-methylquinazoline (L)

A mixture of compound (E) (3.328 g, 13.63 mmol) and ammonium formate(3.271 g, 54.52 mmol) in formamide (34 mL) was refluxed at 150° C. for 7h. The reaction mixture was cooled to r.t., diluted with water (150 mL)and extracted with EtOAc (100 mL×3). The combined organic layers werewashed with water (100 mL×2) and brine (100 mL), dried over anhydrousNa₂SO₄, filtered and concentrated. The residue was purified with flashcolumn chromatography (silica gel, PE/EtOAc=10:1, and then 4:1, v/v) toafford the product (L) as a yellow solid (2.492 g, 72.2% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 9.09 (s, 1H), 8.00 (d, J=1.9 Hz, 1H), 7.54(d, J=1.9 Hz, 1H), 4.00 (s, 3H), 2.87 (s, 3H).

Step 6: Preparation of 6-bromo-4-methylquinazolin-8-ol (M)

To a solution of compound (L) (4.36 g, 17.23 mmol) in DCE (390 mL) wasadded AlCl₃ (6.90 g, 51.69 mmol). The resulting reaction mixture wasstirred at 80° C. for 1.5 h. The reaction mixture was cooled to r.t.,diluted with water (400 mL) and extracted with DCM (300 mL×2). Thecombined organic layers were washed with water (200 mL) and brine (100mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residuewas purified with flash column chromatography (silica gel,DCM/MeOH=100:1, v/v) to afford the product (M) as a yellow solid (3.02g, 73.3% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 10.83 (s, 1H), 9.10 (s, 1H), 7.87 (d, J=2.0Hz, 1H), 7.41 (d, J=2.0 Hz, 1H), 2.86 (s, 3H).

Example 1:N-(5-(2-amino-4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(1)

Step 1: Preparation of6-bromo-2-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazoline(I-1)

To a stirred solution of compound (H) (3.322 g, 10 mmol),triphenylphosphine (3.148 g, 12 mmol) and tetrahydro-2H-pyran-4-yl(1.226 g, 12 mmol) in anhydrous THF (50 mL) was added diethylazodicarboxylate (2.09 g, 12 mmol) at r.t. under Ar atmosphere. Theresulting reaction mixture was stirred at r.t. overnight. Silica gel (10g) was added, and the resulting mixture was evaporated to dry underreduced pressure. The residue was purified by flash columnchromatography (silica gel, PE/EtOAc=10:1, v/v) to afford the product(I-1) as a yellow oil (2.097 g, 50% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 8.04 (d, J=1.9 Hz, 1H), 7.70 (d, J=1.8 Hz,1H), 5.86 (s, 2H), 5.01-4.91 (m, 1H), 3.94-3.80 (m, 2H), 3.56 (ddd,J=11.2, 8.0, 3.2 Hz, 2H), 2.92 (s, 3H), 2.36 (s, 3H), 2.09-1.94 (m, 2H),1.77-1.65 (m, 2H).

Step 2: Preparation of6-bromo-4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-2-amine(J-1)

A mixture of compound (I-1) (2.082 g, 5.0 mmol) and hydroxylaminehydrochloride (1.734 g, 25 mmol) in ethanol (40 mL) and water (4 mL) wasrefluxed overnight. The resulting mixture was evaporated to dry underreduced pressure, diluted with water (100 mL), neutralized withsaturated aqueous NaHCO₃ solution, and extracted with DCM (50 mL×3). Thecombined organic layers were washed with water (50 mL) and brine (50mL), dried over anhydrous Na₂SO₄, filtered, and concentrated. Theresidue was purified by column chromatography (silica gel,DCM/MeOH=50:1, v/v) to afford the product (J-1) as a yellow oil (0.667g, 39% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 7.68 (d, J=2.0 Hz, 1H), 7.36 (d, J=2.0 Hz,1H), 6.85 (s, 2H), 4.82-4.73 (m, 1H), 3.94-3.87 (m, 2H), 3.53-3.45 (m,2H), 2.65 (s, 3H), 2.05-1.96 (m, 2H), 1.68-1.58 (m, 2H).

MS (ESI+) m/z 337.8, 339.8 [M+H]⁺.

Step 3: Preparation ofN-(5-(2-amino-4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(1)

A mixture of compound (J-1) (538 mg, 1.59 mmol),N-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(814 mg, 1.91 mmol) and 2M aqueous K₂CO₃ solution (2.40 mL, 4.8 mmol) indioxane (15 mL) was degassed and then PdCl₂(dppf) (58 mg, 0.08 mmol) wasadded. The resulting reaction mixture was degassed and back-filled withargon (three cycles), and then stirred at 100° C. under Ar atmospherefor 5 h. The reaction mixture was cooled to r.t., diluted with EtOAc (50mL) and water (50 mL), acidified with 2M HCl solution until the pH valuewas 5-6. The two layers were separated and the aqueous layer wasextracted with EtOAc (30 mL×2). The combined organic layers were washedwith water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄,filtered and concentrated. The residue was purified by flash columnchromatography (silica gel, DCM/MeOH=50:1, v/v) to afford the product(1) as a yellow foamed solid (400 mg, 45% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 10.29 (s, 1H), 8.44 (d, J=2.2 Hz, 1H), 7.96(d, J=2.2 Hz, 1H), 7.76 (dt, J=8.4, 2.4 Hz, 1H), 7.66 (d, J=1.2 Hz, 1H),7.64-7.54 (m, 1H), 7.46 (d, J=1.2 Hz, 1H), 7.23 (dt, J=8.6, 2.0 Hz, 1H),6.79 (s, 2H), 4.97-4.82 (m, 1H), 3.98-3.89 (m, 2H), 3.64 (s, 3H),3.56-3.45 (m, 2H), 2.75 (s, 3H), 2.10-1.99 (m, 2H), 1.75-1.58 (m, 2H).

MS (ESI+) m/z 558.2 [M+H]⁺.

Example 2:N-(5-(2-amino-4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2-chloro-4-fluorobenzenesulfonamide(2)

Compound (2) was prepared from compound (J-1) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2-chloro-4-fluorobenzenesulfonamide,according to the method of step 3 in Example 1.

¹H NMR (400 MHz, DMSO-d₆) δ 10.17 (s, 1H), 8.42 (d, J=2.3 Hz, 1H), 7.94(dd, J=8.8, 6.0 Hz, 1H), 7.90 (d, J=2.4 Hz, 1H), 7.76 (dd, J=8.8, 2.4Hz, 1H), 7.62 (d, J=1.6 Hz, 1H), 7.43 (d, J=1.4 Hz, 1H), 7.40-7.33 (m,1H), 6.79 (s, 2H), 4.94-4.81 (m, 1H), 3.98-3.89 (m, 2H), 3.66 (s, 3H),3.57-3.45 (m, 2H), 2.75 (s, 3H), 2.10-1.99 (m, 2H), 1.74-1.58 (m, 2H).

MS (ESI+) m/z 574.1 [M+H]⁺.

Example 3:N-(5-(2-amino-4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)-4-fluorobenzenesulfonamide(3)

Compound (3) was prepared from compound (J-1) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide,according to the method of step 3 in Example 1.

¹H NMR (400 MHz, DMSO-d₆) δ 10.04 (s, 1H), 8.39 (d, J=2.4 Hz, 1H), 7.88(d, J=2.4 Hz, 1H), 7.86-7.79 (m, 2H), 7.61 (d, J=1.8 Hz, 1H), 7.47-7.39(m, 3H), 6.79 (s, 2H), 4.95-4.82 (m, 1H), 3.98-3.89 (m, 2H), 3.65 (s,3H), 3.56-3.42 (m, 2H), 2.75 (s, 3H), 2.11-1.98 (m, 2H), 1.74-1.59 (m,2H).

MS (ESI+) m/z 540.2 [M+H]⁺.

Example 4:N-(5-(2-amino-4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)-5-chlorothiophene-2-sulfonamide(4)

Compound (4) was prepared from compound (J-1) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-5-chlorothiophene-2-sulfonamide,according to the method of step 3 in Example 1.

¹H NMR (400 MHz, DMSO-d₆) δ 10.34 (s, 1H), 8.46 (d, J=2.4 Hz, 1H), 7.95(d, J=2.4 Hz, 1H), 7.67 (d, J=1.6 Hz, 1H), 7.47 (d, J=1.6 Hz, 1H), 7.39(d, J=4.0 Hz, 1H), 7.24 (d, J=4.0 Hz, 1H), 6.80 (s, 2H), 4.95-4.84 (m,1H), 4.00-3.86 (m, 2H), 3.74 (s, 3H), 3.58-3.45 (m, 2H), 2.76 (s, 3H),2.11-2.00 (m, 2H), 1.77-1.60 (m, 2H).

MS (ESI+) m/z 562.1 [M+H]⁺.

Example 5:N-(5-(2-amino-4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)methanesulfonamide(5)

Compound (5) was prepared from compound (J-1) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanesulfonamide,according to the method of step 3 in Example 1.

¹H NMR (400 MHz, DMSO-d₆) δ 9.34 (s, 1H), 8.43 (d, J=2.3 Hz, 1H), 7.95(d, J=2.3 Hz, 1H), 7.70 (d, J=1.6 Hz, 1H), 7.47 (d, J=1.6 Hz, 1H), 6.77(s, 2H), 4.97-4.81 (m, 1H), 3.98 (s, 3H), 3.96-3.88 (m, 2H), 3.55-3.44(m, 2H), 3.08 (s, 3H), 2.75 (s, 3H), 2.10-2.00 (m, 2H), 1.76-1.57 (m,2H).

MS (ESI+) m/z 460.2 [M+H]⁺.

Example 6:N-(5-(2-amino-4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)cyclopropanesulfonamide(6)

Compound (6) was prepared from compound (J-1) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)cyclopropanesulfonamide,according to the method of step 3 in Example 1.

¹H NMR (400 MHz, DMSO-d₆) δ 9.37 (s, 1H), 8.43 (d, J=2.3 Hz, 1H), 7.97(d, J=2.3 Hz, 1H), 7.69 (d, J=1.8 Hz, 1H), 7.47 (d, J=1.8 Hz, 1H), 6.78(s, 2H), 4.97-4.80 (m, 1H), 3.98 (s, 3H), 3.96-3.88 (m, 2H), 3.57-3.44(m, 2H), 2.83-2.70 (m, 4H), 2.12-1.98 (m, 2H), 1.74-1.61 (m, 2H),1.01-0.89 (m, 4H).

MS (ESI+) m/z 486.2 [M+H]⁺.

Example 7:N-(5-(2-amino-4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-6-yl)-2-methylpyridin-3-yl)-2,4-difluorobenzenesulfonamide(7)

A mixture of compound (J-1) (75 mg, 0.22 mmol), anhydrous potassiumacetate (65 mg, 0.66 mmol) and bis(pinacolato)diboron (64 mg, 0.25 mmol)in dioxane (8 mL) was degassed and then PdCl₂(dppf) (16 mg, 0.022 mmol)was added. The resulting reaction mixture was degassed and back-filledwith argon (three cycles), and then stirred at 100° C. under Aratmosphere for 4 h. After cooling to r.t.,N-(5-bromo-2-methylpyridin-3-yl)-2,4-difluorobenzenesulfonamide (91 mg,0.25 mmol) and 2M aqueous potassium carbonate solution (0.44 mL, 0.88mmol) were added to the reaction mixture. The resulting mixture wasdegassed, and then PdCl₂(dppf) (16 mg, 0.022 mmol) was added. Theresulting reaction mixture was degassed and backfilled with argon (threecycles), and then stirred at 100° C. under Ar atmosphere for 5 h. Thereaction mixture was cooled to r.t., diluted with EtOAc (30 mL) andwater (30 mL), acidified with hydrochloric acid until the pH value was5-6. The two layers were separated and the aqueous layer was extractedwith EtOAc (30 mL×2). The combined organic layers were washed with water(50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄, filtered, andconcentrated. The residue was purified by preparative thin layerchromatography (silica gel, DCM/MeOH/ammonium hydroxide=15:1:0.1, v/v)to afford the produt (7) as a yellow foamed solid (35 mg, 29% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 10.45 (s, 1H), 8.73 (s, 1H), 7.80 (dt,J=8.4, 6.4 Hz, 1H), 7.72-7.54 (m, 3H), 7.40 (s, 1H), 7.27 (dt, J=8.4,2.0 Hz, 1H), 6.84 (s, 2H), 4.91-4.80 (m, 1H), 3.98-3.88 (m, 2H),3.58-3.43 (m, 2H), 2.73 (s, 3H), 2.33 (s, 3H), 2.08-1.98 (m, 2H),1.77-1.58 (m, 2H).

MS (ESI+) m/z 542.2 [M+H]⁺.

Example 8:N-(5-(2-amino-4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-6-yl)-2-chloropyridin-3-yl)-4-fluorobenzenesulfonamide(8)

A mixture of compound (J-1) (75 mg, 0.22 mmol), anhydrous potassiumacetate (65 mg, 0.66 mmol), and bis(pinacolato)diboron (64 mg, 0.25mmol) in dioxane (8 mL) was degassed, and then PdCl₂(dppf) (16 mg, 0.022mmol) was added. The resulting reaction mixture was degassed andbackfilled with argon (three cycles) and then stirred at 100° C. underAr atmosphere for 4 h. After cooling to r.t.,N-(5-bromo-2-chloropyridyn-3-yl)-4-fluorobenzenesulfonamide (91 mg, 0.25mmol) and 2 M aqueous potassium carbonate solution (0.44 mL, 0.88 mmol)were added to the resulting mixture. The resulting reaction mixture wasdegassed, and then PdCl₂(dppf) (16 mg, 0.022 mmol) was added. Theresluting mixture was degassed and backfilled with argon (three cycles)and then stirred at 100° C. under Ar atmosphere for 5 h. The reactionmixture was cooled to r.t., diluted with water (30 mL) and EtOAc (30mL), acidified with hydrochloric acid until the pH value was 5-6. Thetwo layers were separated, and the aqueous layer was extracted withEtOAc (30 mL×2). The combined organic layers were washed with water (50mL) and brine (50 mL), dried over anhydrous Na₂SO₄, filtered, andconcentrated. The residue was purified by preparative thin layerchromatography (silica gel, DCM/MeOH/ammonium hydroxide=15:1:0.1, v/v)to afford the product (8) as a yellow foamed solid (30 mg, 25% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 10.53 (s, 1H), 8.67 (d, J=1.7 Hz, 1H), 7.99(d, J=2.3 Hz, 1H), 7.87-7.77 (m, 2H), 7.71 (d, J=1.7 Hz, 1H), 7.51-7.40(m, 3H), 6.90 (s, 2H), 4.95-4.82 (m, 1H), 3.98-3.88 (m, 2H), 3.57-3.44(m, 2H), 2.76 (s, 3H), 2.12-1.95 (m, 2H), 1.75-1.59 (m, 2H).

MS (ESI+) m/z 544.1 [M+H]⁺.

Example 9:(R)-N-(5-(2-amino-4-methyl-8-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(9)

Step 1: Preparation of(R)-6-bromo-2-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methyl-8-((tetrahydrofuran-3-yl)oxy)quinazoline(I-9)

According to the method of step 1 in Example 1, compound (I-9) wasprepared from compound (H) and (S)-tetrahydrofuran-3-ol.

¹H NMR (400 MHz, CDCl₃) δ 7.82 (d, J=1.6 Hz, 1H), 7.22 (d, J=1.6 Hz,1H), 5.91 (s, 2H), 5.22-5.14 (m, 1H), 4.18-3.94 (m, 4H), 2.91 (s, 3H),2.45 (s, 6H), 2.33-2.26 (m, 2H).

Step 2: Preparation of(R)-6-bromo-4-methyl-8-((tetrahydrofuran-3-yl)oxy)quinazolin-2-amine(J-9)

According to the method of step 2 in Example 1, compound (J-9) wasprepared from compound (I-9).

¹H NMR (400 MHz, DMSO-d₆) δ 7.69 (d, J=2.0 Hz, 1H), 7.21 (d, J=2.0 Hz,1H), 6.89 (s, 2H), 5.25-5.18 (m, 1H), 3.97-3.83 (m, 3H), 3.80-3.72 (m,1H), 2.66 (s, 3H), 2.33-2.21 (m, 1H), 2.05-1.93 (m, 1H).

Step 3: Preparation of(R)-N-(5-(2-amino-4-methyl-8-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(9)

Compound (9) was prepared from compound (J-9) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 3 in Example 1.

¹H NMR (400 MHz, DMSO-d₆) δ 10.28 (s, 1H), 8.44 (d, J=2.3 Hz, 1H), 7.97(d, J=2.3 Hz, 1H), 7.82-7.72 (m, 1H), 7.67 (d, J=1.5 Hz, 1H), 7.64-7.53(m, 1H), 7.32 (d, J=1.5 Hz, 1H), 7.22 (dt, J=8.4, 2.0 Hz, 1H), 6.83 (s,2H), 5.43-5.29 (m, 1H), 4.02-3.85 (m, 3H), 3.83-3.74 (m, 1H), 3.65 (s,3H), 2.75 (s, 3H), 2.35-2.22 (m, 1H), 2.08-2.01 (m, 1H).

MS (ESI+) m/z 544.1 [M+H]⁺.

Example 10:(R)-N-(5-(2-amino-4-methyl-8-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)methanesulfonamide(10)

Compound (10) was prepared from compound (J-9) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanesulfonamide,according to the method of step 3 in Example 1.

¹H NMR (400 MHz, DMSO-d₆) δ 9.35 (s, 1H), 8.44 (d, J=2.3 Hz, 1H), 7.97(d, J=2.3 Hz, 1H), 7.71 (d, J=1.6 Hz, 1H), 7.34 (d, J=1.6 Hz, 1H), 6.83(s, 2H), 5.39-5.33 (m, 1H), 3.98 (s, 3H), 3.97-3.87 (m, 3H), 3.82-3.74(m, 1H), 3.09 (s, 3H), 2.75 (s, 3H), 2.34-2.22 (m, 1H), 2.12-2.00 (m,1H).

MS (ESI+) m/z 446.1 [M+H]⁺.

Example 11:(S)-N-(5-(2-amino-4-methyl-8-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(11)

Step 1: Preparation of(S)-6-bromo-2-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methyl-8-((tetrahydrofuran-3-yl)oxy)quinazoline(I-11)

According to the method of step 1 in Example 1, compound (I-11) wasprepared from compound (H) and (R)-tetrahydrofuran-3-ol.

¹H NMR (400 MHz, DMSO-d₆) δ 8.05 (d, J=1.8 Hz, 1H), 7.58 (d, J=1.8 Hz,1H), 5.85 (s, 2H), 5.38-5.31 (m, 1H), 4.06-3.75 (m, 4H), 2.92 (s, 3H),2.34 (s, 6H), 2.32-2.24 (m, 1H), 2.13-2.02 (m, 1H).

Step 2: Preparation of(S)-6-bromo-4-methyl-8-((tetrahydrofuran-3-yl)oxy)quinazolin-2-amine(J-11)

According to the method of step 2 in Example 1, Compound (J-11) wasprepared from compound (I-11).

¹H NMR (400 MHz, DMSO-d₆) δ 7.69 (d, J=2.0 Hz, 1H), 7.21 (d, J=2.0 Hz,1H), 6.90 (s, 2H), 5.25-5.18 (m, 1H), 3.97-3.82 (m, 3H), 3.80-3.72 (m,1H), 2.66 (s, 3H), 2.33-2.21 (m, 1H), 2.05-1.95 (m, 1H).

Step 3: Preparation of(S)-N-(5-(2-amino-4-methyl-8-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(11)

Compound (11) was prepared from compound (J-11) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)2,4-difluorobenzenesulfonamide,according to the method of step 3 in Example 1.

¹H NMR (400 MHz, DMSO-d₆) δ 10.28 (s, 1H), 8.44 (d, J=2.3 Hz, 1H), 7.97(d, J=2.3 Hz, 1H), 7.76 (dt, J=8.6, 6.4 Hz, 1H), 7.67 (d, J=1.6 Hz, 1H),7.64-7.53 (m, 1H), 7.32 (d, J=1.6 Hz, 1H), 7.22 (dt, J=8.6, 2.3 Hz, 1H),6.84 (s, 2H), 5.43-5.29 (m, 1H), 4.00-3.85 (m, 3H), 3.83-3.73 (m, 1H),3.65 (s, 3H), 2.75 (s, 3H), 2.35-2.22 (m, 1H), 2.12-2.01 (m, 1H).

MS (ESI+) m/z 544.1 [M+H]⁺.

Example 12:(S)-N-(5-(2-amino-4-methyl-8-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)methanesulfonamide(12)

Compound (12) was prepared from compound (J-11) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanesulfonamide,according to the method of step 3 in Example 1.

¹H NMR (400 MHz, DMSO-d₆) δ 9.35 (s, 1H), 8.44 (d, J=2.3 Hz, 1H), 7.97(d, J=2.3 Hz, 1H), 7.71 (d, J=1.8 Hz, 1H), 7.34 (d, J=1.8 Hz, 1H), 6.83(s, 2H), 5.39-5.33 (m, 1H), 3.98 (s, 3H), 3.96-3.86 (m, 3H), 3.83-3.74(m, 1H), 3.09 (s, 3H), 2.75 (s, 3H), 2.35-2.23 (m, 1H), 2.12-2.02 (m,1H).

MS (ESI+) m/z 446.1 [M+H]⁺.

Example 13:N-(5-(2-amino-4-methyl-8-((tetrahydro-2H-pyran-4-yl)methoxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(13)

Step 1: Preparation of6-bromo-2-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methyl-8-((tetrahydro-2H-pyran-4-yl)methoxy)quinazoline(I-13)

According to the method of step 1 in Example 1, compound (I-13) wasprepared from compound (H) and (tetrahydro-2H-pyran-4-yl)methanol.

¹H NMR (400 MHz, DMSO-d₆) δ 8.02 (d, J=1.9 Hz, 1H), 7.55 (d, J=1.9 Hz,1H), 5.85 (s, 2H), 4.07 (d, J=6.2 Hz, 2H), 3.94-3.86 (m, 2H), 3.36 (dt,J=11.6, 2.0 Hz, 2H), 2.91 (s, 3H), 2.35 (s, 6H), 2.19-2.03 (m, 1H),1.78-1.69 (m, 2H), 1.52-1.37 (m, 2H).

Step 2: Preparation of6-bromo-4-methyl-8-((tetrahydro-2H-pyran-4-yl)methoxy)quinazolin-2-amine(J-13)

According to the method of step 2 in Example 1, compound (J-13) wasprepared from compound (I-13).

¹H NMR (400 MHz, DMSO-d₆) δ 7.65 (d, J=2.0 Hz, 1H), 7.22 (d, J=2.0 Hz,1H), 6.83 (s, 2H), 3.95 (d, J=6.7 Hz, 2H), 3.92-3.84 (m, 2H), 3.40-3.32(m, 2H), 2.65 (s, 3H), 2.14-1.99 (m, 1H), 1.78-1.69 (m, 2H), 1.43-1.28(m, 2H).

Step 3: Preparation ofN-(5-(2-amino-4-methyl-8-((tetrahydro-2H-pyran-4-yl)methoxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(13)

Compound (13) was prepared from compound (J-13) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 3 in Example 1.

¹H NMR (400 MHz, DMSO-d₆) δ 10.28 (s, 1H), 8.45 (d, J=2.1 Hz, 1H), 7.97(d, J=2.2 Hz, 1H), 7.76 (dt, J=8.6, 6.4 Hz, 1H), 7.64 (s, 1H), 7.63-7.55(m, 1H), 7.34 (s, 1H), 7.22 (dt, J=8.6, 2.4 Hz, 1H), 6.79 (s, 2H), 4.05(d, J=6.6 Hz, 2H), 3.90 (dd, J=11.0, 3.0 Hz, 2H), 3.64 (s, 3H), 3.37 (t,J=11.0 Hz, 2H), 2.75 (s, 3H), 2.20-2.05 (m, 1H), 1.84-1.74 (m, 2H), 1.38(qd, J=12.2, 4.2 Hz, 2H).

MS (ESI+) m/z 572.2 [M+H]⁺.

Example 14:N-(5-(2-amino-4-methyl-8-((tetrahydro-2H-pyran-4-yl)methoxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)methanesulfonamide(14)

Compound (14) was prepared from compound (J-13) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanesulfonamide,according to the method of step 3 in Example 1.

¹H NMR (400 MHz, DMSO-d₆) δ 9.35 (s, 1H), 8.44 (d, J=2.2 Hz, 1H), 7.97(d, J=2.2 Hz, 1H), 7.67 (d, J=1.2 Hz, 1H), 7.36 (d, J=1.2 Hz, 1H), 6.77(s, 2H), 4.06 (d, J=6.6 Hz, 2H), 3.98 (s, 3H), 3.90 (dd, J=11.2, 3.0 Hz,2H), 3.36 (t, J=10.9 Hz, 2H), 3.08 (s, 3H), 2.75 (s, 3H), 2.20-2.04 (m,1H), 1.77 (d, J=12.4 Hz, 2H), 1.38 (qd, J=12.4, 4.4 Hz, 2H).

MS (ESI+) m/z 474.2 [M+H]⁺.

Example 15:N-(5-(2-amino-4-methyl-8-((1-methylpiperidin-4-yl)oxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(15)

Step 1: Preparation of6-bromo-2-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methyl-8-((1-methylpiperidin-4-yl)oxy)quinazoline(I-15)

According to the method of step 1 in Example 1, compound (I-15) wasprepared from compound (H) and 1-methylpiperidin-4-ol.

¹H NMR (400 MHz, CDCl₃) δ 8.02 (d, J=2.0 Hz, 1H), 7.64 (d, J=2.0 Hz,1H), 5.86 (s, 2H), 4.88-4.73 (m, 1H), 2.91 (s, 3H), 2.64-2.54 (m, 2H),2.37 (s, 6H), 2.35-2.25 (m, 2H), 2.18 (s, 3H), 2.04-1.89 (m, 2H),1.87-1.71 (m, 2H).

Step 2: Preparation of6-bromo-4-methyl-8-((1-methylpiperidin-4-yl)oxy)quinazolin-2-amine(J-15)

According to the method of step 2 in Example 1, compound (J-15) wasprepared from compound (I-15).

¹H NMR (400 MHz, DMSO-d₆) δ 7.66 (d, J=2.0 Hz, 1H), 7.28 (d, J=2.0 Hz,1H), 6.83 (s, 2H), 4.64-4.47 (m, 1H), 2.78-2.69 (m, 2H), 2.65 (s, 3H),2.19 (s, 3H), 2.18-2.10 (m, 2H), 2.04-1.93 (m, 2H), 1.73-1.60 (m, 2H).

Step 3: Preparation ofN-(5-(2-amino-4-methyl-8-((1-methylpiperidin-4-yl)oxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(15)

Compound (15) was prepared from compound (J-15) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 3 in Example 1.

¹H NMR (400 MHz, DMSO-d₆) δ 10.56 (br s, 1H), 8.40 (d, J=2.4 Hz, 1H),7.94 (d, J=2.4 Hz, 1H), 7.76 (dt, J=8.6, 6.4 Hz, 1H), 7.71 (d, J=1.6 Hz,1H), 7.61-7.51 (m, 2H), 7.22 (dt, J=8.4, 2.1 Hz, 1H), 6.84 (s, 2H),4.95-4.85 (m, 1H), 3.64 (s, 3H), 3.10-2.95 (m, 2H), 2.76 (s, 3H), 2.69(s, 3H), 2.25-2.13 (m, 2H), 2.07-1.95 (m, 2H).

MS (ESI+) m/z 571.18994 [M+H]⁺.

Example 16:N-(5-(2-amino-4-methyl-8-(2-morpholinoethoxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(16)

Step 1: Preparation of4-(2-((6-bromo-2-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methylquinazolin-8-yl)oxy)ethyl)morpholine(I-16)

According to the method of step 1 in Example 1, compound (I-16) wasprepared from compound (H) and 2-(morpholinyl)-ethanol.

¹H NMR (400 MHz, CDCl₃) δ 8.02 (d, J=2.0 Hz, 1H), 7.64 (d, J=2.0 Hz,1H), 5.85 (s, 2H), 4.33 (t, J=5.1 Hz, 2H), 4.04 (q, J=7.0 Hz, 4H),3.64-3.46 (m, 4H), 2.92 (s, 3H), 2.81 (t, J=5.1 Hz, 2H), 2.53 (s, 6H).

Step 2: Preparation of6-bromo-4-methyl-8-(2-morpholinoethoxy)quinazolin-2-amine (J-16)

According to the method of step 2 in Example 1, compound (J-16) wasprepared from compound (I-16).

¹H NMR (500 MHz, DMSO-d₆) δ 7.67 (s, 1H), 7.28 (s, 1H), 6.90 (s, 2H),4.21 (t, J=5.9 Hz, 2H), 3.67-3.50 (m, 4H), 2.74 (t, J=5.8 Hz, 2H), 2.66(s, 3H), 2.51 (br s, 4H).

Step 3: Preparation ofN-(5-(2-amino-4-methyl-8-(2-morpholinoethoxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(16)

Compound (16) was prepared from compound (J-16) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 3 in Example 1.

¹H NMR (400 MHz, DMSO-d₆) δ 8.44 (d, J=2.2 Hz, 1H), 7.97 (d, J=2.2 Hz,1H), 7.76 (dt, J=8.6, 6.4 Hz, 1H), 7.65 (d, J=1.6 Hz, 1H), 7.58 (ddd,J=10.4, 9.4, 2.4 Hz, 1H), 7.38 (d, J=1.6 Hz, 1H), 7.26-7.17 (m, 1H),6.84 (s, 2H), 4.31 (t, J=6.0 Hz, 2H), 3.64 (s, 3H), 3.61 (t, J=4.6 Hz,4H), 2.81 (t, J=6.0 Hz, 2H), 2.75 (s, 3H), 2.61-2.52 (m, 4H).

MS (ESI+) m/z 587.2 [M+H]⁺.

Example 17:N-(5-(2-amino-8-((4,4-difluorocyclohexyl)oxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(17)

Step 1: Preparation of6-bromo-8-((4,4-difluorocyclohexyl)oxy)-2-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methylquinazoline(I-17)

According to the method of step 1 in Example 1, compound (I-17) wasprepared from compound (H) and 4,4-difluorocyclohexanol.

¹H NMR (400 MHz, CDCl₃) δ 7.82 (d, J=1.8 Hz, 1H), 7.31 (d, J=1.8 Hz,1H), 5.92 (s, 2H), 4.85-4.77 (m, 1H), 2.91 (s, 3H), 2.45 (s, 6H),2.28-2.14 (m, 4H), 2.07-1.92 (m, 4H).

Step 2: Preparation of6-bromo-8-((4,4-difluorocyclohexyl)oxy)-4-methylquinazolin-2-amine(J-17)

According to the method of step 2 in Example 1, compound (J-17) wasprepared from compound (I-17).

¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, J=1.6 Hz, 1H), 7.20 (d, J=1.6 Hz,1H), 5.28 (br s, 2H), 4.71-4.62 (m, 1H), 2.74 (s, 3H), 2.41-2.23 (m,2H), 2.23-2.10 (m, 2H), 2.07-1.86 (m, 4H).

Step 3: Preparation ofN-(5-(2-amino-8-((4,4-difluorocyclohexyl)oxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(17)

Compound (17) was prepared from compound (J-17) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 3 in Example 1.

¹H NMR (400 MHz, DMSO-d₆) δ 10.28 (s, 1H), 8.43 (d, J=2.2 Hz, 1H), 7.96(d, J=2.2 Hz, 1H), 7.76 (dt, J=8.4, 6.6 Hz, 1H), 7.69 (d, J=1.4 Hz, 1H),7.63-7.54 (m, 1H), 7.50 (d, J=1.4 Hz, 1H), 7.22 (dt, J=8.4, 2.0 Hz, 1H),6.76 (s, 2H), 4.97-4.88 (m, 1H), 3.64 (s, 3H), 2.76 (s, 3H), 2.28-2.11(m, 2H), 2.08-1.81 (m, 6H).

MS (ESI+) m/z 592.2 [M+H]⁺.

Example 18:N-(5-(2-amino-8-((4-methoxycyclohexyl)oxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(18)

Step 1: Preparation of6-bromo-2-(2,5-dimethyl-1H-pyrrol-1-yl)-8-((4-methoxycyclohexyl)oxy)-4-methylquinazoline(I-18)

According to the method of step 1 in Example 1, compound (I-18) wasprepared from compound (H) and 4-methoxycyclohexyl-1-ol.

¹H NMR (400 MHz, CDCl₃) δ 8.01 (d, J=1.9 Hz, 1H), 8.00 (d, J=1.9 Hz,1H), 7.64 (d, J=1.9 Hz, 1H), 7.62 (d, J=1.8 Hz, 1H), 5.85 (s, 2H),4.86-4.74 (m, 2H), 3.36-3.26 (m, 2H), 3.25 (s, 3H), 3.24 (s, 3H), 2.91(s, 6H), 2.36 (s, 6H), 2.35 (s, 6H), 2.08-1.84 (m, 6H), 1.76-1.68 (m,6H), 1.65-1.54 (m, 2H), 1.53-1.42 (m, 2H).

Step 2: Preparation of6-bromo-8-((4-methoxycyclohexyl)oxy)-4-methylquinazolin-2-amine (J-18)

According to the method of step 2 in Example 1, compound (J-18) wasprepared from compound (I-18), obtaining two new spots with similarpolarity.

The spot of lower polarity:

¹H NMR (400 MHz, DMSO-d₆) δ 7.65 (d, J=1.8 Hz, 1H), 7.29 (d, J=1.8 Hz,1H), 6.82 (s, 2H), 4.62-4.52 (m, 1H), 3.29-3.20 (m, 4H), 2.65 (s, 3H),2.08-1.95 (m, 4H), 1.57-1.30 (m, 4H).

MS (ESI+) m/z 366.1 [M+H]⁺.

The spot of higher polarity:

¹H NMR (400 MHz, DMSO-d₆) δ 7.65 (d, J=2.0 Hz, 1H), 7.27 (d, J=2.0 Hz,1H), 6.80 (s, 2H), 4.71-4.54 (m, 1H), 3.36-3.32 (m, 1H), 3.24 (s, 3H),2.65 (s, 3H), 1.86-1.54 (m, 8H).

MS (ESI+) m/z 366.1 [M+H]⁺.

Step 3:N-(5-(2-amino-8-((4-methoxycyclohexyl)oxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(18)

Compound 18-1: prepared from the spot of lower polarity in step 2,according to the method of step 3 in Example 1.

¹H NMR (400 MHz, DMSO-d₆) δ 10.28 (s, 1H), 8.43 (d, J=2.2 Hz, 1H), 7.95(d, J=2.2 Hz, 1H), 7.75 (dt, J=8.6, 6.4 Hz, 1H), 7.64 (s, 1H), 7.62-7.55(m, 1H), 7.41 (s, 1H), 7.22 (dt, J=8.4, 2.4 Hz, 1H), 6.77 (s, 2H),4.76-4.65 (m, 1H), 3.64 (s, 3H), 3.28-3.22 (m, 4H), 2.75 (s, 3H),2.12-1.30 (m, 4H), 1.60-1.30 (m, 4H).

MS (ESI+) m/z 586.2 [M+H]⁺.

Compound 18-2: prepared from the spot of higher polarity in step 2,according to the method of step 3 in Example 1.

¹H NMR (400 MHz, DMSO-d₆) δ 10.28 (s, 1H), 8.42 (d, J=2.2 Hz, 1H), 7.93(d, J=2.2 Hz, 1H), 7.76 (dt, J=8.4, 6.4 Hz, 1H), 7.64 (s, 1H), 7.63-7.54(m, 1H), 7.38 (s, 1H), 7.22 (dt, J=8.4, 2.4 Hz, 1H), 6.74 (s, 2H),4.83-4.67 (m, 1H), 3.65 (s, 3H), 3.38-3.28 (m, 1H), 3.25 (s, 3H), 2.75(s, 3H), 1.88-1.70 (m, 6H), 1.69-1.55 (m, 2H).

MS (ESI+) m/z 586.2 [M+H]⁺.

Example 19:N-(5-(2-amino-8-((2,2-dimethyltetrahydro-2H-pyran-4-yl)oxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(19)

Step 1: Preparation of6-bromo-2-(2,5-dimethyl-1H-pyrrol-1-yl)-8-((2,2-dimethyltetrahydro-2H-pyran-4-yl)oxy)-4-methylquinazoline(I-19)

According to the method of step 1 in Example 1, compound (I-19) wasprepared from compound (H) and 2,2-dimethyl-tetrahydro-2H-pyran-4-ol.

¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, J=1.9 Hz, 1H), 7.29 (d, J=1.9 Hz,1H), 4.85-4.76 (m, 1H), 4.03-3.95 (m, 1H), 3.80-3.70 (m, 1H), 2.91 (s,3H), 2.44 (s, 6H), 2.17-2.08 (m, 1H), 2.08-1.99 (m, 1H), 1.92-1.75 (m,2H), 1.34 (s, 3H), 1.28 (s, 3H).

Step 2: Preparation of6-bromo-8-((2,2-dimethyltetrahydro-2H-pyran-4-yl)oxy)-4-methylquinazolin-2-amine(J-19)

According to the method of step 2 in Example 1, compound (J-19) wasprepared from compound (I-19).

¹H NMR (500 MHz, DMSO-d₆) δ 7.67 (d, J=1.5 Hz, 1H), 7.36 (d, J=1.5 Hz,1H), 6.83 (s, 2H), 4.95-4.84 (m, 1H), 3.80-3.61 (m, 2H), 2.66 (s, 3H),2.06-1.94 (m, 2H), 1.54-1.39 (m, 2H), 1.24 (s, 3H), 1.21 (s, 3H).

Step 3: Preparation ofN-(5-(2-amino-8-((2,2-dimethyltetrahydro-2H-pyran-4-yl)oxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(19)

Compound (19) was prepared from compound (J-19) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 3 in Example 1.

¹H NMR (400 MHz, DMSO-d₆) δ 10.29 (s, 1H), 8.44 (d, J=2.3 Hz, 1H), 7.96(d, J=2.3 Hz, 1H), 7.76 (dt, J=8.6, 6.4 Hz, 1H), 7.65 (d, J=1.6 Hz, 1H),7.63-7.54 (m, 1H), 7.44 (d, J=1.6 Hz, 1H), 7.22 (dt, J=8.4, 2.4 Hz, 1H),6.78 (s, 2H), 5.08-4.93 (m, 1H), 3.82-3.66 (m, 2H), 3.65 (s, 3H), 2.75(s, 3H), 2.13-1.93 (m, 2H), 1.59-1.41 (m, 2H), 1.25 (s, 3H), 1.22 (s,3H).

MS (ESI+) m/z 586.2 [M+H]⁺.

Example 20:N-(5-(2-amino-4-methyl-8-((tetrahydrofuran-2-yl)methoxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(20)

Step 1: Preparation of6-bromo-2-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methyl-8-((tetrahydrofuran-2-yl)methoxy)quinazoline(I-20)

According to the method of step 1 in Example 1, compound (I-20) wasprepared from compound (H) and tetrahydrofurfuryl alcohol.

¹H NMR (400 MHz, DMSO-d₆) δ 8.03 (d, J=1.8 Hz, 1H), 7.58 (d, J=1.8 Hz,1H), 5.85 (s, 2H), 4.32-4.14 (m, 3H), 3.86-3.77 (m, 1H), 3.74-3.66 (m,1H), 2.92 (s, 3H), 2.34 (s, 6H), 2.10-1.91 (m, 2H), 1.90-1.77 (m, 2H).

Step 2: Preparation of6-bromo-4-methyl-8-((tetrahydrofuran-2-yl)methoxy)quinazolin-2-amine(J-20)

According to the method of step 2 in Example 1, compound (J-20) wasprepared from compound (I-20).

¹H NMR (400 MHz, DMSO-d₆) δ 7.66 (d, J=2.0 Hz, 1H), 7.24 (d, J=2.0 Hz,1H), 6.91 (s, 2H), 4.28-4.18 (m, 1H), 4.11-3.98 (m, 2H), 3.87-3.75 (m,1H), 3.6673-3.66 (m, 1H), 2.66 (s, 3H), 2.08-1.97 (m, 1H), 1.97-1.77 (m,2H), 1.74-1.62 (m, 1H).

Step 3: Preparation ofN-(5-(2-amino-4-methyl-8-((tetrahydrofuran-2-yl)methoxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(20)

According to the method of step 3 in Example 1, Compound (20) wasprepared from compound (J-20) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide.

¹H NMR (400 MHz, DMSO-d₆) δ 10.28 (s, 1H), 8.45 (d, J=2.3 Hz, 1H), 7.97(d, J=2.3 Hz, 1H), 7.76 (dt, J=8.6, 6.4 Hz, 1H), 7.65 (d, J=1.6 Hz, 1H),7.63-7.55 (m, 1H), 7.37 (d, J=1.6 Hz, 1H), 7.22 (dt, J=8.4, 2.0 Hz, 1H),6.85 (s, 2H), 4.32-4.22 (m, 1H), 4.20-4.08 (m, 2H), 3.87-3.79 (m, 1H),3.71 (dt, J=7.6, 6.4 Hz, 1H), 3.64 (s, 3H), 2.75 (s, 3H), 2.11-2.00 (m,1H), 2.00-1.80 (m, 2H), 1.78-1.67 (m, 1H).

MS (ESI+) m/z 558.2 [M+H]⁺.

Example 21:N-(5-(2-amino-4-methyl-8-((tetrahydrofuran-3-yl)methoxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(21)

Step 1: Preparation of6-bromo-2-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methyl-8-((tetrahydrofuran-3-yl)methoxy)quinazoline(I-21)

According to the method of step 1 in Example 1, compound (1-21) wasprepared from compound (H) and (tetrahydrofuran-3-yl) methanol.

¹H NMR (400 MHz, DMSO-d₆) δ 8.03 (d, J=1.6 Hz, 1H), 7.58 (d, J=1.6 Hz,1H), 5.85 (s, 2H), 4.23-4.08 (m, 2H), 3.88-3.75 (m, 2H), 3.69 (dd,J=14.8, 7.6 Hz, 1H), 3.62 (dd, J=8.6, 5.6 Hz, 1H), 2.92 (s, 3H),2.84-2.71 (m, 1H), 2.35 (s, 6H), 2.12-2.00 (m, 1H), 1.81-1.70 (m, 1H).

Step 2: Preparation of6-bromo-4-methyl-8-((tetrahydrofuran-3-yl)methoxy)quinazolin-2-amine(J-21)

According to the method of step 2 in Example 1, compound (J-21) wasprepared from compound (I-21).

¹H NMR (400 MHz, DMSO-d₆) δ 7.67 (d, J=2.0 Hz, 1H), 7.26 (d, J=2.0 Hz,1H), 6.86 (s, 2H), 4.08-3.95 (m, 2H), 3.84-3.74 (m, 2H), 3.67 (dt,J=8.0, 6.6 Hz, 1H), 3.59 (dd, J=8.6, 5.0 Hz, 1H), 2.78-2.68 (m, 1H),2.66 (s, 3H), 2.09-1.98 (m, 1H), 1.75-1.65 (m, 1H).

Step 3: Preparation ofN-(5-(2-amino-4-methyl-8-((tetrahydrofuran-3-yl)methoxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(21)

According to the method of step 3 in Example 1, Compound (21) wasprepared from compound (J-21) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide.

¹H NMR (400 MHz, DMSO-d₆) δ 10.27 (s, 1H), 8.45 (d, J=2.2 Hz, 1H), 7.97(d, J=2.2 Hz, 1H), 7.75 (dt, J=8.4, 6.4 Hz, 1H), 7.66 (d, J=1.2 Hz, 1H),7.63-7.54 (m, 1H), 7.38 (d, J=1.2 Hz, 1H), 7.21 (dt, J=8.4, 2.2 Hz, 1H),6.80 (s, 2H), 4.19-4.03 (m, 2H), 3.85-3.77 (m, 2H), 3.73-3.60 (m, 5H),2.85-2.70 (m, 4H), 2.12-1.99 (m, 1H), 1.79-1.69 (m, 1H).

MS (ESI+) m/z 558.2 [M+H]⁺.

Example 22:N-(5-(2-amino-8-(cyclohexyloxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(22)

Step 1: Preparation of6-bromo-8-(cyclohexyloxy)-2-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methylquinazoline(I-22)

A mixture of compound (H) (1.661 g, 5 mmol), cyclohexyl bromide (8.15 g,50 mmol), and potassium carbonate (6.91 g, 50 mmol) in acetonitrile (40mL) in a sealed tube was refluxed overnight. The reaction mixture wascooled to r.t. and then filtered. Silica gel (5 g) was added to thefiltrate, and the resulting mixture was evaporated to dry under reducedpressure. The residue was purified by flash column chromatography(silica gel, PE/EtOAc=100:1, v/v) to afford the product (I-22) as ayellow oil (1.7 g, 82% yield).

¹H NMR (500 MHz, DMSO-d₆) δ 8.00 (d, J=2.0 Hz, 1H), 7.61 (d, J=2.0 Hz,1H), 5.85 (s, 2H), 4.79-4.72 (m, 1H), 2.91 (s, 3H), 2.35 (s, 6H),1.95-1.86 (m, 2H), 1.79-1.70 (m, 2H), 1.69-1.57 (m, 2H), 1.56-1.31 (m,4H).

Step 2: Preparation of6-bromo-8-(cyclohexyloxy)-4-methylquinazolin-2-amine (J-22)

According to the method of step 2 in Example 1, compound (J-22) wasprepared from compound (I-22).

¹H NMR (400 MHz, DMSO-d₆) δ 7.64 (d, J=2.0 Hz, 1H), 7.25 (d, J=2.0 Hz,1H), 6.83 (s, 2H), 4.58-4.45 (m, 1H), 2.65 (s, 3H), 2.04-1.95 (m, 2H),1.82-1.67 (m, 2H), 1.65-1.27 (m, 6H).

Step 3: Preparation ofN-(5-(2-amino-8-(cyclohexyloxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(22)

According to the method of step 3 in Example 1, Compound (22) wasprepared from compound (J-22) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide.

¹H NMR (400 MHz, DMSO-d₆) δ 10.28 (s, 1H), 8.42 (d, J=2.3 Hz, 1H), 7.93(d, J=2.3 Hz, 1H), 7.76 (dt, J=8.4, 6.4 Hz, 1H), 7.63 (d, J=1.6 Hz, 1H),7.62-7.56 (m, 1H), 7.36 (d, J=1.4 Hz, 1H), 7.22 (dt, J=8.4, 2.0 Hz, 1H),6.76 (s, 2H), 4.70-4.60 (m, 1H), 3.65 (s, 3H), 2.74 (s, 3H), 2.09-1.97(m, 2H), 1.85-1.71 (m, 2H), 1.66-1.30 (m, 6H).

MS (ESI+) m/z 556.2 [M+H]⁺.

Example 23:N-(5-(2-amino-8-(cyclopentyloxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(23)

Step 1: Preparation of6-bromo-8-(cyclopentyloxy)-2-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methylquinazoline(I-23)

According to the method of step 1 in Example 22, compound (I-23) wasprepared from compound (H) and cyclopentyl bromide.

¹H NMR (500 MHz, DMSO-d₆) δ 8.00 (d, J=1.5 Hz, 1H), 7.53 (d, J=1.5 Hz,1H), 5.85 (s, 2H), 5.18-5.09 (m, 1H), 2.91 (s, 3H), 2.34 (s, 6H),2.03-1.92 (m, 2H), 1.89-1.80 (m, 2H), 1.80-1.70 (m, 2H), 1.69-1.58 (m,2H).

Step 2: Preparation of6-bromo-8-(cyclopentyloxy)-4-methylquinazolin-2-amine (J-23)

According to the method of step 2 in Example 1, compound (J-23) wasprepared from compound (I-23).

¹H NMR (400 MHz, DMSO-d₆) δ 7.64 (d, J=2.0 Hz, 1H), 7.16 (d, J=2.0 Hz,1H), 6.83 (s, 2H), 5.00-4.94 (m, 1H), 2.65 (s, 3H), 2.04-1.91 (m, 2H),1.80-1.68 (m, 4H), 1.66-1.53 (m, 2H).

Step 3: Preparation ofN-(5-(2-amino-8-(cyclopentyloxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(23)

According to the method of step 3 in Example 1, Compound (23) wasprepared from compound (J-23) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,¹H NMR (400 MHz, DMSO-d₆) δ 10.30 (s, 1H), 8.43 (d, J=2.4 Hz, 1H), 7.93(d, J=2.4 Hz, 1H), 7.77 (dt, J=8.4, 6.4 Hz, 1H), 7.63 (d, J=1.8 Hz, 1H),7.63-7.56 (m, 1H), 7.27 (d, J=1.6 Hz, 1H), 7.22 (dt, J=8.4, 2.2 Hz, 1H),6.79 (s, 2H), 5.14-5.08 (m, 1H), 3.66 (s, 3H), 2.75 (s, 3H), 2.10-1.93(m, 2H), 1.88-1.69 (m, 4H), 1.69-1.51 (m, 2H).

MS (ESI+) m/z 542.2 [M+H]⁺.

Example 24:N-(5-(2-amino-8-cyclobutoxy-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(24)

Step 1: Preparation of6-bromo-8-cyclobutoxy-2-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methylquinazoline(I-24)

According to the method of step 1 in Example 22, compound (I-24) wasprepared from compound (H) and cyclobutyl bromide.

¹H NMR (400 MHz, DMSO-d₆) δ 8.02 (d, J=1.9 Hz, 1H), 7.35 (d, J=1.9 Hz,1H), 5.85 (s, 2H), 4.98 (p, J=7.0 Hz, 1H), 2.91 (s, 3H), 2.60-2.51 (m,2H), 2.33 (s, 6H), 2.19-2.05 (m, 2H), 1.92-1.77 (m, 1H), 1.77-1.64 (m,1H).

Step 2: Preparation of 6-bromo-8-cyclobutoxy-4-methylquinazolin-2-amine(J-24)

According to the method of step 2 in Example 1, compound (J-24) wasprepared from compound (I-24).

¹H NMR (400 MHz, DMSO-d₆) δ 7.65 (d, J=2.0 Hz, 1H), 7.00 (d, J=2.0 Hz,1H), 6.89 (s, 2H), 4.81 (p, J=7.0 Hz, 1H), 2.65 (s, 3H), 2.49-2.42 (m,2H), 2.16-2.00 (m, 2H), 1.89-1.57 (m, 2H).

Step 3: Preparation ofN-(5-(2-amino-8-cyclobutoxy-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(24)

According to the method of step 3 in Example 1, Compound (24) wasprepared from compound (J-24) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,

¹H NMR (400 MHz, DMSO-d₆) δ 10.30 (s, 1H), 8.42 (d, J=2.3 Hz, 1H), 7.92(d, J=2.3 Hz, 1H), 7.77 (dt, J=8.6, 6.4 Hz, 1H), 7.64 (d, J=1.6 Hz, 1H),7.63-7.55 (m, 1H), 7.23 (dt, J=8.6, 2.4 Hz, 1H), 7.12 (d, J=1.6 Hz, 1H),6.84 (s, 2H), 4.94 (p, J=7.2 Hz, 1H), 3.66 (s, 3H), 2.75 (s, 3H),2.55-2.46 (m, 2H), 2.19-2.06 (m, 2H), 1.89-1.62 (m, 2H).

MS (ESI+) m/z 528.1 [M+H]⁺.

Example 25: Preparation ofN-(5-(2-amino-8-(2-methoxyethoxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(25)

Step 1: Preparation of6-bromo-2-(2,5-dimethyl-1H-pyrrol-1-yl)-8-(2-methoxyethoxy)-4-methylquinazoline(I-25)

According to the method of step 1 in Example 22, compound (I-25) wasprepared from compound (H) and 2-chloroethyl methyl ether.

¹H NMR (400 MHz, DMSO-d₆) δ 7.80 (d, J=1.9 Hz, 1H), 7.31 (d, J=1.9 Hz,1H), 5.90 (s, 2H), 4.33 (t J=4.8 Hz, 2H), 3.90 (t, J=4.8 Hz, 3H), 3.48(s, 3H), 2.91 (s, 3H), 2.43 (s, 6H).

Step 2: Preparation of6-bromo-8-(2-methoxyethoxy)-4-methylquinazolin-2-amine (J-25)

According to the method of step 2 in Example 1, compound (J-25) wasprepared from compound (I-25).

¹H NMR (400 MHz, DMSO-d₆) δ 7.67 (d, J=1.8 Hz, 1H), 7.23 (d, J=1.8 Hz,1H), 6.90 (s, 2H), 4.21 (t, J=4.4 Hz, 2H), 3.90 (t, J=4.4 Hz, 3H), 3.32(s, 3H), 2.66 (s, 3H).

Step 3: Preparation ofN-(5-(2-amino-8-(2-methoxyethoxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(25)

According to the method of step 3 in Example 1, Compound (25) wasprepared from compound (J-25) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,

¹H NMR (400 MHz, DMSO-d₆) δ 10.32 (br s, 1H), 8.43 (s, 1H), 7.95 (s,1H), 7.76 (dt, J=8.5, 6.6 Hz, 1H), 7.64 (d, J=1.4 Hz, 1H), 7.63-7.55 (m,1H), 7.34 (d, J=1.4 Hz, 1H), 7.22 (dt, J=8.4, 2.4 Hz, 1H), 6.87 (s, 2H),4.35-4.28 (m, 2H), 3.79-3.73 (m, 2H), 3.64 (s, 3H), 3.35 (s, 3H), 2.75(s, 3H).

MS (ESI+) m/z 532.1 [M+H]⁺.

Example 26:N-(5-(2-amino-8-isopropoxy-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(26)

Step 1: Preparation of6-bromo-2-(2,5-dimethyl-1H-pyrrol-1-yl)-8-(2-methoxyethoxy)-4-methylquinazoline(I-26)

According to the method of step 1 in Example 22, compound (I-26) wasprepared from compound (H) and isopropyl bromide.

¹H NMR (400 MHz, DMSO-d₆) δ 8.02 (d, J=1.8 Hz, 1H), 7.59 (d, J=1.8 Hz,1H), 5.85 (s, 2H), 4.98-4.88 (m, 1H), 2.92 (s, 3H), 2.34 (s, 6H), 1.36(d, J=6.0 Hz, 6H).

Step 2: Preparation of 6-bromo-8-isopropoxy-4-methylquinazolin-2-amine(J-26)

According to the method of step 2 in Example 22, compound (J-26) wasprepared from compound (I-26).

¹H NMR (400 MHz, DMSO-d₆) δ 7.64 (d, J=2.0 Hz, 1H), 7.22 (d, J=2.0 Hz,1H), 6.84 (s, 2H), 4.86-4.75 (m, 1H), 2.65 (s, 3H), 1.31 (d, J=6.0 Hz,6H).

Step 3: Preparation ofN-(5-(2-amino-8-isopropoxy-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(26)

According to the method of step 3 in Example 1, Compound (26) wasprepared from compound (J-26) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,

¹H NMR (400 MHz, DMSO-d₆) δ 10.30 (s, 1H), 8.44 (d, J=2.3 Hz, 1H), 7.94(d, J=2.3 Hz, 1H), 7.76 (dt, J=8.6, 6.4 Hz, 1H), 7.64 (d, J=1.6 Hz, 1H),7.63-7.56 (m, 1H), 7.33 (s, 1H), 7.22 (dt, J=8.4, 2.0 Hz, 1H), 6.83 (s,2H), 5.00-4.89 (m, 1H), 3.64 (s, 3H), 2.75 (s, 3H), 1.34 (d, J=6.0 Hz,6H).

MS (ESI+) m/z 516.1 [M+H]⁺.

Example 27:N-(5-(2-amino-8-(cyclopropylmethoxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(27)

Step 1: Preparation of6-bromo-8-(cyclopropylmethoxy)-2-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methylquinazoline(I-27)

According to the method of step 1 in Example 22, compound (I-27) wasprepared from compound (H) and cyclopropylmethylbromide.

¹H NMR (400 MHz, DMSO-d₆) δ 7.64 (d, J=1.8 Hz, 1H), 7.14 (d, J=1.8 Hz,1H), 6.91 (s, 2H), 3.90 (d, J=7.2 Hz, 2H), 2.65 (s, 3H), 1.33-1.23 (m,1H), 0.65-0.55 (m, 2H), 0.35 (q, J=4.8 Hz, 2H).

Step 2: Preparation of6-bromo-8-(cyclopropylmethoxy)-4-methylquinazolin-2-amine (J-27)

According to the method of step 2 in Example 22, compound (J-27) wasprepared from compound (I-27).

¹H NMR (400 MHz, DMSO-d₆) δ 7.64 (d, J=1.8 Hz, 1H), 7.14 (d, J=1.8 Hz,1H), 6.91 (s, 2H), 3.90 (d, J=7.2 Hz, 2H), 2.65 (s, 3H), 1.33-1.23 (m,1H), 0.65-0.55 (m, 2H), 0.35 (q, J=4.8 Hz, 2H).

Step 3: Preparation ofN-(5-(2-amino-8-(cyclopropylmethoxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(27)

Compound (27) was prepared from compound (J-27) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 3 in Example 1.

¹H NMR (400 MHz, DMSO-d₆) δ 10.27 (s, 1H), 8.43 (d, J=2.2 Hz, 1H), 7.94(d, J=2.2 Hz, 1H), 7.75 (dt, J=8.6, 6.4 Hz, 1H), 7.63 (d, J=1.6 Hz, 1H),7.62-7.55 (m, 1H), 7.27 (d, J=1.6 Hz, 1H), 7.24-7.18 (m, 1H), 6.85 (brs, 2H), 4.00 (d, J=7.0 Hz, 2H), 3.63 (s, 3H), 2.75 (s, 3H), 1.37-1.27(m, 1H), 0.67-0.57 (m, 2H), 0.40-0.33 (m, 2H).

MS (ESI+) m/z 528.1 [M+H]⁺.

Example 28: Preparation ofN-(5-(2-amino-8-methoxy-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(28)

Compound (28) was prepared from compound (F) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 3 in Example 1.

¹H NMR (400 MHz, DMSO-d₆) δ 10.28 (s, 1H), 8.46 (d, J=2.4 Hz, 1H), 7.97(d, J=2.4 Hz, 1H), 7.76 (dt, J=8.6, 6.4 Hz, 1H), 7.65 (d, J=1.7 Hz, 1H),7.63-7.55 (m, 1H), 7.31 (d, J=1.7 Hz, 1H), 7.26-7.18 (m, 1H), 6.83 (s,2H), 3.95 (s, 3H), 3.64 (s, 3H), 2.76 (s, 3H).

MS (ESI+) m/z 488.1 [M+H]⁺.

Example 29:N-(2-methoxy-5-(4-methyl-2-(methylamino)-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(29)

Step 1: Preparation of6-bromo-N,4-dimethyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-2-amine(K-1)

To a solution of compound (J-1) (517 mg) in DMF (50 mL) at 0° C. wasadded NaH (60% dispersion in mineral oil, 153 mg, 3.82 mmol). Theresulting reaction mixture was stirred at 0° C. for 30 min, and thenmethyl iodide (217 mg, 1.53 mmol) was added. The resulting reactionmixture was stirred at r.t. for 3 h. The mixture was diluted with water(250 mL), neutralized with 2 M HCl, and extracted with EtOAc (50 mL×3).The combined organic layers were washed with water (50 mL×2) and brine(50 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated. Theresidue was purified by flash column chromatography (silica gel,DCM/EtOAc=4:1, v/v) to afford the product (K-1) as a yellow solid (113mg, 21%).

¹H NMR (400 MHz, DMSO-d₆) δ 7.74 (d, J=1.8 Hz, 1H), 7.39 (d, J=1.8 Hz,1H), 7.34 (q, J=4.8 Hz, 1H), 4.94-4.76 (m, 1H), 3.99-3.82 (m, 2H),3.53-3.43 (m, 2H), 2.88 (d, J=4.8 Hz, 3H), 2.66 (s, 3H), 2.06-1.88 (m,2H), 1.77-1.57 (m, 2H).

Step 2:N-(2-methoxy-5-(4-methyl-2-(methylamino)-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(29)

A mixture of compound (K-1) (35 mg, 0.1 mmol),N-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(51 mg, 0.12 mmol) and 2M aqueous potassium carbonate solution (0.15 mL,0.63 mmol) in dioxane (7 mL) was degassed and then PdCl₂(dppf) (8 mg,0.01 mmol) was added. The resulting reaction mixture was degassed andback-filled with argon (three cycles), and then stirred at 100° C. underAr atmosphere for 5 h. The reaction mixture was cooled to r.t., dilutedwith EtOAc (30 mL) and water (30 mL), acidified with hydrochloric aciduntil the pH value was 5-6. The two phases were separated and theaqueous layer was extracted with EtOAc (30 mL×2). The combined organiclayers were washed with water (50 mL) and brine (50 mL), dried overanhydrous Na₂SO₄, filtered and concentrated. The residue was purified bycolumn chromatography (silica gel, DCM/MeOH=20:1, v/v) to afford theproduct (29) as a yellow solid (40 mg, 70% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 10.28 (s, 1H), 8.42 (d, J=2.0 Hz, 1H), 7.93(d, J=2.0 Hz, 1H), 7.83-7.66 (m, 2H), 7.63-7.53 (m, 1H), 7.50 (s, 1H),7.28 (q, J=4.0 Hz, 1H), 7.21 (dt, J=8.4, 2.0 Hz, 1H), 4.97-4.88 (m 1H),4.01-3.88 (m, 2H), 3.64 (s, 3H), 3.53-3.44 (m, 2H), 2.91 (d, J=4.4 Hz,3H), 2.76 (s, 3H), 2.08-1.90 (m, 2H), 1.81-1.63 (m, 2H).

MS (ESI+) m/z 572.2 [M+H]⁺.

Example 30:N-(5-(2-(ethylamino)-4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(30)

Step 1: Preparation of6-bromo-N-ethyl-4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-2-amine(K-2)

According to the method of step 1 in Example 29, compound (K-2) wasprepared from compound (J-1) and iodoethane.

¹H NMR (400 MHz, DMSO-d₆) δ 7.73 (d, J=1.6 Hz, 1H), 7.41 (br s, 1H),7.38 (d, J=1.6 Hz, 1H), 4.90-4.78 (m, 1H), 3.98-3.82 (m, 2H), 3.52-3.43(m, 2H), 3.43-3.33 (m, 2H), 2.66 (s, 3H), 2.02-1.90 (m, 2H), 1.73-1.61(m, 2H), 1.17 (t, J=7.2 Hz, 3H).

Step 2: Preparation ofN-(5-(2-(ethylamino)-4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(30)

Compound (30) was prepared from compound (K-2) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 29.

¹H NMR (400 MHz, DMSO-d₆) δ 10.28 (s, 1H), 8.42 (d, J=2.1 Hz, 1H), 7.93(d, J=2.3 Hz, 1H), 7.80-7.69 (m, 2H), 7.59 (ddd, J=10.4, 9.6, 2.4 Hz,1H), 7.49 (d, J=1.2 Hz, 1H), 7.35 (t, J=5.0 Hz, 1H), 7.26-7.16 (m, 1H),4.95-4.87 (m, 1H), 3.98-3.89 (m, 2H), 3.64 (s, 3H), 3.52-3.36 (m, 4H),2.75 (s, 3H), 2.05-1.92 (m, 2H), 1.80-1.63 (m, 2H), 1.19 (t, J=7.1 Hz,3H).

MS (ESI+) m/z 586.2 [M+H]⁺.

Example 31:N-(5-(2-((cyclopropylmethyl)amino)-4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(31)

Step 1: Preparation of6-bromo-N-(cyclopropylmethyl)-4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-2-amine(K-3)

According to the method of step 1 in Example 29, compound (K-3) wasprepared from compound (J-1) and cyclopropylmethyl bromide.

¹H NMR (400 MHz, DMSO-d₆) δ 7.73 (s, 1H), 7.51 (br s, 1H), 7.37 (d,J=1.7 Hz, 1H), 4.88-4.78 (m, 1H), 3.95-3.83 (m, 2H), 3.55-3.39 (m, 2H),3.24 (t, J=6.3 Hz, 2H), 2.66 (s, 3H), 2.03-1.91 (m, 2H), 1.74-1.59 (m,2H), 1.15-1.06 (m, 1H), 0.45-0.35 (m, 2H), 0.27 (q, J=4.4 Hz, 2H).

Step 2: Preparation ofN-(5-(2-((cyclopropylmethyl)amino)-4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(31)

Compound (31) was prepared from compound (K-3) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 29.

¹H NMR (400 MHz, DMSO-d₆) δ 10.28 (s, 1H), 8.43 (d, J=2.4 Hz, 1H), 7.94(d, J=2.4 Hz, 1H), 7.80-7.70 (m, 2H), 7.63-7.55 (m, 1H), 7.48 (d, J=1.2Hz, 1H), 7.45 (br s, 1H), 7.22 (dt, J=8.4, 2.0 Hz, 1H), 4.96-4.86 (m,1H), 4.00-3.89 (m, 2H), 3.64 (s, 3H), 3.54-3.42 (m, 2H), 3.28 (t, J=6.4Hz, 2H), 2.76 (s, 3H), 2.06-1.94 (m, 2H), 1.80-1.63 (m, 2H), 1.21-1.05(m, 1H), 0.50-0.38 (m, 2H), 0.29 (q, J=4.8 Hz, 2H).

MS (ESI+) m/z 612.2 [M+H]⁺.

Example 32:(R)-N-(2-methoxy-5-(4-methyl-2-(methylamino)-8-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(32)

Step 1: Preparation of(R)-6-bromo-N,4-dimethyl-8-((tetrahydrofuran-3-yl)oxy)quinazolin-2-amine(K-4)

According to the method of step 1 in Example 29, compound (K-4) wasprepared from compound (J-9).

¹H NMR (400 MHz, DMSO-d₆) δ 7.72 (d, J=2.0 Hz, 1H), 7.34 (q, J=4.8 Hz,1H), 7.25 (s, 1H), 5.32-5.22 (m, 1H), 3.96-3.86 (m, 3H), 3.81-3.73 (m,1H), 2.87 (d, J=4.8 Hz, 3H), 2.66 (s, 3H), 2.28-2.15 (m, 1H), 2.11-1.98(m, 1H).

Step 2:(R)-N-(2-methoxy-5-(4-methyl-2-(methylamino)-8-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)pyridin-3-yl)-2,4-dinuorobenzenesulfonamide(32)

Compound (32) was prepared from compound (K-4) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 29.

¹H NMR (400 MHz, DMSO-d₆) δ 10.28 (s, 1H), 8.44 (d, J=2.2 Hz, 1H), 7.96(d, J=2.2 Hz, 1H), 7.80-7.70 (m, 2H), 7.63-7.54 (m, 1H), 7.38 (s, 1H),7.29 (q, J=4.8 Hz, 1H), 7.25-7.17 (m, 1H), 5.43-5.36 (m, 1H), 4.00-3.89(m, 3H), 3.83-3.76 (m, 1H), 3.64 (s, 3H), 2.91 (d, J=4.8 Hz, 3H), 2.76(s, 3H), 2.28-2.15 (m, 1H), 2.15-2.02 (m, 1H).

MS (ESI+) m/z 558.2 [M+H]⁺.

Example 33:(R)-N-(2-methoxy-5-(4-methyl-2-(methylamino)-8-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)pyridin-3-yl)-2-chloro-4-fluorobenzenesulfonamide(33)

Compound (33) was prepared from compound (K-4) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2-chloro-4-fluorobenzenesulfonamide,according to the method of step 2 in Example 29.

¹H NMR (400 MHz, DMSO-d₆) δ 10.17 (s, 1H), 8.42 (d, J=2.4 Hz, 1H), 7.94(dd, J=8.8, 6.0 Hz, 1H), 7.90 (d, J=2.4 Hz, 1H), 7.76 (dd, J=8.8, 2.6Hz, 1H), 7.69 (d, J=1.6 Hz, 1H), 7.40-7.32 (m, 2H), 7.29 (q, J=4.8 Hz,1H), 5.42-5.35 (m, 1H), 4.00-3.89 (m, 3H), 3.79 (dt, J=8.0, 4.4 Hz, 1H),3.66 (s, 3H), 2.90 (d, J=4.8 Hz, 3H), 2.75 (s, 3H), 2.28-2.15 (m, 1H),2.14-2.04 (m, 1H).

MS (ESI+) m/z 574.1 [M+H]⁺.

Example 34:(R)-N-(2-methoxy-5-(4-methyl-2-(methylamino)-8-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)pyridin-3-yl)-5-chlorothiophene-2-sulfonamide(34)

Compound (34) was prepared from compound (K-4) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-5-chlorothiophene-2-sulfonamide,according to the method of step 2 in Example 29.

¹H NMR (400 MHz, DMSO-d₆) δ 10.33 (s, 1H), 8.48 (d, J=2.4 Hz, 1H), 7.96(d, J=2.4 Hz, 1H), 7.73 (d, J=1.6 Hz, 1H), 7.42-7.38 (m, 2H), 7.29 (t,J=4.8 Hz, 1H), 7.25 (d, J=4.4 Hz, 1H), 5.43-5.36 (m, 1H), 4.00-3.90 (m,3H), 3.80 (dt, J=8.0, 4.4 Hz, 1H), 3.75 (s, 3H), 2.91 (d, J=4.8 Hz, 3H),2.77 (s, 3H), 2.30-2.16 (m, 1H), 2.15-2.05 (m, 1H).

Example 35:(S)-N-(2-methoxy-5-(4-methyl-2-(methylamino)-8-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(35)

Step 1: Preparation of(S)-6-bromo-N,4-dimethyl-8-((tetrahydrofuran-3-yl)oxy)quinazolin-2-amine(K-7)

According to the method of step 1 in Example 29, compound (K-7) wasprepared from compound (J-11).

¹H NMR (400 MHz, DMSO-d₆) δ 7.72 (d, J=2.0 Hz, 1H), 7.34 (q, J=4.8 Hz,1H), 7.25 (s, 1H), 5.32-5.22 (m, 1H), 3.96-3.86 (m, 3H), 3.77 (dt,J=8.2, 4.6 Hz, 1H), 2.87 (d, J=4.8 Hz, 3H), 2.66 (s, 3H), 2.27-2.17 (m,1H), 2.09-1.99 (m, 1H).

Step 2: Preparation of(S)-N-(2-methoxy-5-(4-methyl-2-(methylamino)-8-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluoro-benzenesulfonamide(35)

According to the method of step 2 in Example 29, compound (35) wasprepared from compound (K-7).

¹H NMR (400 MHz, DMSO-d₆) δ 10.28 (s, 1H), 8.44 (d, J=2.4 Hz, 1H), 7.97(d, J=2.4 Hz, 1H), 7.80-7.70 (m, 2H), 7.59 (ddd, J=10.4, 9.2, 2.4 Hz,1H), 7.38 (s, 1H), 7.29 (q, J=4.8 Hz, 1H), 7.22 (dt, J=8.4, 2.4 Hz, 1H),5.43-5.36 (m, 1H), 4.03-3.87 (m, 3H), 3.79 (dt, J=8.2, 4.6 Hz, 1H), 3.64(s, 3H), 2.91 (d, J=4.8 Hz, 3H), 2.76 (s, 3H), 2.28-2.16 (m, 1H),2.15-2.04 (m, 1H).

MS (ESI+) m/z 558.2 [M+H]⁺.

Example 36:N-(2-methoxy-5-(4-methyl-2-(methylamino)-8-((tetrahydro-2H-pyran-4-yl)methoxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluoro-benzenesulfonamide(36)

Step 1: Preparation of6-bromo-N,4-dimethyl-8-((tetrahydro-2H-pyran-4-yl)methoxy)quinazolin-2-amine(K-8)

According to the method of step 1 in Example 29, compound (K-8) wasprepared from compound (J-13).

¹H NMR (400 MHz, DMSO-d₆) δ 7.66 (d, J=2.0 Hz, 1H), 7.28 (q, J=4.8 Hz,1H), 7.24 (d, J=1.4 Hz, 1H), 3.98 (d, J=6.8 Hz, 2H), 3.94-3.84 (m, 2H),3.35 (dt, J=11.6, 2.0 Hz, 2H), 2.87 (d, J=4.8 Hz, 3H), 2.66 (s, 3H),2.16-2.02 (m, 1H), 1.80-1.71 (m, 2H), 1.39 (qd, J=12.4, 4.4 Hz, 2H).

Step 2: Preparation ofN-(2-methoxy-5-(4-methyl-2-(methylamino)-8-((tetrahydro-2H-pyran-4-yl)methoxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(36)

Compound (36) was prepared from compound (K-8) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 29.

¹H NMR (400 MHz, DMSO-d₆) δ 10.27 (s, 1H), 8.44 (d, J=2.0 Hz, 1H), 7.95(d, J=2.0 Hz, 1H), 7.76 (dt, J=8.6, 6.3 Hz, 1H), 7.65 (d, J=1.6 Hz, 1H),7.63-7.54 (m, 1H), 7.37 (s, 1H), 7.28-7.17 (m, 2H), 4.08 (d, J=6.4 Hz,2H), 3.95-3.87 (m, 2H), 3.64 (s, 3H), 3.37 (dt, J=11.6, 2.0 Hz, 2H),2.90 (d, J=4.8 Hz, 3H), 2.75 (s, 3H), 2.19-2.05 (m, 1H), 1.85-1.74 (m,2H), 1.49-1.35 (m, 2H).

MS (ESI+) m/z 586.2 [M+H]⁺.

Example 37:N-(5-(8-((2,2-dimethyltetrahydro-2H-pyran-4-yl)oxy)-4-methyl-2-(methylamino)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(37)

Step 1: Preparation of6-bromo-8-((2,2-dimethyltetrahydro-2H-pyran-4-yl)oxy)-N,4-dimethylquinazolin-2-amine(K-9)

According to the method of step 1 in Example 29, compound (K-9) wasprepared from compound (J-19).

¹H NMR (400 MHz, DMSO-d₆) δ 7.72 (d, J=2.0 Hz, 1H), 7.35 (d, J=2.0 Hz,1H), 7.32 (q, J=4.8 Hz, 1H), 5.04-4.92 (m, 1H), 3.78 (dt, J=12.0, 4.4Hz, 1H), 3.58 (t, J=10.0 Hz, 1H), 2.87 (d, J=4.8 Hz, 3H), 2.66 (s, 3H),2.01-1.83 (m, 2H), 1.67-1.43 (m, 2H), 1.29 (s, 3H), 1.17 (s, 3H).

Step 2: Preparation ofN-(5-(8-((2,2-dimethyltetrahydro-2H-pyran-4-yl)oxy)-4-methyl-2-(methylamino)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(37)

Compound (37) was prepared from compound (K-9) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 29.

¹H NMR (400 MHz, DMSO-d₆) δ 10.28 (s, 1H), 8.43 (d, J=2.4 Hz, 1H), 7.94(d, J=2.4 Hz, 1H), 7.79-7.71 (m, 2H), 7.59 (ddd, J=10.4, 9.2, 2.4 Hz,1H), 7.46 (d, J=1.8 Hz, 1H), 7.27 (q, J=4.8 Hz, 1H), 7.25-7.18 (m, 1H),5.16-4.97 (m, 1H), 3.85-3.76 (m, 1H), 3.64 (s, 3H), 3.62-3.53 (m, 1H),2.90 (d, J=4.8 Hz, 3H), 2.76 (s, 3H), 2.04-1.91 (m, 2H), 1.66-1.50 (m,2H), 1.29 (s, 3H), 1.18 (s, 3H).

MS (ESI+) m/z 600.2 [M+H]⁺.

Example 38:N-(2-methoxy-5-(4-methyl-2-(methylamino)-8-((tetrahydrofuran-3-yl)methoxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(38)

Step 1: Preparation of6-bromo-N,4-dimethyl-8-((tetrahydrofuran-3-yl)methoxy)quinazolin-2-amine(K-10)

According to the method of step 1 in Example 29, compound (K-10) wasprepared from compound (J-21).

¹H NMR (400 MHz, DMSO-d₆) δ 7.68 (d, J=2.0 Hz, 1H), 7.30 (d, J=4.8 Hz,1H), 7.28 (d, J=1.7 Hz, 1H), 4.18-4.07 (m, 1H), 4.07-3.96 (m, 1H),3.87-3.76 (m, 2H), 3.74-3.58 (m, 2H), 2.87 (d, J=4.8 Hz, 3H), 2.78-2.68(m, 1H), 2.66 (s, 3H), 2.10-1.96 (m, 1H), 1.82-1.68 (m, 1H).

Step 2: Preparation ofN-(2-methoxy-5-(4-methyl-2-(methylamino)-8-((tetrahydrofuran-3-yl)methoxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(38)

According to the method of step 2 in Example 29, Compound (38) wasprepared from compound (K-10).

¹H NMR (400 MHz, DMSO-d₆) δ 10.27 (s, 1H), 8.44 (d, J=2.1 Hz, 1H), 7.96(d, J=2.2 Hz, 1H), 7.75 (dt, J=8.6, 6.4 Hz, 1H), 7.68 (d, J=1.6 Hz, 1H),7.63-7.53 (m, 1H), 7.41 (s, 1H), 7.28-7.16 (m, 2H), 4.26-4.16 (m, 1H),4.11 (dd, J=9.2, 8.0 Hz, 1H), 3.89-3.79 (m, 2H), 3.70 (dt, J=8.0, 6.4Hz, 2H), 3.63 (s, 3H), 2.90 (d, J=4.8 Hz, 3H), 2.82-2.70 (m, 4H),2.12-2.00 (m, 1H), 1.85-1.72 (m, 1H).

MS (ESI+) m/z 572.2 [M+H]⁺.

Example 39:N-(5-(8-(cyclohexyloxy)-4-methyl-2-(methylamino)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(39)

Step 1: Preparation of6-bromo-8-(cyclohexyloxy)-N4-dimethylquinazolin-2-amine (K-11)

According to the method of step 1 in Example 29, compound (K-11) wasprepared from compound (J-22).

¹H NMR (400 MHz, DMSO-d₆) δ 7.70 (d, J=2.0 Hz, 1H), 7.34-7.25 (m, 2H),4.69-4.54 (m, 1H), 2.87 (d, J=4.8 Hz, 3H), 2.66 (s, 3H), 1.98-1.86 (m,2H), 1.82-1.71 (m, 2H), 1.61-1.45 (m, 3H), 1.41-1.27 (m, 3H).

Step 2: Preparation ofN-(5-(8-(cyclohexyloxy)-4-methyl-2-(methylamino)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(39)

Compound (39) was prepared from compound (K-11) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 29.

¹H NMR (400 MHz, DMSO-d₆) δ 10.28 (s, 1H), 8.42 (d, J=2.4 Hz, 1H), 7.92(d, J=2.4 Hz, 1H), 7.76 (dt, J=8.6, 6.4 Hz, 1H), 7.70 (d, J=1.2 Hz, 1H),7.59 (ddd, J=10.4, 9.2, 2.4 Hz, 1H), 7.41 (d, J=1.2 Hz, 1H), 7.28-7.18(m, 2H), 4.76-4.66 (m, 1H), 3.65 (s, 3H), 2.91 (d, J=4.8 Hz, 3H), 2.75(s, 3H), 2.04-1.91 (m, 2H), 1.88-1.73 (m, 2H), 1.67-1.47 (m, 3H),1.39-1.27 (m, 3H).

MS (ESI+) m/z 570.2 [M+H]⁺.

Example 40:N-(5-(8-(cyclopentyloxy)-4-methyl-2-(methylamino)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(40)

Step 1: Preparation of6-bromo-8-(cyclopentyloxy)-N4-dimethylquinazolin-2-amine (K-12)

According to the method of step 1 in Example 29, compound (K-12) wasprepared from compound (J-23).

¹H NMR (400 MHz, DMSO-d₆) δ 7.66 (d, J=2.0 Hz, 1H), 7.27 (q, J=4.8 Hz,1H), 7.20 (s, 1H), 5.11-4.98 (m, 1H), 2.87 (d, J=4.8 Hz, 3H), 2.66 (s,3H), 1.98-1.85 (m, 2H), 1.84-1.68 (m, 4H), 1.68-1.53 (m, 2H).

Step 2: Preparation ofN-(5-(8-(cyclopentyloxy)-4-methyl-2-(methylamino)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(40)

According to the method of step 2 in Example 29, compound (40) wasprepared from compound (K-12).

¹H NMR (400 MHz, DMSO-d₆) δ 10.28 (s, 1H), 8.43 (d, J=2.4 Hz, 1H), 7.92(d, J=2.4 Hz, 1H), 7.76 (dt, J=8.6, 6.4 Hz, 1H), 7.67 (d, J=1.6 Hz, 1H),7.64-7.55 (m, 1H), 7.32 (s, 1H), 7.27-7.17 (m, 2H), 5.20-5.13 (m, 1H),3.65 (s, 3H), 2.90 (d, J=4.8 Hz, 3H), 2.75 (s, 3H), 1.99-1.87 (m, 2H),1.87-1.75 (m, 4H), 1.69-1.55 (m, 2H).

MS (ESI+) m/z 556.2 [M+H]⁺.

Example 41:N-(5-(8-cyclobutoxy-4-methyl-2-(methylamino)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(41)

Step 1: 6-bromo-8-cyclobutoxy-N,4-dimethylquinazolin-2-amine (K-13)

According to the method of step 1 in Example 29, compound (K-13) wasprepared from compound (J-24).

¹H NMR (400 MHz, DMSO-d₆) δ 7.65 (d, J=2.0 Hz, 1H), 7.30 (br s, 1H),7.01 (d, J=1.6 Hz, 1H), 4.84 (p, J=7.2 Hz, 1H), 2.88 (d, J=4.8 Hz, 3H),2.65 (s, 3H), 2.49-2.42 (m, 2H), 2.19-2.03 (m, 2H), 1.89-1.75 (m, 1H),1.74-1.58 (m, 1H).

Step 2:N-(5-(8-cyclobutoxy-4-methyl-2-(methylamino)quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(41)

Compound (41) was prepared from compound (K-13) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 29.

¹H NMR (400 MHz, DMSO-d₆) δ 10.29 (s, 1H), 8.41 (d, J=2.4 Hz, 1H), 7.91(d, J=2.4 Hz, 1H), 7.77 (dt, J=8.6, 6.4 Hz, 1H), 7.59 (ddd, J=10.4, 9.2,2.4 Hz, 1H), 7.31-7.17 (m, 2H), 7.14 (d, J=1.2 Hz, 1H), 5.05-4.88 (m,1H), 3.66 (s, 3H), 2.91 (d, J=4.8 Hz, 3H), 2.75 (s, 3H), 2.55-2.45 (m,2H), 2.22-2.09 (m, 2H), 1.90-1.78 (m, 1H), 1.76-1.61 (m, 1H).

MS (ESI+) m/z: 542.2 [M+H]⁺.

Example 42:N-(6-(5-(2,4-difluorophenylsulfonamido)-6-methoxypyridin-3-yl)-4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-2-yl)acetamide(42)

Step 1: Preparation ofN-(6-bromo-4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-2-yl)acetamide(K-14)

To a mixture of compound (J-1) (338 mg, 1 mmol) and pyridine (396 mg, 5mmol) in DMF (10 mL) was added acetyl chloride (234 mg, 3 mmol) at r.t.The resulting reaction mixture was stirred at r.t. for 4 h. The reactionmixture was diluted with water (50 mL), acidified with 2M aqueous HClsolution until the pH value was 5, and then extracted with EtOAc (30mL×3). The combined organic layers were washed with water (30 mL×2) andbrine (30 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated.The residue was purified by flash column chromatography (silica gel,DCM/MeOH=70:1, v/v) to afford the product (K-14) as a yellow solid (290mg, 76%).

¹H NMR (400 MHz, DMSO-d₆) δ 10.57 (s, 1H), 7.94 (d, J=2.0 Hz, 1H), 7.61(d, J=2.0 Hz, 1H), 5.07-4.94 (m, 1H), 3.93-3.85 (m, 2H), 3.55-3.47 (m,2H), 2.81 (s, 3H), 2.34 (s, 3H), 2.09-1.93 (m, 2H), 1.74-1.58 (m, 2H).

Step 2: Preparation ofN-(6-(5-(2,4-difluorophenylsulfonamido)-6-methoxypyridin-3-yl)-4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-2-yl)acetamide(42)

Compound (42) was prepared from compound (K-14) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 3 in Example 1.

¹H NMR (400 MHz, DMSO-d₆) δ 10.55 (s, 1H), 10.32 (s, 1H), 8.52 (d, J=2.0Hz, 1H), 8.06 (d, J=2.0 Hz, 1H), 7.91 (d, J=1.0 Hz, 1H), 7.76 (dt,J=8.6, 6.8 Hz, 1H), 7.69 (d, J=1.0 Hz, 1H), 7.64-7.55 (m, 1H), 7.22 (dt,J=8.8, 2.4 Hz, 1H), 5.16-5.07 (m, 1H), 3.96-3.89 (m, 2H), 3.65 (s, 3H),3.58-3.45 (m, 2H), 2.91 (s, 3H), 2.36 (s, 3H), 2.09-1.99 (m, 2H),1.79-1.63 (m, 2H).

MS (ESI+) m/z: 600.2 [M+H]⁺.

Example 43:N-(6-(6-methoxy-5-(methylsulfonamido)pyridin-3-yl)-4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-2-yl)acetamide(43)

Compound (43) was prepared from compound (K-14) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanesulfonamide,according to the method of step 3 in Example 1.

¹H NMR (400 MHz, DMSO-d₆) δ 10.55 (s, 1H), 9.39 (s, 1H), 8.51 (d, J=2.3Hz, 1H), 8.04 (d, J=2.3 Hz, 1H), 7.93 (d, J=1.7 Hz, 1H), 7.70 (d, J=1.7Hz, 1H), 5.16-5.08 (m, 1H), 3.99 (s, 3H), 3.97-3.87 (m, 2H), 3.55-3.47(m, 2H), 3.10 (s, 3H), 2.91 (s, 3H), 2.36 (s, 3H), 2.11-1.98 (m, 2H),1.78-1.64 (m, 2H).

MS (ESI+) m/z 502.2 [M+H]⁺.

Example 44:N-(2-methoxy-5-(4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(44)

Step 1: Preparation of6-bromo-4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazoline (N-1)

To a stirred mixture of compound (M) (0.717 g, 3 mmol),triphenylphosphine (0.944 g, 3.6 mmol), and tetrahydro-2H-pyran-4-ol(0.368 g, 3.6 mmol) in anhydrous THF (30 mL) was added DEAD (0.627 g,3.6 mmol) at r.t. under Ar atmosphere. The resulting reaction mixturewas stirred at r.t. overnight. Silica gel (4 g) was added, and themixture was evaporated to dry under reduced pressure. The residue waspurified by flash column chromatography (silica gel, PE/EtOAc=4:1, v/v)to afford the product (N-1) as a yellow solid (0.95 g, 98% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 9.11 (s, 1H), 8.00 (d, J=2.0 Hz, 1H), 7.71(d, J=2.0 Hz, 1H), 5.03-4.88 (m, 1H), 3.95-3.87 (m, 2H), 3.58-3.49 (m,2H), 2.87 (s, 3H), 2.10-2.01 (m, 2H), 1.78-1.61 (m, 2H).

Step 2: Preparation ofN-(2-methoxy-5-(4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(44)

A mixture of compound (N-1) (125 mg, 0.39 mmol),N-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(199 mg, 0.47 mmol) and 2M aqueous potassium carbonate solution (0.585mL, 1.17 mmol) in dioxane (7 mL) was degassed, and then PdCl₂(dppf) (29mg, 0.04 mmol) was added. The resulting reaction mixture was degassedand back-filled with argon (three cycles), and then stirred at 100° C.under Ar atmosphere for 5 h. The reaction mixture was cooled to r.t.,diluted with EtOAc (30 mL) and water (30 mL), acidified withhydrochloric acid until the pH value was 5-6. The two phases wereseparated and the aqueous layer was extracted with EtOAc (30 mL×2). Thecombined organic layers were washed with water (50 mL) and brine (50mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residuewas purified by flash column chromatography (silica gel, DCM/MeOH=70:1,and then 50:1, v/v) to afford the product (44) as a yellow foamed solid(178 mg, 85% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 10.35 (s, 1H), 9.08 (s, 1H), 8.56 (d, J=2.3Hz, 1H), 8.11 (d, J=2.3 Hz, 1H), 7.94 (d, J=1.6 Hz, 1H), 7.81-7.70 (m,2H), 7.66-7.54 (m, 1H), 7.22 (dt, J=8.8, 2.4 Hz, 1H), 5.12-4.98 (m, 1H),3.98-3.90 (m, 2H), 3.66 (s, 3H), 3.61-3.48 (m, 2H), 2.96 (s, 3H),2.16-2.03 (m, 2H), 1.80-1.65 (m, 2H).

MS (ESI+) m/z 543.1 [M+H]⁺.

Example 45:N-(2-methoxy-5-(4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-6-yl)pyridin-3-yl)-2-chloro-4-fluorobenzenesulfonamide(45)

Compound (45) was prepared from compound (N-1) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2-chloro-4-fluorobenzenesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 10.23 (s, 1H), 9.08 (s, 1H), 8.54 (d, J=2.3Hz, 1H), 8.05 (d, J=2.2 Hz, 1H), 7.94 (dd, J=8.8, 6.0 Hz, 1H), 7.90 (d,J=1.6 Hz, 1H), 7.77 (dd, J=8.8, 2.4 Hz, 1H), 7.74 (d, J=1.6 Hz, 1H),7.37 (dt, J=8.4, 2.4 Hz, 1H), 5.11-5.00 (m, 1H), 3.97-3.90 (m, 2H), 3.67(s, 3H), 3.58-3.50 (m, 2H), 2.95 (s, 3H), 2.15-2.03 (m, 2H), 1.81-1.66(m, 2H).

MS (ESI+) m/z 559.1 [M+H]⁺.

Example 46:N-(2-methoxy-5-(4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-6-yl)pyridin-3-yl)-5-chlorothiophene-2-sulfonamide(46)

Compound (46) was prepared from compound (N-1) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-5-chlorothiophene-2-sulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 10.40 (s, 1H), 9.09 (s, 1H), 8.59 (d, J=2.2Hz, 1H), 8.10 (d, J=2.2 Hz, 1H), 7.94 (d, J=1.4 Hz, 1H), 7.77 (d, J=1.4Hz, 1H), 7.40 (d, J=4.0 Hz, 1H), 7.25 (d, J=4.0 Hz, 1H), 5.14-5.00 (m,1H), 3.98-3.90 (m, 2H), 3.76 (s, 3H), 3.62-3.48 (m, 2H), 2.96 (s, 3H),2.16-2.03 (m, 2H), 1.82-1.66 (m, 2H).

MS (ESI+) m/z 547.1 [M+H]⁺.

Example 47:N-(2-methoxy-5-(4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-6-yl)pyridin-3-yl)methanesulfonamide(47)

Compound (47) was prepared from compound (N-1) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 9.42 (s, 1H), 9.08 (s, 1H), 8.55 (d, J=2.3Hz, 1H), 8.08 (d, J=2.3 Hz, 1H), 7.96 (d, J=1.6 Hz, 1H), 7.77 (d, J=1.6Hz, 1H), 5.13-4.99 (m, 1H), 4.00 (s, 3H), 3.97-3.90 (m, 2H), 3.61-3.47(m, 2H), 3.10 (s, 3H), 2.96 (s, 3H), 2.14-2.01 (m, 2H), 1.82-1.66 (m,2H).

MS (ESI+) m/z 445.2 [M+H]⁺.

Example 48:N-(2-methoxy-5-(4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-6-yl)pyridin-3-yl)cyclopropanesulfonamide(48)

Compound (48) was prepared from compound (N-1) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)cyclopropanesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 9.48 (s, 1H), 9.08 (s, 1H), 8.56 (d, J=2.4Hz, 1H), 8.10 (d, J=2.4 Hz, 1H), 7.96 (d, J=1.6 Hz, 1H), 7.78 (d, J=1.6Hz, 1H), 5.12-5.02 (m, 1H), 4.01 (s, 3H), 3.99-3.90 (m, 2H), 3.60-3.48(m, 2H), 2.96 (s, 3H), 2.81-2.73 (m, 1H), 2.16-2.03 (m, 2H), 1.81-1.66(m, 2H), 1.01-0.86 (m, 4H).

MS (ESI+) m/z 471.2 [M+H]⁺.

Example 49:(R)-N-(2-methoxy-5-(4-methyl-8-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(49)

Step 1: Preparation of(R)-6-bromo-4-methyl-8-((tetrahydrofuran-3-yl)oxy)quinazoline (N-6)

According to the method of step 1 in Example 44, compound (N-6) wasprepared from compound (M) and (S)-tetrahydrofuran-3-ol.

¹H NMR (400 MHz, DMSO-d₆) δ 9.10 (s, 1H), 8.02 (d, J=1.9 Hz, 1H), 7.55(d, J=1.9 Hz, 1H), 5.37-5.31 (m, 1H), 4.05-3.85 (m, 3H), 3.83-3.76 (m,1H), 2.87 (s, 3H), 2.39-2.25 (m, 1H), 2.14-2.01 (m, 1H).

Step 2: Preparation of(R)-N-(2-methoxy-5-(4-methyl-8-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(49)

Compound (49) was prepared from compound (N-6) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 10.35 (s, 1H), 9.08 (s, 1H), 8.57 (d, J=2.4Hz, 1H), 8.12 (d, J=2.4 Hz, 1H), 7.95 (d, J=1.6 Hz, 1H), 7.76 (dt,J=8.6, 6.4 Hz, 1H), 7.65-7.54 (m, 2H), 7.22 (dt, J=8.6, 2.4 Hz, 1H),5.51-5.45 (m, 1H), 4.05-3.90 (m, 3H), 3.86-3.78 (m, 1H), 3.66 (s, 3H),2.96 (s, 3H), 2.40-2.29 (m, 1H), 2.21-2.08 (m, 1H).

MS (ESI+) m/z 529.1 [M+H]⁺.

Example 50:(R)-N-(2-methoxy-5-(4-methyl-8-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)pyridin-3-yl)methanesulfonamide(50)

Compound (50) was prepared from compound (N-6) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 9.42 (s, 1H), 9.08 (s, 1H), 8.55 (d, J=2.4Hz, 1H), 8.09 (d, J=2.4 Hz, 1H), 7.97 (d, J=1.6 Hz, 1H), 7.63 (d, J=1.6Hz, 1H), 5.53-5.42 (m, 1H), 4.06-3.90 (m, 6H), 3.86-3.78 (m, 1H), 3.11(s, 3H), 2.96 (s, 3H), 2.41-2.28 (m, 1H), 2.20-2.09 (m, 1H).

MS (ESI+) m/z 431.1 [M+H]⁺.

Example 51:(S)-N-(2-methoxy-5-(4-methyl-8-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(51)

Step 1: Preparation of(S)-6-bromo-4-methyl-8-((tetrahydrofuran-3-yl)oxy)quinazoline (N-8)

According to the method of step 1 in Example 44, compound (N-8) wasprepared from compound (M) and (R)-tetrahydrofuran-3-ol.

¹H NMR (400 MHz, DMSO-d₆) δ 9.10 (s, 1H), 8.02 (d, J=1.9 Hz, 1H), 7.55(d, J=1.9 Hz, 1H), 5.37-5.31 (m, 1H), 4.05-3.85 (m, 3H), 3.83-3.76 (m,1H), 2.87 (s, 3H), 2.39-2.27 (m, 1H), 2.14-2.01 (m, 1H).

Step 2: Preparation of(S)-N-(2-methoxy-5-(4-methyl-8-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(51)

Compound (51) was prepared from compound (N-8) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 10.35 (s, 1H), 9.08 (s, 1H), 8.57 (d, J=2.2Hz, 1H), 8.12 (d, J=2.2 Hz, 1H), 7.95 (d, J=1.2 Hz, 1H), 7.77 (dt,J=8.8, 6.6 Hz, 1H), 7.66-7.55 (m, 2H), 7.22 (dt, J=8.8, 2.4 Hz, 1H),5.52-5.43 (m, 1H), 4.06-3.89 (m, 3H), 3.86-3.78 (m, 1H), 3.66 (s, 3H),2.96 (s, 3H), 2.40-2.29 (m, 1H), 2.20-2.08 (m, 1H).

MS (ESI+) m/z 529.1 [M+H]⁺.

Example 52:(S)-N-(2-methoxy-5-(4-methyl-8-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)pyridin-3-yl)methanesulfonamide(52)

Compound (52) was prepared from compound (N-8) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 9.42 (s, 1H), 9.08 (s, 1H), 8.55 (d, J=2.3Hz, 1H), 8.09 (d, J=2.3 Hz, 1H), 7.98 (d, J=1.6 Hz, 1H), 7.63 (d, J=1.6Hz, 1H), 5.51-5.45 (m, 1H), 4.04-3.9 (m, 6H), 3.88-3.76 (m, 1H), 3.11(s, 3H), 2.96 (s, 3H), 2.42-2.26 (m, 1H), 2.22-2.06 (m, 1H).

MS (ESI+) m/z 431.1 [M+H]⁺.

Example 53:N-(2-methoxy-5-(4-methyl-8-((tetrahydro-2H-pyran-4-yl)methoxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(53)

Step 1: Preparation of6-bromo-4-methyl-8-((tetrahydro-2H-pyran-4-yl)methoxy)quinazoline (N-10)

According to the method of step 1 in Example 44, compound (N-10) wasprepared from compound (M) and (tetrahydro-2H-pyran-4-yl)methanol.

¹H NMR (400 MHz, DMSO-d₆) δ 9.11 (s, 1H), 7.99 (d, J=1.9 Hz, 1H), 7.56(d, J=1.9 Hz, 1H), 4.08 (d, J=6.5 Hz, 2H), 3.94-3.87 (m, 2H), 3.38 (dt,J=11.8, 2.0 Hz, 2H), 2.87 (s, 3H), 2.21-2.08 (m, 1H), 1.80-1.72 (m, 2H),1.48-1.34 (m, 2H).

Step 2: Preparation ofN-(2-methoxy-5-(4-methyl-8-((tetrahydro-2H-pyran-4-yl)methoxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(53)

Compound (53) was prepared from compound (N-10) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 10.34 (s, 1H), 9.08 (s, 1H), 8.58 (d, J=2.3Hz, 1H), 8.12 (d, J=2.3 Hz, 1H), 7.92 (d, J=1.6 Hz, 1H), 7.76 (dt,J=8.6, 6.4 Hz, 1H), 7.63 (d, J=1.6 Hz, 1H), 7.62-7.55 (m, 1H), 7.22 (dt,J=8.4, 2.2 Hz, 1H), 4.17 (d, J=6.5 Hz, 2H), 3.96-3.87 (m, 2H), 3.66 (s,3H), 3.40 (dt, J=11.4, 1.8 Hz, 2H), 2.96 (s, 3H), 2.26-2.11 (m, 1H),1.84-1.76 (m, 2H), 1.51-1.38 (m, 2H).

MS (ESI+) m/z 557.2 [M+H]⁺.

Example 54:N-(2-methoxy-5-(4-methyl-8-((tetrahydro-2H-pyran-4-yl)methoxy)quinazolin-6-yl)pyridin-3-yl)methanesulfonamide(54)

Compound (54) was prepared from compound (N-10) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 9.41 (s, 1H), 9.08 (s, 1H), 8.56 (d, J=2.4Hz, 1H), 8.09 (d, J=2.4 Hz, 1H), 7.94 (d, J=1.6 Hz, 1H), 7.65 (d, J=1.6Hz, 1H), 4.17 (d, J=6.5 Hz, 2H), 4.01 (s, 3H), 3.96-3.88 (m, 2H), 3.39(dt, J=11.7, 1.9 Hz, 2H), 3.10 (s, 3H), 2.95 (s, 3H), 2.25-2.11 (m, 1H),1.84-1.75 (m, 2H), 1.51-1.37 (m, 2H).

MS (ESI+) m/z 459.2 [M+H]⁺.

Example 55:N-(5-(8-(cyclohexyloxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(55)

Step 1: Preparation of 6-bromo-8-(cyclohexyloxy)-4-methylquinazoline(N-12)

According to the method of step 1 in Example 44, compound (N-12) wasprepared from compound (M) and cyclohexanol.

¹H NMR (400 MHz, DMSO-d₆) δ 9.09 (s, 1H), 7.97 (d, J=1.9 Hz, 1H), 7.61(d, J=1.9 Hz, 1H), 4.78-4.65 (m, 1H), 2.86 (s, 3H), 2.05-1.93 (m, 2H),1.82-1.72 (m, 2H), 1.62-1.49 (m, 3H), 1.49-1.37 (m, 2H), 1.37-1.25 (m,1H).

Step 2: Preparation ofN-(5-(8-(cyclohexyloxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(55)

Compound (55) was prepared from compound (N-12) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 10.35 (s, 1H), 9.07 (s, 1H), 8.55 (d, J=2.4Hz, 1H), 8.09 (d, J=2.4 Hz, 1H), 7.90 (d, J=1.6 Hz, 1H), 7.76 (dt,J=8.6, 6.4 Hz, 1H), 7.67 (d, J=1.6 Hz, 1H), 7.64-7.56 (m, 1H), 7.26-7.19(m, 1H), 4.90-4.77 (m, 1H), 3.67 (s, 3H), 2.95 (s, 3H), 2.08-1.95 (m,2H), 1.87-1.73 (m, 2H), 1.65-1.53 (m, 3H), 1.52-1.27 (m, 3H).

MS (ESI+) m/z 541.2 [M+H]⁺.

Example 56:N-(5-(8-(cyclopentyloxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(56)

Step 1: Preparation of 6-bromo-8-(cyclopentyloxy)-4-methylquinazoline(N-13)

According to the method of step 1 in Example 44, compound (N-13) wasprepared from compound (M) and cyclopentanol.

¹H NMR (400 MHz, DMSO-d₆) δ 9.09 (s, 1H), 7.96 (d, J=2.0 Hz, 1H), 7.50(d, J=2.0 Hz, 1H), 5.17-5.06 (m, 1H), 2.86 (s, 3H), 2.09-1.96 (m, 2H),1.88-1.72 (m, 4H), 1.68-1.57 (m, 2H).

Step 2: Preparation ofN-(5-(8-(cyclopentyloxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(56)

Compound (56) was prepared from compound (N-13) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 10.35 (s, 1H), 9.06 (s, 1H), 8.55 (d, J=2.4Hz, 1H), 8.08 (d, J=2.4 Hz, 1H), 7.90 (d, J=1.6 Hz, 1H), 7.77 (dt,J=8.6, 6.4 Hz, 1H), 7.64-7.57 (m, 1H), 7.57 (d, J=1.6 Hz, 1H), 7.27-7.19(m, 1H), 5.29-5.21 (m, 1H), 3.67 (s, 3H), 2.95 (s, 3H), 2.12-1.96 (m,2H), 1.94-1.73 (m, 4H), 1.73-1.57 (m, 2H).

MS (ESI+) m/z 527.2 [M+H]⁺.

Example 57:N-(5-(8-((4,4-difluorocyclohexyl)oxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(57)

Step 1: Preparation of6-bromo-8-((4,4-difluorocyclohexyl)oxy)-4-methylquinazoline (N-14)

According to the method of step 1 in Example 44, compound (N-14) wasprepared from compound (M) and 4,4-difluorocyclohexanol.

¹H NMR (400 MHz, DMSO-d₆) δ 9.12 (s, 1H), 8.03 (d, J=1.9 Hz, 1H), 7.75(d, J=1.9 Hz, 1H), 5.02-4.94 (m, 1H), 2.87 (s, 3H), 2.25-1.85 (m, 8H).

Step 2: Preparation ofN-(5-(8-((4,4-difluorocyclohexyl)oxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide57

Compound (57) was prepared from compound (N-14) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 10.35 (s, 1H), 9.10 (s, 1H), 8.57 (d, J=2.4Hz, 1H), 8.12 (d, J=2.4 Hz, 1H), 7.97 (d, J=1.6 Hz, 1H), 7.82 (d, J=1.6Hz, 1H), 7.76 (dt, J=8.6, 6.4 Hz, 1H), 7.64-7.55 (m, 1H), 7.22 (dt,J=8.4, 2.2 Hz, 1H), 5.15-5.05 (m, 1H), 3.66 (s, 3H), 2.96 (s, 3H),2.31-2.11 (m, 2H), 2.10-1.93 (m, 6H).

MS (ESI+) m/z 577.2 [M+H]⁺.

Example 58:N-(5-(8-((2,2-dimethyltetrahydro-2H-pyran-4-yl)oxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(58)

Step 1: Preparation of6-bromo-8-((2,2-dimethyltetrahydro-2H-pyran-4-yl)oxy)-4-methylquinazoline(N-15)

According to the method of step 1 in Example 44, compound (N-15) wasprepared from compound (M) and 2,2-dimethyltetrahydro-2H-pyran-4-ol.

¹H NMR (400 MHz, DMSO-d₆) δ 9.09 (s, 1H), 7.99 (d, J=1.8 Hz, 1H), 7.72(d, J=1.8 Hz, 1H), 5.12-4.97 (m, 1H), 3.84-3.62 (m, 2H), 2.86 (s, 3H),2.14-1.94 (m, 2H), 1.64-1.45 (m, 2H), 1.25 (s, 3H), 1.24 (s, 3H).

Step 2: Preparation ofN-(5-(8-((2,2-dimethyltetrahydro-2H-pyran-4-yl)oxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(58)

Compound (58) was prepared from compound (N-15) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 10.35 (s, 1H), 9.07 (s, 1H), 8.57 (d, J=2.4Hz, 1H), 8.12 (d, J=2.4 Hz, 1H), 7.93 (d, J=1.6 Hz, 1H), 7.81-7.71 (m,2H), 7.64-7.56 (m, 1H), 7.26-7.19 (m, 1H), 5.24-5.09 (m, 1H), 3.86-3.77(m, 1H), 3.75-3.67 (m, 1H), 3.66 (s, 3H), 2.96 (s, 3H), 2.14-2.01 (m,2H), 1.65-1.52 (m, 2H), 1.26 (s, 3H), 1.25 (s, 3H).

MS (ESI+) m/z 571.2 [M+H]⁺.

Example 59:N-(2-methoxy-5-(4-methyl-8-((3-methyloxetan-3-yl)methoxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluoro-benzenesulfonamide(59)

Step 1: Preparation of6-bromo-4-methyl-8-((3-methyloxetan-3-yl)methoxy)quinazoline (N-16)

According to the method of step 1 in Example 44, compound (N-16) wasprepared from compound (M) and (3-methyloxetan-3-yl)methanol.

¹H NMR (400 MHz, DMSO-d₆) δ 9.13 (s, 1H), 8.02 (d, J=1.9 Hz, 1H), 7.64(d, J=1.9 Hz, 1H), 4.57 (d, J=5.8 Hz, 2H), 4.37 (d, J=5.8 Hz, 2H), 4.32(s, 2H), 2.88 (s, 3H), 1.45 (s, 3H).

Step 2: Preparation ofN-(2-methoxy-5-(4-methyl-8-((3-methyloxetan-3-yl)methoxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluoro-benzenesulfonamide(59)

Compound (59) was prepared from compound (N-16) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 10.34 (s, 1H), 9.10 (s, 1H), 8.59 (d, J=2.4Hz, 1H), 8.14 (d, J=2.4 Hz, 1H), 7.96 (d, J=1.6 Hz, 1H), 7.80-7.74 (m,1H), 7.73 (d, J=1.6 Hz, 1H), 7.64-7.56 (m, 1H), 7.22 (dt, J=8.4, 2.4 Hz,1H), 4.61 (d, J=5.8 Hz, 2H), 4.41 (s, 2H), 4.40 (d, J=5.8 Hz, 2H), 3.65(s, 3H), 2.97 (s, 3H), 1.49 (s, 3H).

MS (ESI+) m/z 543.1 [M+H]⁺.

Example 60:N-(2-methoxy-5-(4-methyl-8-((tetrahydrofuran-2-yl)methoxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(60)

Step 1: Preparation of6-bromo-4-methyl-8-((tetrahydrofuran-2-yl)methoxy)quinazoline (N-17)

According to the method of step 1 in Example 44, compound (N-17) wasprepared from compound (M) and tetrahydrofurfuryl alcohol.

¹H NMR (400 MHz, DMSO-d₆) δ 9.11 (s, 1H), 7.99 (d, J=1.8 Hz, 1H), 7.57(d, J=1.8 Hz, 1H), 4.34-4.25 (m, 1H), 4.24-4.12 (m, 2H), 3.83 (dd,J=14.2, 7.2 Hz, 1H), 3.71 (dd, J=14.2, 7.2 Hz, 1H), 2.87 (s, 3H),2.11-1.92 (m, 2H), 1.90-1.70 (m, 2H).

Step 2: Preparation ofN-(2-methoxy-5-(4-methyl-8-((tetrahydrofuran-2-yl)methoxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluoro-benzenesulfonamide(60)

Compound (60) was prepared from compound (N-17) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 10.34 (s, 1H), 9.08 (s, 1H), 8.58 (d, J=2.2Hz, 1H), 8.13 (d, J=2.2 Hz, 1H), 7.93 (d, J=1.2 Hz, 1H), 7.76 (dt,J=8.4, 6.4 Hz, 1H), 7.65 (d, J=1.2 Hz, 1H), 7.64-7.55 (m, 1H), 7.21 (dt,J=8.6, 2.2 Hz, 1H), 4.39-4.21 (m, 3H), 3.86 (dd, J=14.2, 7.0 Hz, 1H),3.73 (dd, J=14.2, 7.0 Hz, 1H), 3.65 (s, 3H), 2.96 (s, 3H), 2.14-1.93 (m,2H), 1.93-1.73 (m, 2H).

MS (ESI+) m/z 543.1 [M+H]⁺.

Example 61:N-(2-methoxy-5-(4-methyl-8-((tetrahydrofuran-3-yl)methoxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(61)

Step 1: Preparation of6-bromo-4-methyl-8-((tetrahydrofuran-3-yl)methoxy)quinazoline (N-18)

According to the method of step 1 in Example 44, compound (N-18) wasprepared from compound (M) and (tetrahydrofuran-3-yl)methanol.

¹H NMR (400 MHz, DMSO-d₆) δ 9.12 (s, 1H), 8.00 (d, J=1.8 Hz, 1H), 7.59(d, J=1.8 Hz, 1H), 4.21-4.08 (m, 2H), 3.91-3.75 (m, 2H), 3.74-3.59 (m,2H), 2.87 (s, 3H), 2.84-2.75 (m, 1H), 2.11-2.02 (m, 1H), 1.80-1.69 (m,1H).

Step 2: Preparation ofN-(2-methoxy-5-(4-methyl-8-((tetrahydrofuran-3-yl)methoxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluoro-benzenesulfonamide(61)

Compound (61) was prepared from compound (N-18) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 10.34 (s, 1H), 9.09 (s, 1H), 8.58 (d, J=2.2Hz, 1H), 8.13 (d, J=2.2 Hz, 1H), 7.94 (d, J=1.0 Hz, 1H), 7.76 (dd,J=8.6, 6.6 Hz, 1H), 7.67 (d, J=1.0 Hz, 1H), 7.65-7.53 (m, 1H), 7.22 (dt,J=8.6, 2.4 Hz, 1H), 4.35-4.16 (m, 2H), 3.93-3.78 (m, 2H), 3.75-3.60 (m,5H), 2.96 (s, 3H), 2.92-2.76 (m, 1H), 2.16-2.05 (m, 1H), 1.83-1.73 (m,1H).

MS (ESI+) m/z 543.1 [M+H]⁺.

Example 62:N-(2-methoxy-5-(4-methyl-8-((1-methylpiperidin-4-yl)oxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluoro-benzenesulfonamide(62)

Step 1: Preparation of6-bromo-4-methyl-8-((1-methylpiperidin-4-yl)oxy)quinazoline (N-19)

According to the method of step 1 in Example 44, compound (N-19) wasprepared from compound (M) and 1-methylpiperidin-4-ol.

¹H NMR (400 MHz, DMSO-d₆) δ 9.10 (s, 1H), 7.99 (d, J=1.9 Hz, 1H), 7.64(d, J=1.9 Hz, 1H), 4.80-4.66 (m, 1H), 2.88-2.85 (m, 3H), 2.74-2.63 (m,2H), 2.30-2.14 (m, 6H), 2.07-1.95 (m, 2H), 1.82-1.69 (m, 2H).

Step 2: Preparation ofN-(2-methoxy-5-(4-methyl-8-((1-methylpiperidin-4-yl)oxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(62)

Compound (62) was prepared from compound (N-19) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 9.07 (s, 1H), 8.35 (d, J=2.2 Hz, 1H), 7.93(d, J=2.2 Hz, 1H), 7.86 (d, J=1.6 Hz, 1H), 7.79 (dt, J=8.6, 6.6 Hz, 1H),7.66 (d, J=1.6 Hz, 1H), 7.54-7.44 (m, 1H), 7.18 (dt, J=8.4, 2.4 Hz, 1H),4.95-4.82 (m, 1H), 3.70 (s, 3H), 2.94 (s, 3H), 2.93-2.86 (m, 2H), 2.51(s, 1H), 2.39 (s, 3H), 2.15-2.04 (m, 2H), 1.92-1.80 (m, 2H).

MS (ESI+) m/z 556.2 [M+H]⁺.

Example 63:N-(2-methoxy-5-(4-methyl-8-(2-(pyrrolidin-1-yl)ethoxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(63)

Step 1: Preparation of6-bromo-4-methyl-8-(2-(pyrrolidin-1-yl)ethoxy)quinazoline (N-20)

According to the method of step 1 in Example 44, compound (N-20) wasprepared from compound (M) and 2-(pyrrolidin-1-yl)ethan-1-ol.

¹H NMR (400 MHz, DMSO-d₆) δ 9.10 (s, 1H), 7.99 (d, J=1.9 Hz, 1H), 7.58(d, J=1.9 Hz, 1H), 4.30 (t, J=5.8 Hz, 2H), 2.93 (t, J=5.8 Hz, 2H), 2.87(s, 3H), 2.64-2.55 (m, 4H), 1.76-1.62 (m, 4H).

Step 2: Preparation ofN-(2-methoxy-5-(4-methyl-8-(2-(pyrrolidin-1-yl)ethoxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(63)

Compound (63) was prepared from compound (N-20) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 9.08 (s, 1H), 8.37 (d, J=2.2 Hz, 1H), 7.96(d, J=2.2 Hz, 1H), 7.86 (d, J=1.4 Hz, 1H), 7.80 (dt, J=8.6, 6.6 Hz, 1H),7.61 (d, J=1.4 Hz, 1H), 7.53-7.45 (m, 1H), 7.19 (dt, J=8.4, 2.4 Hz, 1H),4.45 (t, J=5.5 Hz, 2H), 3.69 (s, 3H), 3.18 (t, J=5.5 Hz, 2H), 2.95 (s,3H), 2.91-2.81 (m, 4H), 1.83-1.75 (m, 4H).

MS (ESI+) m/z 556.2 [M+H]⁺.

Example 64:N-(5-(8-(2-(1H-pyrazol-1-yl)ethoxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(64)

Step 1: Preparation of8-(2-(1H-pyrazol-1-yl)ethoxy)-6-bromo-4-methylquinazoline (N-21)

According to the method of step 1 in Example 44, Compound (N-21) wasprepared from compound (M) and 2-(1H-pyrazol-1-yl) ethan-1-ol.

¹H NMR (400 MHz, DMSO-d₆) δ 9.11 (s, 1H), 8.01 (d, J=1.9 Hz, 1H), 7.87(dd, J=2.2, 0.6 Hz, 1H), 7.54 (d, J=1.9 Hz, 1H), 7.46 (dd, J=1.8, 0.6Hz, 1H), 6.24 (t, J=2.0 Hz, 1H), 4.65-4.57 (m, 4H), 2.86 (s, 3H).

Step 2: Preparation ofN-(5-(8-(2-(1H-pyrazol-1-yl)ethoxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(64)

Compound (64) was prepared from compound (N-21) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 10.33 (s, 1H), 9.09 (s, 1H), 8.56 (d, J=2.3Hz, 1H), 8.12 (d, J=2.3 Hz, 1H), 7.95 (d, J=1.6 Hz, 1H), 7.92 (dd,J=2.2, 0.6 Hz, 1H), 7.76 (dt, J=8.4, 6.4 Hz, 1H), 7.62 (d, J=1.6 Hz,1H), 7.61-7.56 (m, 1H), 7.46 (dd, J=1.8, 0.6 Hz, 1H), 7.22 (dt, J=8.4,2.0 Hz, 1H), 6.27-6.23 (m, 1H), 4.76-4.60 (m, 4H), 3.65 (s, 3H), 2.95(s, 3H).

MS (ESI+) m/z 553.1 [M+H]⁺.

Example 65:N-(2-methoxy-5-(4-methyl-8-(2-morpholinoethoxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(65)

Step 1: Preparation of4-(2-((6-bromo-4-methylquinazolin-8-yl)oxy)ethyl)morpholine (N-22)

According to the method of step 1 in Example 44, compound (N-22) wasprepared from compound (M) and 2-morpholinoethan-1-ol.

¹H NMR (400 MHz, DMSO-d₆) δ 9.10 (s, 1H), 7.99 (d, J=1.9 Hz, 1H), 7.61(d, J=1.9 Hz, 1H), 4.33 (t, J=5.7 Hz, 2H), 3.63-3.53 (m, 4H), 2.87 (s,3H), 2.82 (t, J=5.7 Hz, 2H), 2.59-2.51 (m, 4H).

Step 2: Preparation ofN-(2-methoxy-5-(4-methyl-8-(2-morpholinoethoxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluoro-benzenesulfonamide(65)

Compound (65) was prepared from compound (N-22) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 10.33 (s, 1H), 9.08 (s, 1H), 8.57 (d, J=2.4Hz, 1H), 8.12 (d, J=2.4 Hz, 1H), 7.93 (d, J=1.6 Hz, 1H), 7.76 (dt,J=8.6, 6.4 Hz, 1H), 7.67 (d, J=1.6 Hz, 1H), 7.59 (ddd, J=10.6, 9.2, 2.4Hz, 1H), 7.27-7.18 (m, 1H), 4.43 (t, J=5.6 Hz, 2H), 3.66 (s, 3H),3.64-3.57 (m, 4H), 2.96 (s, 3H), 2.89 (t, J=5.6 Hz, 2H), 2.65-2.56 (m,4H).

MS (ESI+) m/z 571.2 [M+H]⁺.

Example 66:N-(2-methoxy-5-(4-methyl-8-((1-methylpiperidin-4-yl)methoxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluoro-benzenesulfonamide(66)

Step 1: Preparation of6-bromo-4-methyl-8-((1-methylpiperidin-4-yl)methoxy)quinazoline (N-23)

According to the method of step 1 in Example 44, compound (N-23) wasprepared from compound (M) and (1-methylpiperidin-4-yl)methanol.

¹H NMR (400 MHz, DMSO-d₆) δ 9.11 (s, 1H), 7.98 (d, J=1.8 Hz, 1H), 7.54(d, J=1.8 Hz, 1H), 4.06 (d, J=6.0 Hz, 2H), 2.86 (s, 3H), 2.84-2.76 (m,1H), 2.17 (s, 3H), 1.95-1.75 (m, 5H), 1.44-1.31 (m, 2H).

Step 2: Preparation ofN-(2-methoxy-5-(4-methyl-8-((1-methylpiperidin-4-yl)methoxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(66)

Compound (66) was prepared from compound (N-23) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 9.06 (s, 1H), 8.25 (d, J=1.6 Hz, 1H),7.86-7.80 (m, 2H), 7.78 (d, J=1.4 Hz, 1H), 7.51 (d, J=1.4 Hz, 1H), 7.43(dt, J=9.8, 2.4 Hz, 1H), 7.16 (dt, J=8.4, 2.4 Hz, 1H), 4.15 (d, J=6.0Hz, 2H), 3.72 (s, 3H), 3.16-3.07 (m, 2H), 2.93 (s, 3H), 2.48-2.34 (m,5H), 2.08-1.87 (m, 3H), 1.61-1.41 (m, 2H).

MS (ESI+) m/z 570.2 [M+H]⁺.

Example 67:N-(5-(8-(2-(dimethylamino)ethoxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(67)

Step 1: Preparation of2-((6-bromo-4-methylquinazolin-8-yl)oxy)-N,N-dimethylethanol-1-amine(N-24)

According to the method of step 1 in Example 44, compound (N-24) wasprepared from compound (M) and 2-(dimethylamino) ethan-1-ol.

¹H NMR (400 MHz, DMSO-d₆) δ 9.11 (s, 1H), 8.03 (d, J=1.9 Hz, 1H), 7.63(d, J=1.9 Hz, 1H), 4.40 (t, J=5.2 Hz, 2H), 3.03 (t, J=5.2 Hz, 2H), 2.88(s, 3H), 2.48 (s, 6H).

Step 2: Preparation ofN-(5-(8-(2-(dimethylamino)ethoxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(67)

Compound (67) was prepared from compound (N-24) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 9.08 (s, 1H), 8.44 (d, J=2.3 Hz, 1H), 8.01(d, J=2.3 Hz, 1H), 7.89 (d, J=1.6 Hz, 1H), 7.79 (dt, J=8.6, 6.4 Hz, 1H),7.64 (d, J=1.6 Hz, 1H), 7.56-7.48 (m, 1H), 7.24-7.16 (m, 1H), 4.43 (t,J=5.6 Hz, 2H), 3.68 (s, 3H), 2.98 (t, J=5.6 Hz, 2H), 2.95 (s, 3H), 2.44(s, 6H).

MS (ESI+) m/z 530.2 [M+H]⁺.

Example 68:N-(5-(8-(cyclopropylmethoxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(68)

Step 1: Preparation of6-bromo-8-(cyclopropylmethoxy)-4-methylquinazoline (N-25)

A mixture of compound (M) (0.120 g, 0.5 mmol), cyclopropylmethyl bromide(0.675 g, 5 mmol), and potassium carbonate (0.691 g, 5 mmol) inacetonitrile (8 mL) in a sealed tube was stirred at 85° C. overnight.The reaction mixture was cooled to r.t. and filtered. Silica gel (1 g)was added to the filtrate, and the resulting mixture was evaporated todry under reduced pressure. The residue was purified by flash columnchromatography (silica gel, PE/EtOAc=150:1, v/v) to afford the product(N-25) as a yellow oil (0.142 g, 97% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 9.11 (s, 1H), 7.97 (d, J=2.0 Hz, 1H), 7.49(d, J=2.0 Hz, 1H), 4.05 (d, J=7.1 Hz, 2H), 2.87 (s, 3H), 1.41-1.29 (m,1H), 0.68-0.57 (m, 2H), 0.43-0.36 (m, 2H).

Step 2: Preparation ofN-(5-(8-(cyclopropylmethoxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(68)

Compound (68) was prepared from compound (N-25) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 10.33 (s, 1H), 9.08 (s, 1H), 8.55 (d, J=2.2Hz, 1H), 8.09 (d, J=2.2 Hz, 1H), 7.91 (d, J=1.4 Hz, 1H), 7.76 (dt,J=8.6, 6.4 Hz, 1H), 7.63-7.57 (m, 1H), 7.57 (d, J=1.4 Hz, 1H), 7.21 (dt,J=8.4, 2.4 Hz, 1H), 4.15 (d, J=7.0 Hz, 2H), 3.65 (s, 3H), 2.96 (s, 3H),1.47-1.32 (m, 1H), 0.71-0.60 (m, 2H), 0.46-0.37 (m, 2H).

MS (ESI+) m/z 513.1 [M+H]⁺.

Example 69:N-(5-(8-isopropoxy-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(69)

Step 1: Preparation of 6-bromo-8-isopropoxy-4-methylquinazoline (N-26)

According to the method of step 1 in Example 68, compound (N-26) wasprepared from compound (M) and isopropyl bromide.

¹H NMR (400 MHz, DMSO-d₆) δ 9.08 (s, 1H), 7.97 (d, J=2.0 Hz, 1H), 7.57(d, J=2.0 Hz, 1H), 5.00-4.89 (m, 1H), 2.86 (s, 3H), 1.37 (d, J=6.0 Hz,6H).

Step 2: Preparation ofN-(5-(8-isopropoxy-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(69)

Compound (69) was prepared from compound (N-26) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 10.34 (s, 1H), 9.06 (s, 1H), 8.55 (d, J=2.3Hz, 1H), 8.08 (d, J=2.3 Hz, 1H), 7.91 (d, J=1.6 Hz, 1H), 7.77 (dt,J=8.6, 6.4 Hz, 1H), 7.63 (d, J=1.6 Hz, 1H), 7.62-7.55 (m, 1H), 7.22 (dt,J=8.4, 2.2 Hz, 1H), 5.13-5.02 (m, 1H), 3.67 (s, 3H), 2.95 (s, 3H), 1.40(d, J=6.0 Hz, 6H).

MS (ESI+) m/z 501.1 [M+H]⁺.

Example 70:N-(5-(8-cyclobutoxy-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(70)

Step 1: Preparation of 6-bromo-8-cyclobutoxy-4-methyiquinazoline (N-27)

According to the method of step 1 in Example 68, compound (N-27) wasprepared from compound (M) and cyclobutyl bromide.

¹H NMR (400 MHz, DMSO-d₆) δ 9.10 (s, 1H), 7.99 (d, J=1.9 Hz, 1H), 7.33(d, J=1.9 Hz, 1H), 4.97 (p, J=7.2 Hz, 1H), 2.86 (s, 3H), 2.59-2.52 (m,2H), 2.23-2.08 (m, 2H), 1.91-1.80 (m, 1H), 1.79-1.61 (m, 1H).

Step 2: Preparation ofN-(5-(8-cyclobutoxy-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(70)

Compound (70) was prepared from compound (N-27) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 10.36 (s, 1H), 9.07 (s, 1H), 8.54 (d, J=2.2Hz, 1H), 8.07 (d, J=2.2 Hz, 1H), 7.92 (s, 1H), 7.76 (dt, J=8.4, 6.4 Hz,1H), 7.64-7.56 (m, 1H), 7.40 (s, 1H), 7.23 (dt, J=8.4, 2.4 Hz, 1H),5.16-5.02 (m, 1H), 3.68 (s, 3H), 2.95 (s, 3H), 2.62-2.52 (m, 2H),2.29-2.10 (m, 2H), 1.94-1.81 (m, 1H), 1.80-1.65 (m, 1H).

MS (ESI+) m/z 513.1 [M+H]⁺.

Example 71:N-(5-(8-(difluoromethoxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(71)

Step 1: Preparation of 6-bromo-8-(difluoromethoxy)-4-methylquinazoline(N-28)

A mixture of compound (M) (0.120 g, 0.5 mmol), methylchlorodifluoroacetate (0.217 g, 1.5 mmol), and sodium carbonate (0.159g, 1.5 mmol) in dimethylformamide (3 mL) in a sealed tube was stirred at70° C. for 8 h. The resulting mixture was cooled to r.t., diluted withwater (30 mL), and extracted with EtOAc (30 mL×3). The combined organiclayers were washed with water (30 mL) and brine (30 mL), dried overanhydrous Na₂SO₄, filtered and concentrated. The residue was purified bypreparative thin layer chromatography (silica gel, DCM/MeOH=40:1, v/v)to afford the product (N-28) as a yellow oil (0.080 g, 55% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 9.21 (s, 1H), 8.43 (d, J=2.0 Hz, 1H), 7.98(d, J=2.0 Hz, 1H), 7.53 (t, J=73.8 Hz, 1H), 2.94 (s, 3H).

Step 2: Preparation ofN-(5-(8-(difluoromethoxy)-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide(71)

Compound (71) was prepared from compound (N-28) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 10.37 (s, 1H), 9.18 (s, 1H), 8.59 (d, J=2.4Hz, 1H), 8.35 (d, J=1.8 Hz, 1H), 8.16 (d, J=2.4 Hz, 1H), 8.06 (d, J=1.8Hz, 1H), 7.76 (dt, J=8.6, 6.4 Hz, 1H), 7.64-7.55 (m, 1H), 7.56 (t,J=74.0 Hz, 1H), 7.21 (dt, J=8.4, 2.0 Hz, 1H), 3.66 (s, 3H), 3.03 (s,3H).

Example 72:N-(2-methoxy-5-(8-methoxy-4-methylquinazolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(72)

Compound (72) was prepared from compound (L) andN-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide,according to the method of step 2 in Example 44.

¹H NMR (400 MHz, DMSO-d₆) δ 10.35 (s, 1H), 9.06 (s, 1H), 8.58 (d, J=2.2Hz, 1H), 8.13 (d, J=2.2 Hz, 1H), 7.93 (d, J=1.6 Hz, 1H), 7.77 (dt,J=8.4, 6.4 Hz, 1H), 7.65-7.54 (m, 2H), 7.23 (dt, J=8.6, 2.4 Hz, 1H),4.08 (s, 3H), 3.67 (s, 3H), 2.96 (s, 3H).

MS (ESI+) m/z 473.1 [M+H]⁺.

Example 73:N-(2-chloro-5-(4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide(73)

A mixture of compound (N-1) (71 mg, 0.22 mmol), anhydrous potassiumacetate (65 mg, 0.66 mmol) and bis(pinacolato)diboron (64 mg, 0.25 mmol)in dioxane (8 mL) was degassed and then PdCl₂(dppf) (16 mg, 0.022 mmol)was added. The resulting reaction mixture was degassed and back-filledwith argon (three cycles), and then stirred at 100 □C under Aratmosphere for 4 h. After cooling to r.t.,N-(5-bromo-2-methylpyridin-3-yl)-2,4-difluorobenzenesulfonamide (91 mg,0.25 mmol) and 2M aqueous potassium carbonate solution (0.44 mL, 0.88mmol) were added to the resulting mixture. The resulting mixture wasdegassed, and then PdCl₂ (dppf) (16 mg, 0.022 mmol) was added. Theresulting reaction mixture was degassed and backfilled with argon (threecycles) and then stirred at 100° C. under Ar atmosphere for 5 h. Thereaction mixture was cooled to r.t., diluted with EtOAc (30 mL) andwater (30 mL), acidified with hydrochloric acid until the pH value was5-6. The two phases were separated and the aqueous layer was extractedwith EtOAc (30 mL×2). The combined organic layers were washed with water(50 mL) and brine (50 mL), dried over Na₂SO₄, filtered, andconcentrated. The residue was purified by preparative thin layerchromatography (silica gel, DCM/MeOH=15:1, v/v) to afford the compound(73) as a yellow foamed solid (42 mg, 35% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 10.57 (s, 1H), 9.12 (s, 1H), 8.79 (d, J=2.2Hz, 1H), 8.16 (d, J=2.2 Hz, 1H), 8.00 (d, J=1.6 Hz, 1H), 7.87-7.80 (m,2H), 7.78 (d, J=1.6 Hz, 1H), 7.50-7.39 (m, 2H), 5.12-5.00 (m, 1H),3.98-3.90 (m, 2H), 3.60-3.50 (m, 2H), 2.97 (s, 3H), 2.15-2.02 (m, 2H),1.82-1.65 (m, 2H).

MS (ESI+) m/z 529.1 [M+H]⁺.

Example 74:N-(2-methyl-5-(4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(74)

A mixture of compound (N-1) (71 mg 022 mmol), anhydrous potassiumacetate (65 mg, 0.66 mmol) and bis(pinacolato)diboron (64 mg, 0.25 mmol)in dioxane (8 mL) was degassed and then PdCl₂(dppf) (16 mg, 0.022 mmol)was added. The resulting reaction mixture was degassed and back-filledwith argon (three cycles), and then stirred at 100 □C under Aratmosphere for 4 h. After cooling to r.t.,N-(5-bromo-2-methylpyridin-3-yl)-2,4-difluorobenzenesulfonamide (91 mg,0.25 mmol) and 2M aqueous potassium carbonate solution (0.44 mL, 0.88mmol) were added to the resluting mixture. The resulting mixture wasdegassed, and then PdCl₂ (dppf) (16 mg, 0.022 mmol) was added. Theresulting reaction mixture was degassed and backfilled with argon (threecycles) and then stirred at 100° C. under Ar atmosphere for 5 h. Thereaction mixture was cooled to r.t., diluted with EtOAc (30 mL) andwater (30 mL), acidified with hydrochloric acid until the pH value was5-6. The two phases were separated and the aqueous layer was extractedwith EtOAc (30 mL×2). The combined organic layers were washed with water(50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄, filtered, andconcentrated. The residue was purified by preparative thin layerchromatography (silica gel, DCM/MeOH=15:1, v/v) to afford the product(74) as a yellow foamed solid (46 mg, 40% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 10.53 (s, 1H), 9.10 (s, 1H), 8.84 (s, 1H),7.88 (d, J=1.6 Hz, 1H), 7.85 (d, J=2.0 Hz, 1H), 7.80 (dt, J=8.6, 6.4 Hz,1H), 7.71 (d, J=1.6 Hz, 1H), 7.67-7.59 (m, 1H), 7.30-7.24 (m, 1H),5.08-4.99 (m, 1H), 3.97-3.90 (m, 2H), 3.58-3.50 (m, 2H), 2.94 (s, 3H),2.34 (s, 3H), 2.16-2.01 (m, 2H), 1.82-1.64 (m, 2H).

MS (ESI+) m/z 527.2 [M+H]⁺.

Evaluation of Pharmacological Activity Experimental Example 1:Biochemical Evaluation of Activity of PI3Kα

The potency of compounds in the present intention against PI3Kα wasassessed by in vitro kinase assay. The kinase activity of PI3Kα wasdetermined by detecting the level of ADP produced in the kinase reactionwith luciferase-based luminescence detection. The Kinase-Glo™ KinaseAssay Kit was purchased from Promega. All assays were performed at roomtemperature using white OptiPlate™-384 well plate. The PI3Kα kinase waspurchased from Invitrogen. The substrate was PIP2 from Invitrogen. Thekinase buffer contained 50 mM Hepes (pH 7.5), 3 mM MgCl2, 100 mM NaCl, 1mM EGTA, 0.03% CHAPS and 2 mM DTT. The PI3Kα kinase solution wasprepared by diluting PI3Kα kinase to 6.6 nM in kinase buffer. Thesubstrate solution contained 100 μM PIP2 and 50 μM ATP. The testcompound was diluted to 10 mM in 100% DMSO and serially diluted threetimes into ten different concentrations in 100% DMSO. The compounddiluted in 100% DMSO was diluted 25-fold in 1× kinase buffer. 2.5 μL ofthe diluted compound solution and 2.5 μL PI3Kα kinase solution wereadded to each well of a 384-well plate. The reaction was initiated byaddition of 5 μL substrate solution to each well. The final reactionvolume was 10 μL, the ATP concentration was 25 μM, the PIP2concentration was 50 μM, and the PI3Kα kinase concentration was 1.65 nM.The plate was then covered and the reaction was allowed to proceed forone hour at room temperature, followed by the addition of 10 μLKinase-Glo™ reagent to each well to stop the reaction. The plate wasincubated for fifteen minutes and the luminescence was read on anEnVision 2014 multilabel microplate detector plate reader.

The percentage of inhibition was calculated as follows:

Inhibition %=100−(max−sample RLU)/(max−min)*100

wherein sample RLU was the luminescence reading for a given compoundconcentration, min was the reading of DMSO control, and max was thereading of the enzyme-free control. The IC₅₀ value was calculated withthe XLfit program in Excel. The results were shown in Table 1.

TABLE 1 The inhibitory activity of PI3Kα Example PI3Kα IC₅₀ (nM)  1 0.80 2 0.72  3 1.1  4 0.74  5 2.7  6 2.3  7 1.1  8 1.0  9 0.86 10 3.8 110.94 12 4.5 13 0.84 14 3.3 15 5.5 16 4.1 17 2.3 18-1 1.1 18-2 0.8 19 1.020 1.3 21 1.0 22 0.6 23 1.1 24 0.8 25 1.6 26 0.79 27 1.7 28 1.2 29 1.130 1.3 31 3.8 32 0.82 33 1.7 34 1.6 35 1.8 36 2.2 37 2.3 38 2.3 39 15 408.5 41 5.0 42 1.1 43 10 44 0.65 45 0.92 46 0.70 47 1.4 48 2.1 49 0.76 502.2 51 0.72 52 2.1 53 0.73 54 1.6 55 1.7 56 0.92 57 1.7 58 1.0 59 0.7460 1.3 61 1.0 62 2.5 63 10 64 1.5 65 2.7 66 1.7 67 6.1 68 1.6 69 2.2 700.90 71 1.9 72 0.70 73 1.3 74 1.1

Experimental Example 2: Measurement of Tumor Cell Viability by MTT Assay

The human lung cancer cell NCI-H460 in logarithmic growth phase wasdigested with 0.25% trypsin-EDTA, and prepared into a single-cellsuspension which was then added in a 96-well plate at 1200 cells/wellwith 100 μL per well. After 24 hours, 100 μL of fresh medium containingdifferent concentrations of test compounds and the corresponding solventcontrol was added into each well to a final concentration of DMSO lessthan 0.2%. Six to nine concentration groups were set for each testcompound, and three parallel wells were set for each group. The platewas incubated at 5% CO₂, 37° C. for 96 hours. 20 μL of freshly preparedPBS solution containing 5 mg/mL MTT was added to each well. Thesupernatant was discarded after incubation for another 4 hours. 150 μLDMSO was added to each well to dissolve the MTT formazan precipitate.After being mixed by a micro-oscillator, the optical density (OD) wasmeasured at the wavelength of 570 nm, and the tumor cells treated withDMSO were used as a control group. The inhibitory rate of the testcompound on tumor cell growth was calculated as follows, and the IC₅₀value was calculated with SPSS 16.0:

Inhibitory rate (%)=(OD_(control)−OD_(compound))/OD_(control)×100%

Wherein OD_(control) the average OD value of the control group, andOD_(compound) was the average OD value of the test compound group at agiven concentration.

The results were shown in Table 2.

TABLE 2 Antiproliferative activity against human lung cancer cellNCI-H460 Example H460 IC₅₀ ( μM )  1 0.029  2 0.017  3 0.096  4 0.025  50.86  6 0.93  7 2.1  8 1.2  9 0.093 10 2.2 11 0.094 12 2.3 13 0.021 142.0 15 0.66 16 1.1 17 0.083 18-1 0.030 18-2 0.057 19 0.041 20 0.24 210.063 22 0.096 23 0.094 24 0.063 25 0.20 26 0.14 27 0.20 28 0.28 290.059 30 0.24 31 0.41 32 0.10 33 0.10 34 0.11 35 0.10 36 0.40 37 0.25 380.31 39 1.7 40 2.0 41 1.4 42 0.53 43 4.0 44 0.029 45 0.045 46 0.029 470.57 48 0.28 49 0.034 50 0.79 51 0.032 52 0.67 53 0.038 54 0.40 55 0.09756 0.073 57 0.45 58 0.056 59 0.017 60 0.24 61 0.045 62 0.26 63 2.1 640.39 65 0.63 66 0.23 67 3.5 68 0.34 69 0.050 70 0.022 71 1.0 72 0.50 730.74 74 0.87

Experimental Example 3: Study on the Xenograft Efficacy in Nude Mice

Human lung cancer NCI-H460 cells were collected under asepticconditions, and the cell density was adjusted to 1×10⁶ cells/mL withsterile saline, 0.2 mL of which was implanted into the back of the nudemice. When the tumor grew to a diameter of about 1 cm, it was removedunder septic condition and cut into pieces of 1 mm×1 mm which wasimplanted into the back of the nude mice. When the tumor grew to 100-300mm, after 6 days, the animals were randomly divided into groups andadministration was started (marked as Day 1). The test compound wasadministered orally every day. Body weight was measured twice a week andthe length and width of the tumor were measured with a vernier caliper.After 16 days of dosing, the nude mice were sacrificed by cervicaldislocation and the tumor issues were exfoliated, weighed andphotographed. Finally, the tumor inhibitory rate was calculated. Theantitumor efficacy was evaluated by the tumor inhibitory rate. Theresults were shown in Table 3, Table 4, FIG. 1 and FIG. 2 .

The tumor volume was calculated as follows:

Tumor volume=(a×b ²)/2,

where a and b represented the length and width of the tumor.

The percentage of tumor growth inhibition was calculated as follows:

Tumor growth inhibition (%)=(1−T/C)×100,

where T was the final volume of the tumor in the test compound group andC was the final volume of the tumor in the solvent control group.

TABLE 3 Growth inhibition of Example 9 on human lung cancer NCI-H460 insubcutaneous xenografts in nude mice Initial tumor Dose Growth CellTumor volume (mg/ inhibition line type (mm³) kg/day) (%) NCI-H460 Lung220.8  0 cancer 287.2  5 39.2 171.5 10 56.3 266.2 20 77.0

TABLE 4 Growth inhibition of Example 44 on human lung cancer NCI-H460 insubcutaneous xenografts in nude mice Initial tumor Dose Growth CellTumor volume (mg/ inhibition line type (mm³) kg/day) (%) NCI-H460 Lung220.8 0 cancer 222.2 1 60.3

Human gastric cancer HGC-27 cells were collected under asepticconditions, and the cell density was adjusted to 1×10⁶ cells/mL withsterile saline, 0.2 mL of which was implanted into the back of the nudemice. When the tumor grew to a diameter of about 1 cm, it was removedunder septic condition and cut into pieces of 1 mm×1 mm which wasimplanted into the back of the nude mice. When the tumor grew to 100-300mm³ after 6 days, the animals were randomly divided into groups andadministration was started (marked as Day 0). The test compound wasadministered orally every day. Body weight was measured twice a week andthe length and width of the tumor were measured with a vernier caliper.After 20 days of dosing, the nude mice were sacrificed by cervicaldislocation and the tumor issues were exfoliated, weighed andphotographed. Finally, the tumor inhibitory rate was calculated. Theantitumor efficacy was evaluated by the tumor inhibitory rate. Theresults were shown in Table 5 and FIG. 3 .

The tumor volume was calculated as follows:

Tumor volume=(a×b ²)/2,

where a and b represented the length and width of the tumor.

The percentage of tumor growth inhibition was calculated as follows:

Tumor growth inhibition (%)=(1−T/C)×100,

where T was the final volume of the tumor in the test compound group andC was the final volume of the tumor in the solvent control group.

The percentage of tumor regression was calculated by 100×(final tumorvolume−initial tumor volume)/initial tumor volume.

TABLE 5 Growth inhibition of Example 32 on human gastric cancer HGC-27in subcutaneous xenografts in nude mice Initial tumor Dose Growth CellTumor volume (mg/ inhibition Regression line type (mm³) kg/day) (%) (%)HGC-27 Gastric 107.0 0 cancer 99.3 2.5 62.3 104.6 5 76.9 103.3 10 70.5

Summary of Pharmacological Activities:

All examples showed strong inhibitory activity against PI3Kα with IC₅₀values of less than 11 nM. All examples showed strong anti-proliferativeactivities against human lung cancer cell NCI-H460 with IC₅₀ values ofless than 5 μM. Among them, Examples 9 and 44 had significant inhibitoryeffects against the growth of human lung cancer cell NCI-H460 insubcutaneous xenografts in nude mice, and Example 32 showed asignificant inhibitory effect on the growth of human gastric cancer cellHGC-27 in subcutaneous xenografts in nude mice.

1. A compound represented by Formula (III), or a stereoisomer, ageometric isomer, a tautomer or a pharmaceutically acceptable saltthereof:

wherein, R₇ is selected from C₁₋₃ alkyl, C₁₋₃ alkylcarbonyl orcyclopropylmethyl; L is selected from a single bond or C₁₋₃ alkylene,wherein said C₁₋₃ alkylene is optionally substituted with one or moreRa; Ra is selected from hydrogen, halogen or C₁₋₃ alkyl; R₃ is selectedfrom C₁₋₃ alkyl, 3- to 7-membered cycloalkyl, 6- to 10-membered aryl or5- to 6-membered heteroaryl, wherein said 6- to 10-membered aryl and 5-to 6-membered heteroaryl are optionally substituted with at least onegroup selected from halogen, C_(1_3) alkyl, amino, C₁₋₃ alkylamino,di(C₁₋₃ alkyl)amino, trifluoromethyl, difluoromethyl, cyano or C₁₋₃alkoxy; ring A is selected from 3- to 7-membered cycloalkyl or 3- to7-membered heterocycloalkyl; each R₆ is independently selected fromhydrogen, C₁₋₃ alkyl, halogen, cyano, trifluoromethyl, C₁₋₃ alkoxy, C₁₋₃alkyl substituted with hydroxyl, C₁₋₃ alkylamino or di(C₁₋₃ alkyl)amino;m is 0, 1, 2, 3 or
 4. 2. The compound according to claim 1, or thestereoisomer, the geometric isomer, the tautomer or the pharmaceuticallyacceptable salt thereof, characterized in that, said ring A is selectedfrom cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; each R₆ isindependently selected from hydrogen, C₁₋₃ alkyl, halogen, cyano,trifluoromethyl, C₁₋₃ alkoxy, C₁₋₃ alkyl substituted with hydroxyl, C₁₋₃alkylamino or di(C₁₋₃ alkyl)amino; m is 0, 1, 2, 3 or
 4. 3. The compoundaccording to claim 1, or the stereoisomer, the geometric isomer, thetautomer or the pharmaceutically acceptable salt thereof, characterizedin that, said ring A is 3- to 7-membered heterocycloalkyl containingoxygen; each R₆ is independently selected from hydrogen, C₁₋₃ alkyl,halogen, cyano, trifluoromethyl, C₁₋₃ alkoxy, C₁₋₃ alkyl substitutedwith hydroxyl, C₁₋₃ alkylamino or di(C₁₋₃ alkyl)amino; m is 0, 1, 2, 3or
 4. 4. The compound according to claim 3, or the stereoisomer, thegeometric isomer, the tautomer or the pharmaceutically acceptable saltthereof, characterized in that, said ring A is selected from:

each R₆ is independently selected from hydrogen, C₁₋₃ alkyl, halogen,cyano, trifluoromethyl, C₁₋₃ alkoxy, C₁₋₃ alkyl substituted withhydroxyl, C₁₋₃ alkylamino or di(C₁₋₃ alkyl)amino; m is 0, 1, 2, 3 or 4.5. The compound according to claim 1, or the stereoisomer, the geometricisomer, the tautomer or the pharmaceutically acceptable salt thereof,characterized in that, each R₆ is independently selected from methyl. 6.The compound according to claim 1, or the stereoisomer, the geometricisomer, the tautomer or the pharmaceutically acceptable salt thereof,wherein, L is selected from a single bond or —CH₂—.
 7. The compoundaccording to claim 1, or the stereoisomer, the geometric isomer, thetautomer or the pharmaceutically acceptable salt thereof, wherein, R₇ isselected from methyl, ethyl, cyclopropylmethyl or acetyl.
 8. Thecompound according to claim 1, or the stereoisomer, the geometricisomer, the tautomer or the pharmaceutically acceptable salt thereof,wherein, R₃ is selected from C₁₋₃ alkyl, 3- to 7-membered cycloalkyl,phenyl or thienyl, wherein said phenyl and thienyl are optionallysubstituted with one or more groups that are independently selected fromhydrogen, halogen, C₁₋₃ alkyl, amino, C₁₋₃ alkylamino, di(C₁₋₃alkyl)amino, trifluoromethyl, difluoromethyl, cyano or C₁₋₃ alkoxy. 9.The compound according to claim 8, or the stereoisomer, the geometricisomer, the tautomer or the pharmaceutically acceptable salt thereof,wherein, R₃ is selected from phenyl or thienyl, said phenyl and thienylare optionally substituted with one or more groups independentlyselected from fluoro or chloro.
 10. The compound according to claim 1,or the stereoisomer, the geometric isomer, the tautomer or thepharmaceutically acceptable salt thereof, wherein, said compound isselected from the group consisting of:


11. A pharmaceutical composition comprising at least one compoundaccording to claim 1, or a stereoisomer, a geometric isomer, a tautomeror a pharmaceutically acceptable salt thereof, and optionally apharmaceutically acceptable carrier and/or excipient.
 12. A method forpreventing and/or treating a PI3K-mediated disease, in a subject in needof such treatment, which method comprises administering to the subjectan effective amount of the compound of claim 1, or a stereoisomer, ageometric isomer, a tautomer or a pharmaceutically acceptable saltthereof.
 13. The method according to claim 12, wherein, saidPI3K-mediated disease includes cancer, immune diseases, cardiovasculardiseases, viral infections, inflammation, metabolism/endocrine functiondisorders or neurological diseases.